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11.1. The Complexity of Drug Discovery & Design 
On January 20th 1961 John F. Kennedy was sworn in as the 35th President of the USA. In 
his inaugural address he committed the US to sending a man to the moon, and returning 
him safely, before the end of that decade. As we all know, Neil Armstrong fulfilled this 
promise in July 1969, this incredible undertaking taking less than 9 years. On average, 
it takes the pharmaceutical industry 10-15 years and more than $800 million to bring a 
new prescription drug to the market [1,2]. Whilst it may not be a truly fair comparison, 
we might be tempted to conclude that drug design is not rocket science, but actually a 
far more difficult undertaking. It is certainly amongst the most intellectually challenging 
and risky pursuits in any commercial enterprise, and judging by falling output compared 
to expenditure, it is becoming more difficult all the time [3].
So why is the pharmaceutical industry finding it so difficult to maintain output? The 
conclusion from most observers is that the questions are becoming more difficult. We 
demand more effective and safer drugs that can be administered for longer periods of 
time, at the same time as regulatory authorities grow increasingly more stringent. In many 
areas, drug designers are working on 4th and 5th generation medications for particular 
diseases, and therefore efficacy and safety alone are not sufficient. These new drugs 
also have to be better and more cost effective than the earlier treatments. In the future, 
personalized medicine (beyond the one size fits all approach of current therapeutics) will 
further challenge an industry already struggling to reach its required output [4].
Science, and the way we undertake research, is changing. The scale of information 
generation is now so great that science has to adapt or drown in a data deluge. 
Additionally, the days of individual researchers working in isolated groups and focused 
only on their own, increasingly narrow expertise, are also numbered. Breakthroughs are 
increasingly made at the interface of disciplines by groups of scientists benefitting from 
the combination of their diverse skills. These changes have allowed some observers to 
suggest we are entering a "4th paradigm" in science, progressing from the 1st and 2nd 
paradigms characterized by Observation, Theory and Experimentation and the 3rd 
paradigm, characterized by Simulation, to a Data-Driven model for research.
The basis for data-driven drug-design is that all information and knowledge related to 
a problem is available so that key parameters/properties requiring improvement can 
identified and compounds synthesized to address these issues [5]. The one shared aspect 
of all conventional drug design and optimization strategies is that they are iterative [6]. A 
compound is designed, synthesized and then tested. The data resulting from this testing 
is evaluated before influencing the next round of design. We refer to this as the discovery 
cycle which is dependent on the premise that new experimental data immediately impacts 
on design. The challenges of this data-driven model center on the need for timely data-
10 Chapter 1
generation, rapid data-dissemination, insightful data-analysis and interpretation (in the 
context of multiple data sources) as well as the vision and empowerment to act decisively 
on new insight.
1.3. The Process of Drug Discovery
Most pharmaceutical companies follow a similar drug discovery and development 
pipeline consisting of a few key phases which are introduced below with focus on the 
role of computing in expediting these tasks:
1.3.1 Target Discovery and Validation
Drug discovery begins with the identification and validation of a protein target; whose 
activity it is believed can be modulated to treat a disease. The use of modern molecular 
biology including functional genomics (such as micro-array technologies) and proteomics 
has revolutionized the way in which we identify new targets. Bioinformatics underpins 
all of this work and is now also a fundamental tool in drug discovery and design. An 
obvious outcome of the genomics and molecular biology revolution of the last two 
decades has been the dramatic increase in the number of possible molecular targets for 
pharmaceutical companies to prioritise. The various -omics technologies are a critical step 
in determining the role of these proteins in disease and therefore validating their potential 
as drug targets [7]. However, there is growing realization that whilst a target may play a 
crucial role in disease, it might not necessarily be a good target for drug discovery. This is 
the difference between a biological validation of the target and the determination of its 
suitability to be modulated by a small molecule. This chemical evaluation of the target 
is often referred to as assessing its "druggability" with protein bioinformatics, including 
methods like sequence analysis, homology modeling, threading, and the identification 
and characterization of binding pockets, providing valuable methods to help determine 
the value of a target. Druggability is often evaluated on a protein family basis as these 
families share characteristics important for ligand-binding and therefore provide valuable 
insight into shared ligand chemo-types and selectivity. 
1.3.2 Lead Discovery
The next step in the process is to identify compounds able to modulate the activity of 
the target in a desirable fashion whilst retaining a chemical structure suitable for future 
compound optimization. The use of robotized high-throughput screening (HTS) methods 
underpins lead discovery and is a process with informatics at its core. Informatics is 
required to manage screening collections, validate experimental data and store and 
disseminate results [8].
The source of compounds for screening varies, but to maintain libraries of hundreds 
of thousands of compounds, pharmaceutical companies must routinely purchase new 
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1compounds. The choice of which compounds to purchase is critical to the quality of a 
screening set and therefore the success of future screening campaigns. Companies tend to 
purchase a mix of optimally chemically "diverse" compounds to cover all areas of chemical 
space and "focused" compounds they believe will be particularly suited to the targets 
that they work on. If we presume that there are 1060 possible compounds, and estimates 
of this number vary greatly, and a typical HTS will test ~250000-500000 compounds, then 
it is clear that we are only scratching the surface of available compounds. In recent years, 
companies have spent tens of millions of dollars increasing the size of their screening 
collections in an attempt to increase hit rate. There is now growing acceptance that 
this increase in size is not necessarily delivering an increase in hits and that rather than 
making HTS strategies larger, they should also make them smarter [9-11].
Knowledge of the target protein or the nature of existing ligands can be used to select 
a smaller number of compounds to test but still identify similar numbers of active 
compounds as a full screen whilst using less resources. This targeted or focused 
screening is becoming increasingly common, and even allows researchers to purchase 
specific novel compounds for planned screens. Once a series of active compounds has 
been identified, common substructures or shared features will be identified. These 
substructures and features as well as physical and chemical characteristics of the most 
interesting compounds can be used to identify other chemically similar compounds to 
test or purchase.
The triage process of evaluating and prioritizing the hits from HTS will include 
considerations such as: How active are the compounds? Are they novel and patentable? 
Is there scope to make new compounds around the series? Is there scope to replace 
undesirable parts of compounds (such as known toxic groups) whilst maintaining activity? 
A validated hit will have a minimum number of liabilities and a maximum potential 
for progression, including a balanced profile of potency, drug-likeness and selectivity. 
Pharmaceutical companies select compounds from screening exercises that are deemed 
to be "progressable" or "optimizable". These terms refer to compounds that have 
physical and chemical properties that make them suitable to eventually become "drug-
like" compounds by the end of an optimization project. It is generally recognized that 
the selection of which compound to initially progress is the most important medicinal 
chemistry decision that will be taken at any point during a project [12].
Whilst Informatics plays an important role in optimizing ligand screening by improving the 
quality of companies screening collections or by making focused selections of compounds 
to test, it is itself an important tool for identifying biologically active compounds in its 
own right. The application of computers to select small sets of molecules to test from 
databases of potential compounds is referred to as virtual screening (VS) [13].
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1.3.3 Lead Optimization
If lead finding is characterized by the testing of large numbers of existing compounds in 
high-throughput low complexity models then lead optimization is characterized by the 
testing of small numbers of compounds, synthesized in response to new data, in lower-
throughput but higher complexity models. New compounds are synthesised based on 
available chemical insight, knowledge of the target protein, or existing active ligands, 
plus a certain amount of trial and error. Chemical insight can include, for example, 
knowledge that one functional group can often be replaced by another similar group 
without losing biological activity, known as bioisosterism. Additional examples of 
chemical insight include prior knowledge that a molecular feature is metabolically labile 
or negatively effects solubility and should therefore be replaced. As each new compound 
is synthesised, its activity and other properties will be measured and the success of the 
chemical modification evaluated and used to help plan the next compounds. Structure-
activity relationships (SAR) are a qualitative understanding of the benefits and hindrances 
of changing various parts of the ligand on the compounds activity. SAR is crucial to guide 
the rational design of the next compounds in an iterative optimisation process. Historically 
SAR has been elucidated on paper and in the heads of medicinal chemists. This has always 
suffered from a certain amount of subjective analysis, and becomes increasingly more 
difficult as the number of compounds and properties increases. It is also not a suitable 
approach for considering multiple parameters simultaneously. For these reasons, SAR 
elucidation is increasingly becoming a "data-mining" task with both bench chemists and 
computational chemists making use of tools to visualize and interpret multivariate data 
for their compound series. Every compound, active or inactive is a step on a journey; 
with both contributing to the understanding required to eventually make the compound 
that will become the drug. Increasingly, it is becoming common for drug design projects 
Drug discovery is often compared to finding a needle 
in a haystack. Whilst this analogy makes some sense, 
it falls down because every piece of hay that you pick 
can easily be discarded as it is not a needle. When you 
eventually find the needle you can be sure that your 
task is complete. Drug discovery can therefore better 
be compared to searching for a specific needle in a 
very large pile of needles. Before you begin your task 
you will set a goal to identify a needle with certain 
properties and then every needle in the haystack is 
evaluated against these criteria until a compound is 
identified that satisfies these characteristics. To add 
another level of complexity to the task, the goals you 
are seeking to satisfy will change and develop over 
time, so that the needle you are initially seeking may 
not be the needle that you are eventually searching 
for. Like molecules in chemistry space, many of the needles will appear to be virtually identical or at least very similar. 
Finding the small differences that separate the majority of needles from the small group of desired needles is a significant 
problem. In medicinal chemistry this is referred to as the similarity issue. How can one describe the differences between 
many compounds in a simple manner and then identify which of these differences is the crucial differentiator in this project? 
It is also important to appreciate that the crucial differentiator in one project may not be the same crucial differentiator 
between the same two compounds when they are evaluated in another project
13Computer-Assisted Drug Discovery
 
Ch
ap
te
r 
1to have early access to information on the nature of the interaction between the ligand 
and the protein target it modulates. This information is extremely important in helping 
to design and optimise compounds and improve our understanding of their SAR [14-16].
A large number of chemical considerations must be balanced during optimization as the 
ideal compound will optimally combine function, potency, selectivity and safety as well 
as issues related to absorption, distribution, metabolism, excretion, chemical stability, 
patentability and production costs. Numerous different assays will be performed and the 
drug-design scientist will try to make sense of this large amount of data and use it to plot 
a course toward an ideal compound. A recurring failure during optimisation has been 
the emphasis on compound potency at the expense of other important properties. This 
begins with selecting the most potent initial hit to optimize and ignoring its tractability 
rather than finding a balance between activity and progressability. This often continues 
during optimization with compounds being designed to be more potent but less drug-like 
than at the beginning of projects [9].
Compound optimization requires imagination and adaptability. It requires the drug 
designer to be able to identify the inadequacies of their series and devise modifications 
to deal with these issues. A life time in medicinal chemistry equips the scientist with 
the personal toolkit required to make the appropriate modifications to a compound 
series. Despite this, there are a few key modifications that are repeatedly applied 
and form the basis for the toolkit of all design chemists. These include increasing the 
number of intermolecular interactions, increasing the strength of existing intermolecular 
interactions and compound rigidification, constraint or simplification.
The progression of a compound optimisation 
project can be compared to the process of 
negotiating a maze. At a certain point, progression 
in bisecting the maze (or in the improvement of 
compounds) will be hindered leaving one literally or 
figuratively lost. The natural action when this state 
is reached is to track back to a previous crossing, the 
point at which a decision was made, and to choose 
a different path. Nothing is gained from repeatedly 
covering the same ground. The same can be said for 
compound optimisation, but all too often time and 
resources are wasted re-treading the same ground, 
or chemical space in this case. At some point, the 
optimisation team have to take the difficult decision 
to trace a few steps back and follow a different 
path rather than synthesising more and more analogs which share the same chemical properties and therefore the same 
benefits and hindrances. A typical scenario here would be a project with potent but non drug-like compounds which 
are active in vitro but not in vivo. It is very easy in that situation to decide to keep tinkering with the active compounds 
and hope that one shows the desired activity in vivo. A more appropriate action might be to make more radical changes 
to the compound, resulting in a gain in drug-likeness but with the additional result that some potency is lost. From this 
new position, new paths, potentially leading more directly to the goal, might be available. Bravery is required to sacrifice 
guaranteed potency in your next compound, but this is often the only way to turn active compound series into active 
drugs. The key for success here is to ensure that from this new point in the optimisation maze, one does not follow the old 
path and produce more potent, but non drug-like compounds.
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1.4. The Molecular Basis for Drug Action
Rationally designing NCEs requires an understanding of how drugs are able to induce 
their biological responses from administration to excretion and the many other factors 
that have to be considered along the way.
1.4.1 Protein-Ligand Binding
A complex between ligand and protein forms when the bound system has a lower energy 
than the energy of its constituent elements. In effect, compounds are in a state of 
equilibrium between binding to the target and remaining in the solute. This is determined 
by enthalpic (∆H) and entropic (∆S) factors resulting in a combined contribution referred to 
as the free energy or ∆G. The goal of compound optimisation is to modify the compounds 
so that the equilibrium between the complex and the protein and ligand remaining in 
the solute is shifted toward ligand-binding. Invariably we focus new compound design on 
improving ∆G rather than individually considering either (∆H) or (∆S), but an appreciation 
of each is important, as is developing a feeling for the mutually compensating changes 
new compound design can have on them including beneficial cooperative effects [17].
Electrostatic interactions, solvation-desolvation and Van der Waals interactions are the 
most important contributions to ligand-protein binding with ∆H mostly associated with 
the electrostatic component and ∆S being associated with the solvation and Van der 
Waals component.
1.4.2 Druglikeness and ADMET
Drug-likeness is defined as those compounds that have sufficiently acceptable ADME 
properties and sufficiently acceptable toxicity properties to survive through the completion 
of Phase I clinical trials. – Christopher A. Lipinski
The action of a drug is dependent on a sufficient amount of it being able to get into 
the body (absorption), find its way to the correct site of action (distribution), and for 
it to remain there unchanged (metabolism) for long enough (excretion) to elicit a 
pharmacological response. This balance between Absorption, Distribution, Metabolism 
and Excretion (ADME) is referred to as Pharmacokinetics (PK) and is dictated by the 
physical and chemical properties of the drug, and as such can be altered by altering the 
drug. Every compound will have a unique PK profile which will affect how well it works 
as a drug. Some compounds benefit from having a high but short exposure whist others 
benefit from a lower but longer presence in the body.
The greatest challenge when optimizing so many different factors simultaneously is that 
some will conflict. Potency may be dependent on a large hydrophobic group, but that 
same group prevents the compound being soluble, or metabolic stability requires the 
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removal of a group that is crucial for selectivity. It is very easy to generate more soluble 
analogs of a compound, but much trickier to retain potency as this is achieved. Making 
local changes to compounds can have global consequences that may not be beneficial 
to the activity of the compound. For example, adding an electronegative group to an 
aromatic ring can alter the basicity of a tertiary amine connected to that ring and therefore 
change the activity and even conformation of the compound dramatically. Many other 
modifications can change the stability, activity, conformation or solubility of a compound 
in a way that is not immediately obvious. Optimizing compounds on multiple conflicting 
parameters is the art of lead optimization, and can only be successful if the compound 
designer considers all of these diverse issues and utilizes insight into the molecular basis 
for the activity of the series. Every piece of molecular and chemical insight is crucial to 
successfully delivering a final optimized compound for development.
1.5. Computer-Assisted Drug Design
In all industries with a high technical component, from architecture to car design to washing 
powder formulation, the utilization of computers to improve quality of work and increase 
efficiency has been embraced. If airplanes, consumer electronics and even factories begin 
life as designs on computer screens, why wouldn’t pharmaceutical products? Computers 
are now crucial tools in all stages and aspects of drug design and development, from the 
identification of disease related genes to the interpretation of clinical trial data and the 
Optimising on multiple parameters can be 
compared to trying to solve a Rubik’s cube. 
Each face represents a required character i.e. 
potency or selectivity, and changing one face 
will affect another face, perhaps detrimentally. 
As with a Rubik’s cube, sometimes you have 
to sacrifice a completed face, taking a local 
step back, in order to make a global step 
forward. With Rubik’s cubes, all faces are of 
equal value and weight, but is this the case 
for drug-design parameters? It can be argued 
that, for a specific compound, stability is less 
important than potency, but how do you 
separate parameters for which their total 
sum equals biological activity? Why decide at 
the beginning of a project to improve target 
engagement by increasing potency when it 
might be possible to improve PK and gain the 
same biological outcome?
 
All drugs are a result of compromise, but 
a more balanced approach to compound 
optimization would give all drug activity and 
property parameters equal weight and search 
for satisfactory compromise amongst them 
from the beginning rather than desperate late stage concession. This approach also has the potential to deliver a number 
of compounds, with differing, but equivalent compromises of the relevant properties rather than a set of compounds 
dominated by one property. Delivering a set of non-dominated solutions with varying properties is also more attractive to 
project pipelines compared to a stream of me-too compounds.
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numerous steps between. Despite this acceptance, drug companies will have to increase 
the utilisation of information technology and computer sciences within the traditional 
drug design sciences of biology, chemistry and pharmacology to improve quality and 
efficiency. The pharmaceutical industry, with science and innovation so fundamentally at 
its core, has actually been very slow to incorporate information technology to the degree 
that it should. This is not to suggest that great steps have not already been taken, but 
more are already required.
The term Computer-Assisted Drug Design (CADD) refers to the application of informatics 
methods, within rational drug design, to discover, design and optimise biologically active 
compounds. CADD must be integrated with traditional medicinal and synthetic chemistry, 
as well as biology and pharmacology to maximise its impact. For some compounds, CADD 
will be the driving force in their design, and in others a less pronounced but still significant 
contributing factor. It is now very difficult to imagine how a new drug could be designed 
in the 21st century with absolutely no contribution from CADD, whether reported or not. 
CADD can be divided into two paradigms, ligand-based and structure-based, with drug-
design often happening at the interface between the two.
1.5.1 Ligand-Based Drug Design
Ligand-based drug design relies on understanding the properties of existing actives and 
selecting or designing new compounds that include the positive features or exclude 
negative features. Once important chemical features are identified it also becomes 
possible to design novel, or search databases of, compounds that share these desirable 
properties. All ligand-based methods require the definition of the important chemical 
Compounds A, B and C have been identified as hits from our screening activities, 
but which of them should we pursue? Is the higher potency of compound A as 
important a factor as the selectivity of the less active compound B. Compound 
C appears more druglike, but is this more or less important than potency. 
Compounds B and C are similar, so should I spread my risk and pursue just one 
of them? Compound A includes a known toxic liability, but should I be scared of 
this so early in the life of the project. Chemical synthesis around compound B 
is easiest, but should I exclude potentially better compounds just because their 
chemistry is more challenging? Compound C is related to IP from our competitor, 
should we risk pursuing this compound knowing that future competitor IP could 
cover it. What are the critical issues that need approving in my chosen compound 
series? I have made 100 analogs of compound C without improving on the critical 
issue should I risk making another 100? I have made 100 analogs of compound 
A and improved on the critical issue, but at the expense of one or more other issues. Is this progress? Should we test the 
activity of compound X from our corporate collection? Should we purchase and test the externally available compound Y? 
Why is compound X more active than compound Y? What can I do to compound Y to make it more like compound X? Can I 
combine the best characteristics of compound X with the best characteristics of compound Y? Which of these compounds 
will compound Z behave like? If compound Z is better than compound X on issue 1 but worse on issue 2 is this a better, 
worse or equal compound? Are there lots more compounds available like compound X, or can I design more compounds 
like it? Is compound X as good as I hope it is? What can I do to make compound X better? Can I design a series of compounds 
that retain the best of compound X but alter a different property? Can the problems with compound X be addressed 
without modifying the structure?
17Computer-Assisted Drug Discovery
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1properties of a compound before comparing them to other compounds. Chemical 
descriptors (sometimes referred to as molecular descriptors) are numerical values 
that characterise properties of molecules. Chemical descriptors are calculated for 
each compound from their molecular formula, fingerprint or connection table, and 
represent some component of the physical-chemical character of the compound which 
might contribute to ligand binding, biological activity or chemical behaviour. Chemical 
descriptors range in complexity from measures as simple as molecular weight and atom 
composition, to multi-parameter ensembles of more complex descriptors. Calculated 
values of the compounds lipophilicity, steric and electrostatic fields, and pharmacophoric 
representations are amongst the most often cited descriptors, but there really is no end 
to the possibilities and combinations. The challenge in using any chemical descriptor 
technology is the ability to define a priori which descriptors and which values correspond 
to the desired chemical property. Knowledge of the problem may suggest a subset of 
descriptors to consider, or one may try to select or optimise a compound to have similar 
values to a previously known active. Without this prior knowledge, chemical descriptor 
selection is difficult, but is as valid for excluding undesirable chemistry as ensuring the 
inclusion of desired features and is of crucial importance in dealing with ADME and 
toxicity issues.
Once a series of chemical descriptors are selected, it becomes relatively easy to identify 
compounds that are similar or divergent from a query molecule. "Similarity" is a crucial 
consideration in all drug design, following the general premise that increasing similarity 
between the physical and chemical properties of a set of compounds is correlated to 
increasingly similar biological activities. Identifying compounds similar to known actives 
In the figure above are six faces. It is very easy 
to identify characteristics (descriptors) that 
differentiate each person. For example one is 
bald, two have centre parted black hair and one 
has medium length curly grey hair etc. There are 
differences in the shape of faces and size of eyes. Some have large noses and others smaller. Based on these simple 
descriptors these people can be distinguished. If each of them is a suspect in a crime and a witness describes seeing a 
person leaving the scene with long red wavy hair and oval eyes the police could easily identify the culprit. The same process 
can be used to differentiate molecules. We know the active compound must have two acceptors and a donor, have a cLogP 
below 4 and include a basic amine. We can then search for compounds sharing these properties.
Whilst the descriptors of face shape, hair colour 
and ear size etc are sufficient to differentiate the 
six humans, would they be sufficient to separate 
each human from their pet dog shown below 
them? Both the man and the dog at the far right 
have small round faces, squashed noses, down 
pointing mouths, and small ears. You could add an 
extra descriptor such as "species" once you identify 
this problem, but this illustrates the difficulty in 
selecting the correct descriptors a priori.
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Similarity itself is subjective. If asked to group the four shown 
animals into two groups of two you could classify the tiger and the 
lion together as they are both from the cat family, leaving the zebra 
and the muntjac together. Some would also classify the two cats 
together as they are both carnivores and the other two animals are 
herbivores. You might call the zebra and tiger similar as they are both 
white with black stripes and the other two animals are brown. You 
could group the zebra and the lion together as they are both natives 
of Africa and the other two are Asian. The same grouping could be 
made if you consider that the lion eats the zebra and the tiger eats the 
muntjac and therefore you would group the related prey and predator 
together. The same issues arise when comparing molecules. Is it their 
size or charge or number of acceptors that is the most important to 
consider when measuring their similarity?
is a valuable way to identify novel actives, and vice versa, allow us to identify compounds 
divergent from those previously studied.
An extension of ligand-based methods is the use of quantitative structure-activity 
relationship (QSAR) or quantitative structure-property relationship (QSPR) analysis. These 
approaches use statistical methods to relate changes in the structure of compounds (or 
other chemical descriptors) to experimentally measured values of biological activity and 
use this to build models to predict the activity of other compounds. This can provide 
a finer and deeper understanding of SAR and therefore an improved understanding of 
why compounds are active. Initially focussed on predicting binding to target receptors 
(QSAR) the methods are now widely applied to calculating properties related to ADME 
and toxicity (QSPR).
1.5.2 Structure-Based Drug Design
Structure-based drug design (SBDD) refers to a collection of methods that rely on an 
understanding of the 3-dimensional properties and characteristics of the target protein 
to guide the optimisation of ligands to enhance their complementarity. Structures of the 
protein-ligand complex can be derived experimentally using X-ray crystallography or NMR 
approaches, or predicted computationally using a combination of homology modeling 
and molecular docking. As the speed of compound synthesis is typically faster than the 
generation of new protein structures, it is often necessary to combine experimental and 
computational methods to ensure structure-based methods can keep pace.
When protein structures are available a number of approaches can be used to guide 
drug-design. The most common is the manual optimisation of compounds utilising 
simple visualisation tools to suggest ways to modify the compound that will improve 
the interaction between the ligand and protein. A similar approach can also be used to 
propose modifications to the compound that can be made to improve another property 
of the ligand without interfering with binding. Protein binding pockets can also be used 
to derive pharmacophores, based on important binding features, which can be used to 
search for complementary compounds from ligand databases. The same databases can 
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The nature of the data and tools available to the 
design team will dictate which methods can be 
employed. In the most limited situation an early 
lead finding project may lack known ligands or 
protein structures (yellow box). Ensuring that 
the compounds being screened are of high 
quality via compound acquisition efforts or 
that medium-throughput screening methods 
test a representative selection of the corporate 
compound collection is as much as can be done. 
If a ligand is known, either from screening efforts 
or from known references, but no related protein 
structure information (blue box) then ligand-
based methods are available. This wide collection 
of methods will allow you to fully understand the 
physical-chemical properties of the compounds 
and deduce the basis for their biological activity 
and either make attempts to improve this or 
identify other compounds that may share these 
properties. QSAR methods may be possible 
depending on access to relevant biological data. 
Even if specific protein structural data is not 
available at this point, teams can already start to 
make use of homology models and should be taking action to ensure they can access more specific X-ray information as 
soon as possible. In the case that only a protein structure, perhaps bound to an endogenous ligand or reference compound 
is available, but a project lacks its own lead (red box) then there are a number of target-based methods available to 
identify new leads. De Novo design provides the possibility to create totally novel NCE’s or at least grow existing fragments. 
Virtual screening via automated docking or pharmacophore-based methods allows us to identify potentially interesting 
compounds from libraries or virtual collections of potential compounds. Finally, if a protein structure, ideally in complex 
with representatives of the compound class of interest (green box), then full SBDD methods can be employed. Whilst this is 
generally considered to be the ideal, we should never ignore the possibility that a method from another of the four boxes 
may still be beneficial. In particular, physical-chemical methods, and computational chemistry approaches are still likely to 
be needed to fully understand the biological activity of the compound of interest.
also be searched directly using molecular docking techniques which evaluate how well 
suited any ligand is to the binding pocket of interest. It is also possible to use de novo 
design methods to build totally novel compounds or expand existing compounds within 
the confines of the binding pocket. Historically, SBDD was undertaken later in projects 
and used to improve already well optimized compound series, but there is growing 
acceptance within the pharmaceutical industry that access to co-crystals of ligands and 
targets will have greater impact the earlier in the process that they can be obtained. 
The primary focus of the research component of this thesis deals with X-ray structure 
studies aimed at improving our knowledge and understanding of the progesterone 
receptor, and specifically how ligands are able to induce different agonist-antagonist 
profiles and the implications for drug design.
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2.1. The Steroid Hormone Receptors
Steroid hormones control a wide variety of cellular functions that are important for cell 
homeostasis, proliferation, differentiation and apoptosis [1]. Although the classic steroid 
hormones (estradiol, progesterone, testosterone, cortisone etc.) were first isolated 
early in the 20th century, their receptors, estrogen (ER), androgen (AR), glucocorticoid 
(GR), mineralocorticoid (MR) and progesterone (PR), remained elusive until the 1960s. 
The receptors, a sub-family of the nuclear receptor (NR) super-family, are now known 
to be ligand-inducible transcription factors whose primary site of action is the nucleus 
where they bind either directly or through adaptor proteins, to specific response 
elements within the regulatory regions of target genes. The formation of the receptor 
and co-regulator protein complex on DNA yields the required chromatin remodeling that 
facilitates the recruitment of transcription machinery which leads to RNA activation and 
protein biosynthesis [2]. 
The shared domain structure of the steroid receptors incorporates a variable N-terminal 
domain, a highly conserved DNA-binding domain and, most importantly for drug 
design, a moderately conserved ligand-binding domain (LBD). The LBD combines a 
number of functions, including hormone-binding, receptor dimerization and binding 
to other transcription co-modulating proteins. These functions can have influences on 
one another; for example, ligand-binding can influence the pattern of co-modulator 
recruitment. Crystal structures have been elucidated for the LBDs of each of the steroid 
receptors, with more than 100 structures available in the public domain. Despite this 
apparent wealth of data, an insufficient diversity in co-ligands, both structure and 
function, hampers our scientific understanding and ability to design new drugs.
The precise mechanism for ligand-mediated transcriptional control of the nuclear 
receptors varies across the family, but key events for steroid receptors begin with 
hormone entering cells and associating with the receptor. In their unliganded state the 
Figure 2.1: The binding of the nuclear receptor DNA-binding domain to DNA 
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receptors are bound to heat shock proteins which then dissociate on ligand-binding [2]. 
Association with ligands also stimulates the formation of homodimers of the receptors 
and stabilizes the dynamic helix-12 in the so-called agonist conformation. Helix-12 (also 
known as the AF-2 helix) sits at the c-terminal of the LBD covering the ligand-binding 
pocket and forming a lid. The correct positioning of helix-12, in addition to helix-3 and 
helix-4, forms a hydrophobic cleft on the surface of the domain which is a binding and 
recognition point for co-activating proteins which contain a LXXLL (or related) helical motif 
[3]. This cleft also includes a negatively charged residue from helix-12 and a positively 
charged residue from helix-3 which form a charge clamp to cap the LXXLL containing helix 
of the co-activator.
The receptor and co-activator complex recruits other transcriptional machinery and 
associates with specific regions of DNA referred to as response elements. This complex of 
transcriptional machinery is able to remodel chromatin in the genes containing response 
Figure 2.2: The common domain structure of nuclear receptors
Figure 2.3: Left shows the binding of the LXXLL containing helix of a co-activator bound to the 
LBD. Right shows the crucial charge-clamp and buried leucine residues that drive co-activator 
binding and recognition.
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elements which allows RNA polymerase enzymes to transcribe them [2]. In addition, co-
repressors also exist who associate with the receptor to remodel chromatin in such a 
way as to prevent the action of RNA polymerase. Co-repressors appear to require the 
same dissociation of heat shock proteins before they can bind to the nuclear receptors, 
but do not need helix-12 to be in its agonist position. Co-repressors are not dependent 
on the charge clamp for binding to the LBD and in fact are able to compete with binding 
of co-activators more easily when helix-12 is not in its agonist conformation due to their 
extended recognition motif LXX(I/H)IXXX(L/I) compared to LXXLL [2].
2.2. Drug Design for the Steroid Hormone Receptors
2.2.1 Receptor Affinity
The LBDs adopt a three-layered antiparallel α-helical canonical sandwich motif and 
despite the moderate to low sequence identity across the steroid receptors (e.g. ~ 25% 
between AR and ERα), the receptors remain structurally well conserved.
The steroid receptor binding cavities, which are completely partitioned from the external 
environment in the classic active conformation, vary in volume between 400 and 600 
Å3 and are predominately hydrophobic in nature, with polar functions at either end. 
The structure of the steroid receptor binding cavity is complementary to the general 
pharmacophore that is observed for the endogenous ligands of steroid receptors, 
which is characterized by the presence of polar groups on the 3 and 17 positions of 
the hydrophobic steroidal scaffolds. Binding pocket plasticity of steroid receptors is of 
growing interest to drug designers. The flexibility that is now observed with these ligands 
Figure 2.4: Rotated views of the steroid receptor LBD with helices numbered
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is less apparent when only steroid-bound structures are studied, but as more diverse 
ligand co-crystals are solved, it is possible to exploit this plasticity when designing new 
drugs. For instance, the wide range of steroidal and non-steroidal compounds that are 
tolerated by ERs can partly be explained by the flexibility that is observed at one of the 
crucial polar residues (His524 in human ERα); the residue adopts different conformations 
depending on the bound ligand, and is thereby able to retain polar interactions that 
would otherwise be lost.
Figure 2.5: Overlay of 120 steroid receptor structures with each receptor sub-type colored 
differently to illustrate conservation of structure across the sub-family.
Figure 2.6: A general description of the steroid receptor binding pocket
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2.2.2 Selectivity
Substitution of the polar residues at either end of the steroid receptor binding pockets 
allows individual receptors to recognize and differentiate their particular endogenous 
ligands. While it may be tempting to focus only on these polar interactions when 
considering the molecular basis for selectivity, this elegant system does not fully explain 
the selectivity of endogenous steroids or of the various non-steroidal ligands that 
increasingly populate the steroid hormone receptor pharmacopeia. In fact, the complete 
picture requires a consideration of more subtle differences in binding pockets, resulting 
from relatively conservative substitutions among hydrophobic residues. Because of 
its dependency on these delicate variances, selectivity generally tends to be a less 
tractable problem than potency, as illustrated by the number of potent but non-selective 
compounds that are described in the literature. Despite the challenges involved in 
designing selective non-steroidal ligands, their generation has been possible, but remains 
a challenge, even when structural information is available.
2.2.3 Functional Activity
The molecular basis for antagonism in steroid receptors is perhaps the most important 
and intriguing information that structural biology has provided for this family of receptors. 
As first described for ERα, the specific addition of bulky groups to typically estrogenic 
scaffolds can induce a dramatic conformational change in the C-terminal α-helix of the 
LBD (often referred to as the AF2 helix), resulting in a disruption in the pattern of co-
modulating protein binding. As a consequence, a divergence in functional activity occurs, 
giving rise to full agonists, full antagonists, and partial (ant)agonists, all of which have 
unique and potentially desirable or deleterious biological activities. 
The ability to select compounds with these activities provides an opportunity to design 
increasingly function-specific steroid-receptor ligands. Raloxifene and Tamoxifen, both 
prototypical selective estrogen receptor modulators (SERMs), have receptor co-crystal 
structures that exemplify the importance of increased bulk for disturbing the AF2 helix, 
but also demonstrate how other, more specific interactions are important. For example, 
the presence of basic nitrogen in both ligands allows for the formation of a salt-bridge 
with an aspartate; this interaction is critical for SERM-type antagonism [4, 5]. 
In addition to a direct steric interference of the AF2 helix, structural biology has revealed 
that certain interactions with the loop and helix that precede the AF2 helix can induce 
antagonism as can manipulation of the typical interaction between helix-3 and helix-5. 
Finally, the abrogation of stabilizing interactions between agonistic ligands and the 
steroid receptor appears to be important as illustrated by the binding of the antagonist 
hydroxyflutamide to AR. Hydroxyflutamide is small enough to be accommodated within 
the agonist conformation of the receptor, and its antagonism appears to be caused by a 
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Figure 2.7: Small differences in degree of clash with helix-12 and interaction with Asp351 
contribute to different biological activities of Raloxifene and Tamoxifen.
loss of the stabilizing interactions, that are made by agonistic ligands, with the receptor. 
Interestingly, the steroid receptors do not have equal sensitivity toward antagonism. 
For example, ERβ (discussed below) generally displays more sensitivity than ERα toward 
antagonists. This difference in sensitivity can be explained at the structural level by the 
absence of stabilizing interactions within the ERβ protein. As a result, ligands such as 
tetrahydrochrysene induce an agonistic conformation when bound to ERα, but induce 
an antagonistic conformation when bound to ERβ. Further elucidation of the interactions 
of non-steroidal ligands and steroid receptors, as well as the discovery of additional 
mechanisms of activity, are considered critical for the continued rational-design of 
function-specific NCEs.
2.4. Conclusion
In the field of steroid receptor drug-design, the main challenge lies in attaining complete 
control in the generation of functionally selective ligands (degree of agonism or 
antagonism). Developing reliable information (based on validated systems) that allows 
for the rational design of ligands with the required selectivity and functional profile is 
essential. Therefore, new technologies (eg, peptide recruitment assays) that allow for 
the screening of desired profiles which correlate with required functional selectivity will 
become increasingly important. The co-crystallization of diverse sets of ligands and LBDs 
of steroid receptors will provide more insight into the correlation between the plasticity 
of these LBDs and the resulting functional selectivity (e.g., selective modulators for 
steroid receptors). 
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Abstract
The molecular basis for agonism and antagonism in steroid receptors is perhaps the most 
important and intriguing lesson that structural biology has provided for this family of 
receptors. Different, but often structurally related ligands are able to elicit profoundly 
divergent responses with the potential that these effects will result in desirable biological 
activities. As our understanding of the factors contributing to these subtle differences 
increases it becomes possible for drug hunters to design function-specific steroid-
receptor ligands with an endless potential to benefit patients.
We will present observations from structural biology, mutation studies and, where 
possible, ligand-based structure-activity relationships, to provide a molecular basis to 
explain how chemically related molecules can have divergent biological effects. Our 
goal is to provide drug hunters, new to the field of steroid receptor drug-design, with 
a framework to approach their goals rationally. We illustrate each of the five key design 
directions with a steroid receptor specific case study.
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3.1. Introduction
The steroid hormone receptors, the Androgen Receptor (AR), Estrogen Receptors (ERα 
and ERβ), Glucocorticoid Receptor (GR), Mineralocorticoid Receptor and Progesterone 
Receptor (PR), have been crucial targets for drug discovery even before their existence 
was known or understood. The drugs on the market for this sub-class of the nuclear 
hormone receptors constitute a significant pharmacopeia for the treatment of a vast 
array of conditions and ailments. Despite the breadth of drugs targeted toward this 
family, they remain a crucial target for the pharmaceutical industry.
Key considerations when designing drugs for any family, beyond the on-target 
pharmaceutical action and safety, is to ensure specificity against related targets, exploration 
of the most appropriate routes of administration and desirable pharmacokinetic (PK) 
profiles. Developing non-steroidal modulators for the steroid receptor family has been 
a key strategy employed to achieve these goals, although there appears to be growing 
consensus that not being steroidal is insufficient to justify new drugs on its own [1]. 
Unlike targeting many families, steroid hormone receptor drug discovery also has to 
balance the need to elicit either agonistic or antagonistic responses depending on the 
desired indication. 
The history of drug discovery for the steroid hormone receptors has tended to follow 
a common path, beginning with the application of purified endogenous hormone and 
followed by the application of the first synthetic analogs with improved PK properties or 
selectivity. For some of the receptors this period was followed by the design of antagonists, 
including non-steroidal structures. More recently, steroid hormone drug discovery has 
been dominated by the search for ligands characterized by partial agonistic or partial 
antagonistic responses, the so called selective modulators. It is hoped and expected 
that partial agonists and antagonists for the various receptors will provide improved 
therapeutic profiles. For example, selective GR modulators (SGRMs) could provide their 
anti-inflammatory action without the undesirable side-effects, including osteoporosis 
and diabetes, currently associated with oral glucocorticoids [2]. Selective ER modulators 
(SERMs) hold the promise of being active on bone but not breast or endometrial tissue 
[3,4], whereas a desirable profile for a selective AR modulator (SARM) would likely have 
a greater action in bone and muscle compared to the prostate [5]
3.2. Molecular basis for partial agonism
The shared domain structure of steroid receptors includes a variable N-terminal domain, 
a highly conserved DNA-binding domain and a moderately conserved ligand-binding 
domain (LBD). The LBD domain tends to be the primary target for drug-design. The LBD 
combines a number of functions, including hormone binding, receptor dimerization and 
binding to other co-modulating proteins that play a role in the control of transcription. 
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These functions have the ability to influence each other, with ligand-binding, as an 
example; influencing the pattern of co-modulator recruitment. Specifically, gene 
activation requires the recruitment of co-modulating proteins to a region of the surface 
of the LBD formed by helices 3, 5 and 12. The position of helix-12, as we will discuss, 
can be influenced by the nature of the ligand bound to the receptor allowing ligands 
to influence the binding of co-modulators and consequently gene activation and the 
resulting biological effects [6-9]. 
Understanding the molecular basis for partial agonism is hampered by the difficulty in 
solving the X-ray structures of steroid-receptors in general and specifically complexes 
including partial active ligands [10]. Full agonists stabilize the receptor, and specifically 
helix-12, in a conformation suited to binding co-activating proteins and full antagonists 
stabilize the receptor in a conformation suited to binding co-repressing proteins. The 
apparent reason for the difficulty in co-crystallizing partial agonists is that they do not 
fully stabilize the receptor in either conformation, adopting some degree of equilibrium 
between the two [10, 11]. This equilibrium allows partially active compounds to bind 
unique patterns of co-modulators compared to full agonists and antagonists, resulting 
in their potentially interesting biological effects. Unfortunately as a result it also renders 
them poorly suited to co-crystallization studies.
The degree of partial activity (how far from either a full agonist or antagonist response) 
will go some way to determining the profile of co-modulators which will bind. 
Additionally, the ratio of co-activators compared to co-repressors in each cell type will 
influence the biological effect of a partial compound. In cells with a high co-activator 
concentration we would expect partial compounds to show a greater degree of agonistic 
activity compared to the same ligand in a cell with a high co-repressor concentration. The 
limitless combination of ligand partiality and co-modulator distribution appears to be a 
major contribution to the tissue selective responses of partial compounds.
3.3. Mechanisms for ligand-induced partial agonist design
In the absence of a complete record of X-ray structures of steroid receptors bound to 
agonists, antagonists and partially active compounds, we have to fill in the knowledge 
gaps with mutation studies and ligand-based structure-activity relationships (SAR). 
Even with this extra information, our understanding of the mechanisms underpinning 
the repositioning of helix-12 and the resulting spectrum of partial responses remains 
relatively naive, but there do appear to be a small number of approaches available to the 
drug designer who wishes to rationally influence the degree of agonism elicited by their 
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compound series.
1. Sterically impede the agonistic orientation of helix-12.
2. Disrupt the function of other indirect stabilizing interactions.
3. Influence the position of helix-12 by modulating the end of helix-11 and the  
 loop between helices 11 & 12.
4. Reduce the stabilizing interactions directly between the ligand and helix-12.
5. Straighten helix-3, and/or disrupt interactions between helices 3 & 5.
Incorporating these approaches into the optimization of steroid receptor ligands allows 
the drug-designer to modulate the degree of agonistic and antagonistic response their 
compounds induce. Pharmacologically it remains difficult to define a priori the precise 
agonistic or antagonistic efficacy (percentage effect or intrinsic activity) required for 
any desired indication, but it is now possible to generate a series of ligands with tuned 
efficacies to cover a broad range and then utilize molecular profiling approaches to select 
the most desirable.
The five basic approaches for generating partially active compounds have been deduced 
by numerous studies from all members of the steroid receptors and nuclear receptor 
family in total. For the purposes of this review we present a single receptor case study to 
demonstrate each of the five mechanisms, but wish to stress that to a greater and lesser 
degree all mechanisms should be applicable to all steroid receptors.
3.3.1 Sterically impede the agonistic orientation of helix-12
3.3.1.1 Case Study: The progesterone receptor
Steroidal anti-progestins are typically differentiated structurally from progestins by the 
presence of a bulky attachment at their position 11 [12]. Recent publications of the anti-
progestin Mifepristone [11] and the SPRM Asoprisnil [13] clearly demonstrate that the role 
of this bulky attachment is to clash with helix-12 and preclude it from adopting its required 
agonistic position. Both studies also demonstrate an important role specifically for Met909 
in the agonism/antagonism balance. Met909 sits within helix-12 at the C-terminal end of 
the ligand binding domain (LBD), and in the classic agonist conformation of the receptor, 
is oriented toward the ligand binding pocket. Met909 is typically the only helix-12 residue 
directly in contact with ligands. The nature of the ligand-Met909 interactions appears to 
be a key determinant of the receptors function [14]. Clashes between Met909 and ligands 
are likely to destabilize helix-12 [11], which results in a reduced agonistic response. It has 
even been suggested that the degree of clash with Met909 might correspond directly to 
the reduction in agonism [12], but this has yet to be shown categorically.
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M909  M909                   M909  M909                M909
Figure 3.1: Binding of PR agonist Drosperinone (left) from X-ray structure compared to SPRM 
Asoprisnil and PR antagonists Mifepristone and Onapristone demonstrating clash between 
antagonists and Met909 in helix-12. Introducing bulky groups onto PR modulating non-steroidal 
scaffolds has also been demonstrated to result in partial agonists on a number of occasions 
[15-18].
3.3.1.2 Additional Examples 
The existence of a clash between antagonists and helix-12 was first demonstrated 
for ER by studies comparing the X-ray structures of Estradiol to Raloxifene [19] and 
Diethylstilbestrol to Tamoxifen [20]. Numerous reviews of these two studies have been 
published [21-25] as have many further studies on the X-ray structures of SERMs, full 
antagonists and full agonists bound to the ERs [26-33].
The same helix-12 clash has also been demonstrated for AR [34] and GR [35] in recent X-ray 
structure determination studies. It was also suggested for GR by a mutagenesis study [36] 
that showed that mutating Leu753 (equivalent to Met909 in PR) to a phenylalanine results 
in a receptor defective in transactivation. We can conclude that the reason for this loss of 
activation is that an increase in the size of the residue at this position prevents helix-12 
from adopting its agonistic conformation due to a clash with the ligand.
3.3.2 Disrupt the function of direct stabilizing interactions
3.3.2.1 Case Study: The androgen receptor
The binding of testosterone and dihydrotestosterone to AR demonstrate the existence of 
crucial receptor stabilizing interactions mediated by agonistic ligands. As we will discuss 
later, the loop between helix-11 and helix-12 is a key region for mediating partial agonism. 
As shown in Figure 3.2, AR is stabilized by a ligand mediated hydrogen-bond network 
from Thr877 in helix-11 to the 17β-OH group in the endogenous steroidal agonists to Asn705 
in helix-3 and finally to the backbone of Asp890 in the loop itself [37].
Hydroxyflutamide is the active metabolite of the androgen receptor antagonist flutamide. 
Its antagonism appears to be a result of its inability to complete the entire network of 
stabilizing hydrogen-bonds [38] also shown in Figure 3.2. The result is that Thr877 is left 
buried in a predominately hydrophobic pocket, destabilizing the receptor and shifting the 
agonist-antagonist equilibrium.
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Figure 3.2: Left shows the X-ray structure of DHT bound to AR including full hydrogen-bond 
network. Right shows a model of hydroxyflutamide bound to AR based on the X-ray structure of 
hydroxyflutamide bound to an AR-T877A mutant.
3.3.2.2 Case Study: The androgen receptor
The residue equivalent to AR residue Asn705 in MR is Asn770. Extensive X-ray, SAR and 
mutation studies have been conducted on Asn770 which demonstrate clearly the existence 
of a ligand-mediated hydrogen bonding network which is critical for the activation of MR 
in a similar fashion to the one described for AR [39, 40]. 
Agonistic steroidal ligands for GR and MR are typified by 11β-hydroxyl groups which 
hydrogen bond to Asn564 in GR and Asn770 in MR respectively. Despite the similarity 
between MR and PR, the endogenous PR agonist progesterone behaves as an antagonist 
of PR. This appears to at least in part be due to a lack of an 11β-hydroxyl group on 
progesterone. It is interesting how the lack of the hydroxyl group doesn’t disturb the 
agonistic activity of PR but does MR.
Another important example of disrupting the function of stabilizing interactions can be 
seen in the estrogen receptors. In addition to their role in sterically precluding helix-12, 
SERM side-chains also contain an important basic amine function which is almost 
ubiquitous amongst this drug class. The role of this nitrogen is to form a salt-bridge to 
Asp351 in helix-3 of ERα (Asp303 in ERβ). The importance of this salt-bridge is that it requires 
Asp351 to adopt a new conformation and prevents it from undertaking is usual function of 
stabilizing the agonistic position of helix-12 by hydrogen-bonding to backbone residues 
in the helix. It also appears that the exact nature of the interaction between the basic 
amine and Asp351, including angle, distance and perhaps pKa can influence the biological 
effect of the ligands.
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3.3.3 Modulate the end of helix-11 & the loop between helices-11 & 12
3.3.3.1 Case Study. The Glucocorticoid Receptor
Due to the difficulty in crystallizing partial agonists in complex with steroid-receptors 
much of the evidence to support these mechanisms has to be inferred from other indirect 
sources. Some of the most valuable evidence comes from mutagenesis studies including 
those that indicate that the loop between helix-11 and helix-12 is a hotspot that is crucial 
to the agonism/antagonism balance in GR.
Mutation of Ile747, which sits in the middle of the helix-11 to helix-12 loop, to methionine 
results in GR having a reduced transactivation potential without affecting the binding of 
classic glucocorticoids [41]. Presumably, the increased size of the residue prevents the 
correct packing of the loop and therefore destabilizes helix-12.
Tyr735 at the end of helix-11 is a surface residue whose role is poorly understood, but it 
has been shown that various mutations (W735F, W735V and W735S) result in a receptor 
with significant reduction in transactivation activity of the receptor without affecting 
ligand binding [42, 43].
In addition to these mutation studies, as discussed already, there is also overwhelming 
evidence across the family to support the hypothesis that Asn564 is crucial for the agonistic 
activity of GR and related receptors [39, 40, 45-48]. The role of Asn564 (Asn705 in AR, Asn770 
in MR) was previously discussed.
Tyr735, Thr739 and Ile747, as shown in Figure 3.3, are all located at the end of helix-11 or 
in the following loop. Asn564 has an important role in stabilizing the loop. The studies 
associated with each of these residues indicate how sensitive this region to influencing 
the agonism/antagonism balance and therefore the potential to modify its function by 
ligand-design.
The helix-11 to helix-12 loop in steroid-receptors is well suited to drug-design intervention 
as it forms around the 17β group of steroids and is therefore likely to be in close proximity 
to most ligands.
Bledsoe and colleagues recognized the importance of this region when solving the 
first GR-Dexamethasone structure [46, 49] as did the group of Kauppi when solving GR 
complexed with Dexamethasone and RU486. They noted the flexibility of this loop [50].
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Figure 3.3: The loop between helix-11 and helix-12 illustrating key residues believed to influence 
GR function
3.3.3.2 Additional Examples.
The importance of the loop region between helix-11 and helix-12 has also been 
demonstrated by X-ray structure studies for ERα [20, 51], and mutagenesis studies on 
MR also support the conclusion that this region of the steroid-receptors is crucial for the 
agonism/antagonism balance [45].
3.3.4 Reduce the stabilizing interactions directly between the ligand and helix-12
3.3.4.1 Case Study. The Estrogen Receptors Alpha & Beta
Methods for antagonizing or reducing the agonism of steroid receptors that do not involve 
direct steric clashes with the receptor are often referred to as “passive antagonism”. This 
term was coined by the group of Geoffrey Greene to explain their observations when 
studying the binding of tetrahydrochyrsene (THC) and its interactions with ERα and ERβ 
[52].
THC is an ERα agonist and an ERβ antagonist. The group of Greene was able to conclude, 
after generating X-ray structures of both complexes that THC stabilizes ERα in its agonist 
conformation but ERβ is in an antagonist conformation. This difference on its own is of 
significant interest, but the study also demonstrated that the reason for ERβ not adopting 
an agonist conformation was due to missing stabilizing interactions between the receptor 
and the ligand. They observe that in ERβ residues Leu476 and Met479 are not positioned 
correctly by the ligand to form interactions with relevant residues in helix-12 to stabilize its 
agonist conformation. The result is a failure of THC to stabilize the agonist conformation 
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of helix-12 and therefore a shift in the agonist-antagonist equilibrium. The fact that THC 
has such differing effects on two such similar receptors illustrates the challenge when 
following this or any of the five described approaches in drug-design.
3.3.5 Straighten helix-3, and/or disrupt interactions between helices-3 & 5
3.3.5.1 Case Study. The Mineralocorticoid Receptor
It is generally accepted that steroid-receptor activation is facilitated by interactions 
between helix-3 and helix-5. The correct positioning of the basic component of the 
charge clamp (Lys579 in GR and Lys785 in MR) and the formation of the hydrophobic pocket 
in which co-activators bind is dependent on a bend forming in the middle of helix-3. 
That bend in helix-3 is induced by a ligand mediated hydrogen bond to helix-5 via the 
3-keto group of steroidal ligands. It was initially believed that the importance of the 
classic interactions between the 3-keto group of steroids and the Glutamine (Glutamate 
in ERα and ERβ) and Arginine residues in steroid hormones was purely to ensure potent 
binding of the steroids, but the work of Bledsoe [40] and Huyet [53] have demonstrated 
that is also has a role in the agonism-antagonism balance. Huyet et al demonstrated that 
mutation of either Gln776 or Arg817 in MR to alanine results in previously ligand-mediated 
agonistic responses being lost. 
Bledsoe et al have further demonstrated the importance of this bend in helix-3 by 
characterizing the S810L mutation in MR. This mutation has the effect of stabilizing the 
agonist conformation of MR, rendering some antagonistic ligands to have an increased 
agonistic response. Their analysis shows that the role of the S810L mutation is to increase 
the hydrophobic stabilization between helix-3 and helix-5.
3.3.5.2 Additional Example
A recent X-ray structure publication from our group suggests that PR antagonism seen 
in a compound series can in part be explained by a loss of these same interactions [54].
3.4. Pictorial summary of five drug design approaches
3.4.1 Pictorial summary of five drug design approaches
The binding of Dexamethasone to the Glucocorticoid Receptor (GR) is shown to 
illustrate the five major routes for reducing agonist efficacy in steroid receptors via the 
destabilisation of the binding of co-activating proteins. Co-activating proteins bind in 
hydrophobic pocket on the surface of the ligand-binding domain (LBD) stabilised by a 
charge-clamp formed by residues Lys579 in helix-3 and Glu755 in helix-12. [1] Direct clashes 
between ligands and helix-12 prevent Glu755 from adopting its necessary position and thus 
prevent the formation of the charge clamp. It has been shown for some receptors that 
clashes with helix-12 result in the helix adopting a new orientation actually precluding 
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Figure 3.4: Binding of Dexamethasone (DEX) to GR
the binding of co-activators by binding in the required hydrophobic pocket. [2] It is 
probably therefore not a surprise that the positioning of helix-12 can be influenced by 
the residues that directly precede it. The loop before helix-12 influences its position and 
is clearly a hotspot that can influence degree of agonism by modifying the ligand. [3] 
Other interactions also help stabilise helix-12 in its agonist position. For example, in GR, 
there is a hydrogen-bond network from the ligand to Asn564 in helix-3 to Glu748 in the 
loop before helix-12. Disruption of this network, by perhaps removing the hydrogen-
bonding function in the ligand, can influence the stabilisation of helix-12. [4] In a number 
of nuclear receptors Helix-12 also makes direct hydrophobic interactions to the ligand. 
Loss of these interactions, by changing the properties of the ligand, can decrease the 
stabilisation of helix-12 and therefore alter the agonistic capability of the complex. [5] 
Finally, the first four approaches are directly or indirectly related to ensuring Glu755, as 
half of the charge-clamp, is correctly positioned. The second residue in the charge-clamp, 
Lys579, should not be overlooked. Lys579 is part of helix-3 which itself bends midway along 
its length. This bend is crucial for ensuring that Lys579 is in the correct position to form the 
charge-clamp. The bend in helix-3 is partly as a result of its interaction with helix-5. For 
GR this is largely mediated by a hydrogen-bond network between Gln570 in helix-3, the 
ligand and Arg611 in helix-5. Disrupting this network by modifying the ligand may influence 
the distortion in helix-3 and therefore the correct formation of the charge-clamp and 
therefore co-activator binding.
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3.5. Other structure-based design considerations
In addition to exploring the development of partial agonists, structure-based approaches 
continue to play an important role in the identification of new ligands via virtual 
screening approaches and other compound optimization tasks. An important lesson in 
this regard has been our change in understanding the dynamic nature of the steroid-
receptor binding pocket. We have seen examples of extensive induced fits for amongst 
others the glucocorticoid receptor which is able to bind ligands beyond the conventional 
confines of its binding pocket whilst remaining in an agonistic conformation [55-57]. 
The pocket, behind the crucial helix-3 and helix-5 binding residues, Gln570 and Arg611, is 
normally water filled. It has already been demonstrated to be a viable ligand-binding 
region with the potential to improve ligand potency. An interesting note regarding the 
exploration of the pocket is that GSK report difficulty in combining the use of this pocket 
with the maintenance of partial agonism [55]. PR has been shown to adapt to steroids 
baring bulky 17α groups [58] and Trp741 in AR adapts to different ligands, adopting a new 
position to open an additional channel in the receptor [59].
3.6. Conclusion
As we look to the future of rational and structure-based drug design for the steroid 
receptors there remain key areas and questions that will dominate research in the short 
to medium term:
Is each of the five described methods for generating partial compounds equally 
applicable for each of the receptors? It is generally considered true that ERβ is easier to 
antagonize than ERα. This is most likely due to the agonist conformation of ERβ being less 
intrinsically stable than ERα and therefore ensuring that ERβ is more sensitive than ERα 
in this respect [51]. Does the choice of the mechanism for instilling partiality affect the 
eventual biological activity? Does a compound with a 40% reduction in agonistic activity 
due to a clash with helix-12 have the same biological effect as a compound with a 40% 
reduction in agonism due to the loss of other stabilizing interactions?
As described earlier, partial agonists and antagonists are often poor candidates for 
co-crystallization Recently we have seen the first publications describing methods to 
circumvent this problem, either by introducing stabilizing mutations into the receptor 
[10,60-62] or by generating stable crystals of the receptor using a receptor stabilizing 
ligand and then exchanging this compound with other compounds of interest via soaking 
[11]. Both approaches have the potential to dramatically increase our understanding of 
the biological mechanisms underpinning partial agonism.
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Abstract 
The progesterone receptor is able to bind to a large number and variety of ligands 
which elicit a broad range of transcriptional responses ranging from full agonism to full 
antagonism and numerous mixed profiles in between. We describe here two new PR 
LBD X-ray structures bound to compounds from a structurally related but functionally 
divergent series, which show different binding modes corresponding to their agonistic or 
antagonistic nature. In addition, we present a third PR LBD dimer bound to an agonist in 
monomer A and an antagonist in monomer B, which display binding modes in agreement 
with the earlier observation that agonists and antagonists from this series adopt different 
binding modes. 
54    Chapter 4
4.1. Introduction
The Progesterone Receptor (PR) is a nuclear receptor, related most closely to the 
glucocorticoid receptor, androgen receptor and mineralocorticoid receptor [1]. PR has a 
primary role in pregnancy, both the initiation and maintenance of gestation [2], as well 
as other functions related to menstruation and the endometrium [3]. PR drug discovery 
has historically focused on three areas; the discovery of pure agonists for contraception, 
discovery of anti-progestins blocking the function of endogenous progesterone for 
pregnancy termination, and, more recently, the development of so-called selective 
progesterone receptor modulators (SPRMs) for a number of indications including uterine 
fibroids and endometriosis [2]. PR modulators continue to provide important medical 
interventions in a number of areas of reproductive medicine [4-5] with an outlook for 
application in other fields including oncology [6]. Clinically relevant PR modulators span 
a spectrum of function from full agonists through to full antagonists [7], with interest 
growing particularly in the development of compounds with mixed profiles [8-9]. The 
most comprehensively studied SPRMs are all steroidal, including compounds such as 
Asoprisnil [10], but, early accounts of non-steroidal SPRMs have been reported as well 
[11-12].
Identifying the molecular determinants for the ligand-induced switch between agonism 
and antagonism, and the infinite number of mixed profiles between, is an important 
step in enabling rational design of novel SPRMs, and is facilitated by structural biology 
studies of the progesterone receptor [13]. Nuclear hormone receptor structural biology 
has proven important in helping to understand the biology and function of this protein 
family including ligand-driven effects [14-19].
X-ray crystallography studies of PR bound to the 11β-substituted steroids; Asoprisnil [20], 
and RU486 [21], along with the full PR agonist Levonorgestrel [22] clearly indicate a crucial 
function for Met909 in the agonism/antagonism balance. This has also been shown to also 
be true for non-steroidal SPRMs [11-12]. Met909 sits within helix-12 at the C-terminal 
end of the ligand binding domain (LBD), and in the classic agonist conformation of the 
receptor, is oriented toward the ligand binding pocket. Met909 is typically the only helix-12 
residue directly in contact with ligands and the nature of these interactions appear to 
be a key determinant of the receptors function. Clashes between Met909 and ligands are 
likely to destabilize helix-12 [21], which results in a reduced agonistic response. It has 
even been suggested that the degree of clash with Met909 might correspond directly to 
the reduction in agonism [2], but this has yet to be shown categorically.
Our group’s earlier work on the discovery and optimization of a selective non-steroidal 
glucocorticoid receptor antagonist [23] resulted in the synthesis of a number of moderately 
active PR modulators including OrgA, OrgB and OrgC (see Table 4.1). Interestingly, OrgA is 
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Table 4.1: Cell based agonism and antagonism, shown for OrgA, OrgB and OrgC with data and 
structures for progesterone, norethindrone and RU486 shown as references. Agonism and 
antagonism shown as EC
50
 (nM) with percentage efficacies associated. Efficacy is measured 
by curve height at maximal effect and expressed as percentage of reference compound effect. 
>1000nM indicates no response at the highest tested concentration.
Compound Name PR-B Agonism 
EC
50
 (nM) & %Eff
PR-B Antagonism
EC
50
 (nM) & %Eff
Progesterone 0.7 & 93 >1000
Norethindrone 0.2 & 99 >1000
RU-486 >1000 0.1 & 96
OrgA 8.6 & 60 >1000
OrgB >1000 40 & 94
OrgC >1000 30 & 87
OrgD >1000 50 & 84
a partial PR agonist despite high chemical similarity to OrgB and OrgC, which are both full 
PR antagonists. Furthermore, earlier descriptions of non-steroidal PR antagonists tended 
to include mimics of the dimethylaniline moiety of RU486 [24], but neither OrgB nor OrgC 
have a likely replacement for this group. 
To investigate the molecular basis for antagonism in OrgB and OrgC and the lack of 
antagonism in OrgA, we have determined their X-ray crystal structures in complex 
with the agonist conformation of PR following a previously described soaking method 
[21]. Comparison of these structures, along with earlier structures of PR bound to 
norethindrone and RU486, indicate a basis for the antagonism of OrgB and OrgC, with a 
clear role for Met909. We also show that OrgA adopts a remarkably different binding mode 
to the other compounds from the series explaining its lack of antagonism.
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4.2. Materials and Methods
4.2.1 Expression and Purification of PR-LBD – The PR LBD, comprising residues 
678–933, was cloned in pET15b (Novagen). Expression was performed in Escherichia 
coli BL21(DE3) star (Invitrogen) in 2xYT medium by overnight induction at 20°C in the 
presence of 10 µM OrgA. Bacteria were lysed in buffer A (50 mM Tris, pH 7.8, 250 mM 
NaCl, 10% glycerol, 10 mM b-mercaptoethanol) with 0.4 mM pefabloc (Roche Applied 
Science) and 50 µM OrgA and purified on nickel-nitrilotriacetic acid. Fractions were 
eluted with buffer A with 100 mM imidazole. Elution fractions were collected and treated 
with 2.5 wt/wt % thrombin (Kordia) overnight at 4°C to cleave the N-terminal His tag. 
Thrombin was removed by adding benzamidine-Sepharose (GE Healthcare), centrifuging 
for 10 min at 5000g, and harvesting the supernatant. To make the final crystallization 
sample, the protein was dialyzed to buffer A to which 1mM EDTA, 1mM dithiothreitol, 
and 10 µM OrgA were added and subsequently concentrated in a stirring cell to about 
4 mg/ml as measured by its absorption at 280nm. The sample was stored at -70°C in 
aliquots of 50µl.
4.2.2 Crystallization – Crystals of the PR LBD in complex with OrgA were grown at 
room temperature from 3.5µl drops hanging over a mother liquor of 20–30% polyethylene 
glycol 3350, 0.1M Hepes, pH6.5, 100mM Mg
2
SO
4
 and 10% glycerol. Drops consisted of 
2µl of protein sample and 1µl of mother liquor and 0.5µl 40% 1,3-propanediol. Crystals 
usually appeared after about 3 days and were kite-shaped. One crystal was transferred 
to a cryoprotectant solution of 80% mother liquor and 20% glycerol, dipped in liquid 
nitrogen, and shipped for data collection to 1.65Å at 100K.
4.2.3 Ligand Replacement – Additional crystals of the PR LBD in complex with OrgA 
were collected and transferred to mother liquor to which 0.25mM of either compound 
OrgB or OrgC were added. 0.25mM is a significant excess of either compound. The crystals 
were stored in a sitting drop at room temperature. The solutions surrounding the crystals 
were replaced by fresh solution 10 times over a period of 2 weeks. After this period, the 
crystals were frozen as described above and shipped for data collection. The dataset for 
OrgB complex was collected to 2.0Å at 100K, and the data for OrgC complex was collected 
to 1.8Å at 100K.
4.2.4 Data Collection – All data were collected by the MXpress service of the 
European Synchrotron Radiation Facility, Grenoble, France. Structures were solved and 
refined using the CCP4i interface of the CCP4 software suite [25]. All figures have been 
generated using PyMOL (The PyMOL molecular graphics system, Schrodinger, LLC). Data 
is summarized in Table. 4.2.
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4.2.5 Cell-based activity measurements – PR agonist and antagonist data for OrgA, 
OrgB, OrgC, and the reference compounds, progesterone and RU486 have been measured 
following procedures outlined in earlier publications [26-28]. Agonism was measured via 
PR induced activation of a stably transfected murine mammary tumor virus-luciferase 
reporter in Chinese hamster ovary cells [27]. Org 2058, a PR agonist, [29] was used as a 
reference. Antagonism was determined by a decrease in Org 2058 induced activation, by 
competition with the compound of interest. Assays are run in a standardized fashion and 
results presented are the average of a duplicate test in two different experiments
4.3. Results and Discussions
4.3.1 Agonism and Antagonism are not Consistent across Series – In Vitro agonism 
and antagonism of OrgA, OrgB and OrgC has been measured in cell-based assays alongside 
Progesterone, Norethindrone and RU486 as references with a summary of results shown 
in Table. 4.1. Figure 4.1A shows the agonistic dose response curves for all six compounds 
with progesterone and norethindrone displaying a full agonist effect compared to no 
effect from RU486, OrgB and OrgC. The reverse is seen in the antagonistic assay with 
RU486, OrgB and OrgC displaying fully antagonistic responses and Norethindrone and 
Progesterone showing no effect. OrgA has the unique (amongst this set) profile of 
showing a partial agonistic response in the agonistic setting and no response in the 
antagonistic setting. The molecular basis of the PR partial agonism of OrgA compared 
to the full PR antagonism of OrgB and OrgC was not apparent, and their X-ray structures 
were determined to explain the basis for the differing functionality.
Figure 4.1: Compound activities on PR-driven MMTV-luciferase reporter activity. Assays were 
run in an agonistic mode (A) or an antagonistic mode (B). In the antagonistic mode, 0.1 nM Org 
2058 was added to activate the reporter. Reporter activities are expressed relative to the activity 
of a saturating concentration of Org 2058, which was set at 100 percent. The figure shows mean 
values and standard deviations from four replicate experiments.
58    Chapter 4
4.3.2 Structure of PR LBD Dimer Complexed to OrgA – The overall fold of the PR-
LBD homodimer bound to OrgA is identical to the structure bound to Norethindrone 
with an average root mean square deviation of 0.21Å for all equivalent Cα atoms. As for 
the previously described PR X-ray structures bound to non-steroidal ligands (12, 30, 31) 
OrgA binds within the traditional ligand-binding pocket in a similar manner to reference 
steroids as shown in Figure 4.2.
Figure 4.2: Figure 2 shows the 2F
o
- DF
c  
OMIT electron density maps around the ligand and Trp755 
in monomers A and B for each of the three complexes shown at 1.0 sigma. Trp755 is included 
as 3D reference to demonstrate that each of the ligands is shown in a comparable orientation. 
A is monomer A from the PR-OrgA complex and B is monomer B from the same complex. C is 
monomer A from the PR-OrgB complex and D is monomer B from the same complex. Trp755 is 
shown in a dual conformation for this monomer as indicated by the electron density map. E is 
monomer A from the PR-OrgC complex and F is monomer B from the same complex. Images 
were generated using Pymol. The ligand in monomer B is OrgC indicating a successful exchange, 
but the electron density indicates that monomer A still contains OrgA indicating that exchange 
did not occur in this monomer.
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OrgA makes a direct H-bond to Asn719 via its sulfonamide nitrogen in contrast to 
Norethindrone and RU486 that both require the presence of a water molecule to 
mediate interactions to this residue. Interaction with the equivalent residue in the 
Glucocorticoid Receptor (GR), Asn564, is a prerequisite for potent glucocorticoid activity. 
H-bond networks between ligands (normally 11-OH groups in steroids) and Asn564 and 
from Asn564 to Glu748 in the loop between helix-11 and helix-12 also appear crucial for 
mediating a full agonistic response in GR [34]. This interaction appears less important 
for progestagenic activity as demonstrated by the lack of any interaction between the 
endogenous ligand progesterone and Asn719 in PR [13].
Electron density maps around the ligand in monomers A and B of the classic dimer are 
shown in Figure 4.3A and Figure 4.3B. The maps account for the entire ligand and enable 
precise positioning of the ligand with high confidence. Published X-ray structures of PR 
bound to Norethindrone [32] and RU486 [21] show direct interactions between the 3-keto 
groups from each ligand to Gln725 and Arg766 as well as a structurally conserved water 
molecule completing complex H-bonding networks as shown in Figure 4.4A and Figure 
4.4B. OrgA, as shown in Figure 4.4C makes no direct H-bond to either Gln725 or Arg766 but 
rather relies on water-mediated interactions to these two residues via the previously 
described conserved water. This appears to be a result of the nitrogen overlaying more 
closely with the carbon at position three in the steroid than the carbonyl oxygen attached 
at this position as seen in Figure 4.2. Whilst this surely has an effect on the strength 
of interaction with Gln725 and Arg766 it does allow the methyl groups on the isoxazole 
to overlay well with the steroid scaffold, specifically positions 2 and 6 (labeled in Table 
4.1). This may have benefits in terms of potency by maximizing hydrophobic van der 
Waals contacts between the ligand and receptor. The implications of OrgA’s modified 
interaction with Gln725 and Arg766 are discussed below. 
Figure 4.6A also shows the pyrazole ring of OrgA reaching into the pocket occupied by 
17α groups from steroids such as the ethinyl group of Norethindrone [13]. OrgA also 
makes use of the space normally filled by 13-methyl groups in classic progestagenic 
steroids with one of the sulfonamide carbonyl oxygens oriented in close proximity and 
direction to the hydroxyl oxygen on the 17β position of Norethindrone. The sulfonamide 
carbonyl actually overlays closely with the carbonyl oxygen in the 17β-acetyl group of 
Progesterone with one the methyl group in the acetyl overlaying with one of the methyl 
substituents on the pyrazole of OrgA (not shown). Figure 4.7A shows an overlay OrgA 
from monomer A and monomer B demonstrating that no significant difference appears 
to exist between the 2 monomers in terms of ligand-binding
4.3.3 Clash with Met909 as a Contributing Factor to Partial Agonism of OrgA – OrgA 
is a PR agonist but shows reduced efficacy (60%) compared to Norethindrone and 
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Figure 4.3: Overview of the binding modes of A; Norethindrone, B; RU486, C; OrgA and D; 
OrgB. The three key H-bonding residues, Asn719, Gln725 and Arg766 are shown, along with water 
molecules directly H-bonding to ligands. The remainder of the protein is hidden for clarity. The 
norethindrone-PR complex is from the PDB, entry 1SQN [20] and the RU486-PR complex is also 
available in the PDB, entry 1W8Y [21]. Protein residues are shown with carbons in orange and 
ligands shown with carbons in green. All structures have been energy minimized using Yasara 
[33] and images were generated using Pymol.
Figure 4.4: Overlay of OrgA (carbons colored orange) compared to norethindrone (carbons 
colored green) in A and RU486 in B (carbons colored green). Protein-ligand complexes aligned 
using the Motif function in Yasara [33] and images were generated using Pymol.
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Progesterone (Figure 4.1). It has previously been shown that clashes between ligands and 
Met909 in Helix-12 of PR are a key determinant for reduced agonistic activity in steroidal 
PR antagonists and partial agonists [21]. OrgA lacks an obvious structural mimic of the 
dimethylaniline of RU486, or any of the other bulky 11β groups common to PR antagonists 
of SPRMs [2]. We did consider the possibility that either the isoxazole end of the ligand 
or more likely the pyrazole end might be oriented to overlay with the 11β-substituent of 
RU486, but comparison of PR-LBDs bound to both ligands demonstrates that this is not 
case as can be seen in Figure 4.2B. However, despite the lack of the classic bulky side-
chain, OrgA does still impede the agonist position of Met909 as determined by its position 
bound to Norethindrone, resulting in the residue having to adopt a modified orientation. 
As can be seen in Figure 4.8A, the methylene linker between the phenyl ring and the 
Figure 4.5: A: Norethindrone shown as sticks with the binding pocket of the PR-norethindrone 
complex shown as a surface. B: PR-OrgA complex overlaid with PR-norethindrone complex using 
the Motif function in Yasara [33]. OrgA is shown in stick format with the binding pocket of the PR-
norethindrone complex shown as a surface for comparison. C: PR-OrgB complex overlaid with 
PR-norethindrone complex using the Motif function in Yasara [33]. OrgB is shown in stick format 
with the binding pocket of the PR-norethindrone complex shown as a surface for comparison. 
Surface and images were generated in Pymol.
Figure 4.5: A: Norethindrone shown as sticks with the binding pocket of the PR-norethindrone 
complex shown as a surface. B: PR-OrgA complex overlaid with PR-norethindrone complex using 
the Motif function in Yasara [33]. OrgA is shown in stick format with the binding pocket of the PR-
norethindrone complex shown as a surface for comparison. C: PR-OrgB complex overlaid with 
PR-norethindrone complex using the Motif function in Yasara [33]. OrgB is shown in stick format 
with the binding pocket of the PR-norethindrone complex shown as a surface for comparison. 
Surface and images were generated in Pymol.
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sulfonamide nitrogen in OrgA is only 2.3Å from the terminal carbon in the side-chain of 
Met909 from the previously described full agonist conformation. This may be sufficient 
to partially disrupt the ideal agonistic packing of helix-12 and result in the reduced 
agonistic efficacy of OrgA (60%) compared to the reference steroids Progesterone and 
Norethindrone. The fact that the clash with Met909 is made by part of the central scaffold 
of the ligand might explain why of nearly 1000 compounds tested in this series, none have 
been identified as full PR agonists. The clash is not as significant as the clash between 
Met909 and RU486, shown in Figure 4.8C, in line with the observation that OrgA is a partial 
agonist and not a full antagonist. 
4.3.4 Soaking Experiments Resulted in Complete Exchange of OrgA by OrgB – In 
order to generate co-crystals of OrgB bound to PR we have taken PR-LBD crystals bound 
to OrgA and soaked in OrgB as described in earlier experiments [21]. To be sure complete 
exchange has occurred it was important to carefully analyze the electron density defining 
the position of the ligand to ensure that it is only compatible with the soaked ligand. OrgB 
has a disubstituted pyridine replacing the dimethyl-isoxazole of OrgA, with the larger 
ring system of the pyridine resulting in a different orientation of the attachments than 
we would expect to see if the isoxazole was still in place. Secondly, the pyrazole of OrgA 
has 3 substituents (2 methyl groups and a chlorine), but the electron density (as shown 
in Figure 4.3C and 3D) indicates a ring with 2 substituents at this end of the structure 
compatible with the dimethyl-isoxazole in OrgB. Finally, OrgB has an additional methyl 
group between the biaryl and sulfonamide ends of its structure which can be seen in the 
electron density of the ligand in monomer B most clearly, but also in monomer A at lower 
sigma levels. These observations together indicate that OrgB has completely displaced 
OrgA in the crystals.  
Figure 4.7: A: Overlay of OrgA from monomer A (shown with carbons colored green) and OrgA 
from monomer B (shown with carbons colored cyan) from X-ray structure-1. B: Overlay of OrgB 
from monomer A (shown with carbons colored green) and OrgA from monomer B (shown with 
carbons colored cyan) from X-ray structure-2. C: Overlay of OrgA from monomer A (shown with 
carbons colored green) and OrgC from monomer B (shown with carbons colored cyan) from 
X-ray structure-3. Images were generated in Pymol.
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44.3.5 Structure of PR LBD Dimer Complexed to OrgB – The successful soaking of 
OrgB into the OrgA co-expressed PR LBD X-ray structures did not result in any significant 
change in the structure of the receptor, despite the fact that OrgB is a full antagonist 
and OrgA is a partial agonist. As discussed in a previous publication [21] it is likely that 
the receptor exists in equilibrium between agonistic and antagonistic states with ligands 
at least partly driving that balance. Therefore, whilst the agonistic conformation of the 
receptor will not be the lowest energy conformation when bound to OrgB, it does remain 
a thermodynamically accessible conformation, even if only present at low concentration. 
A number of clashes between OrgB and the receptor are present in this structure. 
These include a clash between the fluorine from the ligand with Val760, a clash with 
the backbone oxygen of Leu715 and a final clash with Met756. This is in contrast to the 
OrgA structure, which includes only a moderate clash with Cys891, indicating that OrgA 
is better tolerated in the agonistic form of PR than OrgB. Physiologically it is likely that 
Helix-12 is displaced on binding of OrgB, relieving these clashes and by the adoption of 
the antagonist conformation of the receptor.
4.3.6 Comparison of Binding mode of OrgA compared to OrgB –  As for OrgA, OrgB 
makes a direct H-bond to Asn719 via the nitrogen of its sulfonamide group shown in 
Figure 4.3D. Unlike for OrgA, the conserved water molecule between Gln725 and Arg766 is 
not present. Instead, the pyridine nitrogen of OrgB makes a direct H-bond to Gln725, an 
interaction only possible due to the movement of the residue in this structure compared 
to PR-OrgA, PR-RU486 and PR-Norethindrone structures described earlier. Despite this 
interesting difference, the most striking change between the binding of OrgA and OrgB 
was observed around their sulfonamides and the hetero-aryl groups attached to them. 
As outlined earlier, the pyrazole group of OrgA is directed toward the so called 17α 
pocket, but for OrgB, the isoxazole equivalent to this group is directed in a distinctly 
different direction toward Trp755. Despite this significant difference, the two observed 
Figure 4.8: A: Overlay of PR-norethindrone complex (carbons colored green) with PR-OrgA 
complex (carbons colored cyan). Met909 from the PR-norethindrone complex is shown along 
with the ligands. Helix-12 is shown as a red cartoon. Distance between the ε-carbon in Met909 
and the nearest heavy atom in OrgA is shown. B: As per image A, but PR-OrgA complex replaced 
by PR-OrgB. C: As per image A, but PR-OrgA complex replaced by RU 486 Measurements were 
made and images generated in Pymol.
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binding modes for the series share a number of key characteristics. Both are able to mimic 
the 3-keto group of steroids, they both make use of the hydrophobic region around the 
steroidal position 13, make a direct H-bond to Asn719 via the nitrogen of the sulfonamide 
group, and position a carbonyl from the sulfonamide in the same region as the oxygen in 
either the 2 different 17β groups of Progesterone and Norethindrone.
Figure 4.7B shows the overlay of OrgB from monomer-A and monomer-B, demonstrating 
that they are practically identical. Despite this, their binding mode, directed toward 
Trp755, has a different effect depending on the monomer. Specifically, in monomer-B, 
Trp755 shows a double conformation, presumably as a result of the close proximity of the 
ligand. This "flipping" of Trp755 has previously been observed [30], but does not appear to 
correlate with any change in agonism or antagonism.
4.3.7 Clash with Met909 as a Contributing Factor to Full Antagonism of OrgB – Despite 
adopting a different binding mode to OrgA, OrgB still clashes with Met909 in the classic 
agonistic position, but now via one of the methyl groups on the isoxazole ring as shown 
in Figure 4.8B. In fact, compared to a partial agonist like OrgA, the clash between OrgB 
and Met909 appears slightly more significant and likely to be a contributing factor to the 
full antagonism seen in this series. The clash is still not as significant as the clash between 
Met909 and RU486 and it is therefore likely that there are other additional factors that 
render OrgB as a full antagonist compared to the partial agonist OrgA.
4.3.8 Disrupted Interaction between Helix-3 and Helix-5 as a Contributing Factor in 
the Reduced Agonism of OrgA and OrgB  – Agonism in steroid receptors is at least in part 
dependent on the stabilization by interactions between helices 3 and 5. This has most 
clearly been shown for the mineralocorticoid receptor [35-39], a very close relation of PR. 
A key aspect of the helix-3 to helix-5 interaction is the ligand, and often water, bridged 
interaction between Gln725 in helix-3 and Arg766 in helix-5. As previously discussed, and 
shown in Figure 4.4A, agonistic steroids such as Norethindrone participate in directly 
mediating an H-bond network between these two residues via their 3-keto groups. This 
appears to result in the bending of helix-3, and the correct orientation of the charge-
clamp residue Lys734. Lys734 in helix-3 and Glu911 in helix-12 are in part responsible for the 
binding of comodulating proteins by capping either end of classic LXXLL binding helices 
present in comodulators. Neither OrgA nor OrgB faithfully reproduce the important 
H-bond network between Gln725 and Arg766 which may certainly contribute to their 
reduced agonistic efficacy compared to full agonists. For the full antagonist OrgB, no 
interaction between Gln725 and Arg766 is retained, but the partial agonist OrgA does retain 
the often conserved water molecule, allowing for a partial retention of the network. It 
may be possible that this difference contributes to the difference we see in function of 
OrgA compared to OrgB.
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4.3.9 Molecular Basis for Differences in Binding Modes – Understanding the basis for 
the switch in binding mode, which appears to result in a switch from partial agonism to 
full antagonism, was our next goal. An obvious difference between OrgA and the two full 
antagonists is the presence of an extra stereo centre in the latter, due to the presence 
of an additional methyl group between the biaryl and sulfonamide substructures. The 
binding mode of OrgB orients this methyl group toward Leu715 in an area of the pocket 
well able to tolerate its presence. On the other hand, examination of the binding mode 
Structure PR-OrgA PR-OrgB PR-OrgC
Compound(s) OrgA OrgB OrgC & OrgA
Space group P2
1
P2
1
P2
1
Unit cell (Å3) 57.79 X 64.24 X 69.98 56.305 X 64.114 X 69.932  56.25 X 64.06 X 69.69
β-Angle (°) 95.67 96.53 96.62
Resolution (Å) 47.193 - 1.65 (1.74-1.65)  28.12 - 1.9 (1.97- 1.9) 46.17-1.80 (1.9-1.8)
Completeness 95.2% (63.1%) 97.4% (95.5%) 96.5% (95.8)
Rpima 0.038 (0.291) 0.067 (0.388) 0.042 (0.206)
Mn(I/σ) 14.4 (2.8) 9.3 (2.6) 12.9 (3.5)
R factor/Rfreeb 0.177 / 0.206 0.213/.248 0.184/0.221
Atoms 4571 4206 4384
Protein atoms 4135 4062 4077
Ligand atoms 52 54 52
Water molecules 350 85 226
Other molecules (#atoms)
e.g. glycerol 64 5 29
r.m.s.d. bonds, Å 0.01 0.01 0.007
r.m.s.d. angles (°) 1.2 1.128 1.17
B-factors (average Å2 )
Main chain 5.4 20.7 12.2
Side chain 7.8 22.2 14.3
Water molecules 17.4 24.3 21
Ligand A-chain 12.3 37.5 18.5
Ligand B-chain 7.2 45.6 25
Wilson B-factor (Å2) 18.3 30 21.8
PDB identifier 3ZR7 3ZRA 3ZRB
Table 4.2: Final crystallographic data and refinement statistics. Data in parentheses indicate 
the last resolution shell. r.m.s.d. means root mean square deviation.
a Rpim is an indicator of the precision of the final merged and averaged dataset.
b Rfree was determined using 5% of the data.
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of OrgA, shows that the methyl group of OrgB would not be tolerated in this binding 
mode, most likely clashing with Cys891, Trp755 and Met756. Whilst Trp755 could adopt a 
second position that would relieve this clash, the Cys891 clash would remain unresolved. 
We therefore conclude that the presence of this methyl group results in the compound 
series adopting a second binding mode that is only compatible with a displacement of 
helix-12 and therefore induce full antagonism.
4.3.10 Antagonism of OrgD confirms importance of methyl group in determining 
function – OrgD is identical to the agonist OrgA except for the addition of a methyl 
group branched from the carbon atom next to the nitrogen atom in the sulfonamide 
substructure. PR agonism and antagonism was measured for OrgD (Figure 4.1) following 
the earlier described procedure which clearly identifies this compound as a PR antagonist. 
This experiment confirms the importance of the methyl group in differentiating between 
PR agonism and antagonism and therefore supports the structural biology conclusion 
that this methyl induces a different binding mode for the series which results in a switch 
from agonism to antagonism.
4.3.11 Structure of PR LBD Dimer Complexed to OrgA and OrgC  – Following the same 
procedure described for OrgB, we attempted to soak OrgC into PR-LBD co-crystallised 
with OrgA. Analysis of the resulting electron density indicated clearly that OrgC had fully 
replaced OrgA in monomer-B as hoped, but that OrgA was still present in monomer-A. In 
our previous study, RU486 was able to exchange fully with Norethindrone in monomer-B 
but did not replace the co-expressed ligand in monomer-A [21]. It has previously been 
postulated that this difference in success is a result of monomer-B being more open than 
monomer-A [21].
OrgA in monomer-A of this third X-ray structure remains in the same orientation that 
we have seen earlier for the binding of OrgA in PR. OrgC, on the other hand, adopts the 
binding orientation of OrgB as shown in Figure 4.3E and Figure 4.3F. The overlay of the 
ligands from the 2 monomers, demonstrating the divergent binding modes of compounds 
from the same series bound to the same dimer is shown in Figure 4.7C. As the monomer 
with the successful soaking of the full antagonist OrgC adopts the same binding mode 
as the full antagonist OrgB we presume that they also share the mechanism for their 
antagonism. Interestingly though, whilst we see a flip of Trp755 in monomer-B bound to 
OrgB, we do not see the same flipping of Trp755 in the same monomer when bound to 
OrgC. 
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4.4. Conclusions
We describe here three new PR LBD X-ray structures bound to three structurally related 
but pharmacologically different compounds, including the first reported structures of 
PR bound to non-steroidal antagonists. The agonist and antagonist compounds display 
distinct binding modes, with the antagonists displaying a more profound clash with 
Met909 from helix-12 than a partial agonist from the same series. The clash with Met909 
reinforces the key role of this residue in the switch between agonism and antagonism of 
PR ligands as previously shown for 11β-steroids [21] and other non-steroidal antagonists. 
The ability to tolerate two distinct binding modes is further evidence of the plasticity of 
the steroid receptor binding pocket
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Abstract
We present here the X-ray structures of the progesterone receptor (PR) in complex with two 
mixed profile PR modulators whose functional activity results from two differing molecular 
mechanisms. The structure of Asoprisnil bound to the agonist state of PR demonstrates 
the contribution of the ligand to increasing stability of the agonist conformation of 
helix-12 via a specific hydrogen-bond network including Glu723. This interaction is absent 
when the full antagonist, RU486, binds to PR. Combined with a previously reported 
structure of Asoprisnil bound to the antagonist state of the receptor, this structure 
extends our understanding of the complex molecular interactions underlying the mixed 
agonist/antagonist profile of the compound. In addition, we present the structure of PR 
in its agonist conformation bound to the mixed profile compound Org3H whose reduced 
antagonistic activity and increased agonistic activity, compared to reference antagonists, 
is due to an induced fit around Trp755, resulting in a decreased steric clash with Met909, 
but inducing a new internal clash with Val912 in helix-12. This structure also explains the 
previously published observation that 16α attachments to RU486 analogs induce mixed 
profiles by altering the binding of 11β substituents. Together these structures further our 
understanding of the steric and electrostatic factors which contribute to the function of 
steroid-receptor modulators, providing valuable insight for future compound design.
5.1. Introduction
Modulation of the progesterone receptor (PR) is the mechanism of action for an array 
of medications and continues to be a fertile area for research, with special focus on 
the development of mixed profile compounds [1-3]. Mixed profile modulators of PR 
are characterized by decreased transcriptional activity compared to full agonists and 
increased transcriptional activity compared to full antagonists. Partial agonists, often 
referred to as selective progesterone receptor modulators (SPRMs), have the potential 
to treat a variety of women’s health conditions [4-7] with improved safety and treatment 
profiles compared to full agonists or antagonists.
Asoprisnil (Figure 5.1), demonstrating a mixed agonist/antagonist profile depending on 
tissue type, was the first SPRM to progress to late stage clinical development for the 
treatment of uterine fibroids and endometriosis [8-14]. However, the mixed profiles of 
SPRMs are often poorly reflected in classical in vitro models [15]. In our hands Asoprisnil 
is a full PR antagonist in cell-based transactivation assays (PR ago EC
50
 >100nM, PR 
ant EC
50
 0.14nM with 96% efficacy compared to a standard reference [16]) but can 
be characterized as a SPRM by differences in in vivo models such as the McPhail test 
(measuring endometrial proliferation in immature rabbits) compared to the full antagonist 
RU486 [17]. It has also been shown clinically that Asoprisnil mediates unique endometrial 
effects in healthy pre-menopausal women [17]. Difficulties in characterizing SPRMs in 
vitro have historically made their identification and characterization problematic, but 
traditional methods of steroid receptor drug discovery, designed to identify agonists and 
antagonists, are now being supplemented by new design approaches and assay types, 
including peptide recruitment and gene expression, better suited to characterizing mixed 
profile compounds [15].
Figure 5.1: The structures of (a) Progesterone, (b) Norethindrone, (c) RU486, (d) Asoprisnil, (e) 
Org3H and (f) OrgA.
A B
C
E
D
F
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The shared domain structure of steroid receptors, such as PR, includes a variable 
N-terminal domain, a highly conserved DNA-binding domain and a moderately conserved 
ligand-binding domain (LBD). The LBD combines a number of functions, including 
hormone binding, receptor dimerization and binding to other co-modulating proteins 
that play a role in the control of transcription. Specifically, gene activation requires the 
recruitment of co-modulating proteins to a region of the surface of the LBD formed 
by helices 3, 5 and 12. The position of helix-12 can be influenced by the nature of the 
ligand bound to the receptor allowing ligands to influence the binding of co-modulators 
and consequently gene activation. Our understanding of ligand-binding to PR has been 
improved by a number of X-ray crystallography studies [18-23] that have also furthered 
our understanding of the molecular mechanisms underpinning antagonism and partial 
agonism [16, 17, 24-26]. In particular, it is well accepted that clashes between some 
ligands and Met909 in helix-12 is a major contributing factor to reduced agonistic activity.
One important recent publication describes the X-ray structure of Asoprisnil bound to 
the antagonist conformation of PR in the presence of the co-repressors NCoR and SMRT 
[17]. The authors report the PR ligand-binding domain (LBD) in a conformation divergent 
from the classical agonist state explaining the reduced agonistic activity of the compound 
compared to full agonists. However, the structure gives only limited explanation for the 
compound’s increased agonistic activity compared to other fully antagonistic 11β-steroids. 
The X-ray structure of Asoprisnil bound to the antagonistic conformation of PR shows 
the ligands polar oxime group to be in close contact to hydrophobic residues in the two 
described co-repressors (NCoR and SMRT) [17]. RU486 has a less polar dimethyl amine 
group in the position equivalent to Asoprisnil’s oxime, leading the authors to hypothesize 
that RU486 might make stronger hydrophobic contacts to co-repressors and therefore 
facilitate their recruitment, thus explaining the differing biological activity of the two 
compounds.
The same report demonstrates that Asoprisnil bound PR does recruit co-activators 
such as SRC1. The ability for the Asoprisnil-PR complex to recruit co-activators suggests 
the complex is able to adopt an agonistic conformation in addition to the antagonist 
conformation seen when in complex with co-repressors. This is in line with the equilibrium 
model for partial agonism [16,27] which suggests that mixed profile compounds are 
able to partially stabilize their receptors in the agonist conformation, compared to the 
complete stabilization elicited by full agonists. This results in altered patterns of co-
modulator recruitment and modified biological outcomes. It also suggests that whilst 
the agonistic conformation of PR bound to Asoprisnil may not be the lowest energy, it 
remains biologically meaningful.
In an attempt to identify the basis for the ligands retained agonistic activity compared to 
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full antagonists such as RU486 (Figure 5.1) we have used a previously described soaking 
technique [16,26] to determine the X-ray structure of the PR-Asoprisnil complex in its 
agonist state. This has allowed us to identify an interaction between the 11β-benzaldoxime 
of Asoprisnil and Glu723 that helps partially stabilize helix-12 in its agonist conformation.
To establish if this mechanism is universal for 11β substituted steroids we have also solved 
the X-ray structure of an in house SPRM from a class of 11-pyridinylphenyl steroids, 
(17β-cycloproplycarbonyl-16α-ethenyl-11β-[4-(3-pyridinyl)phenyl]-estra-4,9-dien-3-one) 
which we refer to as Org3H (Figure 5.1), with a previously disclosed mixed PR profile (PR 
ago EC
50
 0.66nM with 47% efficacy, PR ant EC
50
 0.61nM with 38% [28]).
Elucidation of Org3H in complex with PR revealed a second mechanism to explain its 
mixed profile compared to full antagonists, with Org3H making a reduced clash with 
Met909 due to an induced fit around Trp755 which itself now clashes with Val912 in helix-12. 
As a further consequence, the flipping of Trp755 results in formation of an additional new 
sub-pocket.
Together these structures improve our molecular understanding of the important steric 
and electrostatic factors contributing to the mixed profile seen for many PR modulators.
5.2. Materials and Methods
5.2.1 Expression and Purification of PR-LBD
The PR LBD, comprising residues 678–933, was cloned in pET15b (Novagen). Expression 
was performed in Escherichia coli BL21(DE3) star (Invitrogen) in 2xYT medium by 
overnight induction at 20°C in the presence of 10 µM OrgA (Figure 5.1). OrgA is a member 
of a compound class described as glucocorticoid receptor antagonists [28], but is a 
relatively potent PR partial agonist whose activity is described in a recent article [26]. 
Bacteria were lysed in buffer A (50 mM Tris, pH 7.8, 250 mM NaCl, 10% glycerol, 10 
mM b-mercaptoethanol) with 0.4 mM pefabloc (Roche Applied Science) and 50 µM OrgA 
and purified on nickel-nitrilotriacetic acid. Fractions were eluted with buffer A with 100 
mM imidazole. Elution fractions were collected and treated with 2.5 wt/wt % thrombin 
(Kordia) overnight at 4°C to cleave the N-terminal His tag. Thrombin was removed by 
adding benzamidine-Sepharose (GE Healthcare), centrifuging for 10 min at 5000g, and 
harvesting the supernatant. To make the final crystallization sample, the protein was 
dialyzed to buffer A to which 1mM EDTA, 1mM dithiothreitol, and 10 µM OrgA were 
added and subsequently concentrated in a stirring cell to about 4 mg/ml as measured by 
its absorption at 280nm. The sample was stored at -70°C in aliquots of 50µl.
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5.2.2 Crystallization – Crystals of the PR LBD in complex with OrgA were grown at 
room temperature from 3.5µl drops hanging over a mother liquor of 20–30% polyethylene 
glycol 3350, 0.1M Hepes, pH6.5, 100mM Mg
2
SO
4
 and 10% (v/v) glycerol. Drops consisted 
of 2µl of protein sample and 1µl of mother liquor and 0.5µl 40% 1,3-propanediol. Kite-
shaped crystals usually appeared after about 3 days.
5.2.3 Ligand Replacement – Crystals of the PR LBD in complex with OrgA were collected 
and transferred to mother liquor to which 0.25mM of either Asoprisnil or Org3H were 
added. 0.25mM is a significant excess of either compound. The crystals were stored in a 
sitting drop at room temperature. The solutions surrounding the crystals were replaced 
by fresh solution 10 times over a period of 2 weeks. After this period, the crystals were 
frozen and transferred for data collection.
5.2.4 Data Collection – Diffraction data were collected using a Rigaku rotating-anode 
X-ray generator operating at 100mA and 50kV. The dataset for the PR-Asoprisnil complex 
was collected to 2.08Å at 100K and processed with mosflm/scala, and the data for the 
PR-Org3H complex was collected to 1.9Å at 100K and processed with d*TREK/scala [29]. 
Structures were solved and refined using the CCP4i interface of the CCP4 software suite 
[30]. Data is summarized in Table 1. Though of similar resolution, the Asoprisnil dataset is 
somewhat weaker than the Org3H dataset and less water molecules were used describe 
the electron density.
5.2.5 Modeling and Visualization – All figures have been generated using PyMOL (The 
PyMOL molecular graphics system, Schrodinger, LLC). Ligands structures were optimized 
using the semi-empirical quantum mechanical MOPAC module in YASARA [31]. YASARA 
was also used to calculate ligand volumes, with all figures representing the volume of the 
solvent accessible surface.
5.3. Results and Discussions
5.3.1 Size of 11β group does not correlate to antagonistic activity  – The generally 
accepted mechanism for introducing PR antagonism into steroidal and non-steroidal 
compounds is via the attachment of a bulky group at the steroids 11β position, or an 
equivalent position in non-steroidal compounds. This group should clash with helix-12 
and preclude it from adopting its agonistic conformation. Impeding helix-12 from 
adopting its agonistic position prevents the correct formation of the AF-2 surface and 
thus excludes the binding of co-activators. This mechanism is supported by the X-ray 
structures of PR bound to RU486 [16] and Asoprisnil [17], and structures of related 
receptors such as the androgen receptor (AR) and glucocorticoid receptor (GR) [32-34]. 
However, it has become clear to us that not all bulky groups are equal in this respect, 
and that more subtle factors must determine how successfully each substituent is able 
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to preclude helix-12. For example, the side-chain of the antagonist RU486 has a volume 
of 436Å3 which, whilst larger than the side-chain of the SPRM Asoprisnil at 385Å3, is 
somewhat smaller than the side chain of the second SPRM Org3H at 504Å3.
This inconsistency suggests that steric contributions alone do not guarantee the 
generation of full antagonists. It also suggests that other factors must be involved in the 
inducement of mixed profiles, and that understanding these factors may help future 
design of SPRMs. This promoted us to review the available X-ray studies and generate 
new X-ray structures to address this question.
5.3.2 The equilibrium model for steroid-receptor function suggests both agonistic 
and antagonistic conformations are relevant for mixed profile compounds  – It has 
been known since the early 1990’s that agonists and antagonists induce different 
conformational changes in PR [35,36] with the demonstration that the C-terminal 
is able to adopt two different positions corresponding to the biological activity of the 
ligand [35,37]. Both of these conformations are distinct from the conformation of the 
unliganded. It was later shown that a third conformation could be detected in the presence 
of 16α-substituted analogs of RU486 [38] known to be mixed-profile PR modulators. It 
has since been postulated that full agonists promote interaction with co-activators and 
full antagonists change the conformation of the receptor to inhibit co-activator binding 
in favor of co-repressor binding [10]. In relation to this, mixed-profile compounds induce 
an intermediate state of interaction between receptor and co-modulators [38-40]. The 
equilibrium model for nuclear receptor agonism/antagonism suggests that mixed profile 
ligands partly stabilize the agonist conformation of their receptor [16,27] and allow co-
activators to bind but with less efficacy than full agonists. The ability for the Asoprisnil-PR 
complex to recruit co-activators [17] suggests the complex is able to adopt an agonistic 
conformation in addition to the antagonist conformation seen when in complex with co-
repressors. It has also been shown for the steroid-receptors that the presence or absence 
of co-modulating proteins can alter the specific conformation of structures resulting from 
X-ray crystallography even after co-expression studies. For example, the X-ray structure 
of Genistein bound to the estrogen receptor-beta has been reported in an agonist 
conformation in the presence of co-activator but also in a conformation similar to the 
classic antagonist conformation in the absence of co-activator [41,42]. The binding of co-
modulating proteins is itself a driving force in the equilibrium and not just a consequence. 
The relative balance of co-activator and co-repressor expression within a given target 
cell determines the relative agonist vs antagonist activity of mixed-profile compounds 
[40]. Whilst the previously reported structure of PR bound to Asoprisnil, resulting from 
co-expression studies, shows the receptor in an antagonist conformation, it is in the 
presence of co-repressor. The ability of the PR-Asoprisnil complex to recruit co-activators 
indicates the agonist conformation of the receptor bound to Asoprisnil is both viable 
79Mixed Profile 11β-Steroidal PR Modulators
 
Ch
ap
te
r 
5
and biologically meaningful. This conclusion led us to utilize our previously described PR 
soaking method [16,26] to study Asoprisnil bound to a fixed agonistic conformation of 
PR in order to determine if this structure would give additional insight into the molecular 
basis for Asoprisnil’s retained agonism compared to RU486.
5.3.3 Asoprisnil successfully replaces OrgA during soaking experiments  – OrgA is a 
nonsteroidal compound (Figure 5.1) with a chemical structure distinct from 11β-steroids 
whose PR activity and binding is well described in an earlier publication which we refer 
readers to [26]. PR forms homodimers endogenously and also after crystallization. Figure 
5.2 shows the electron density around Asoprisnil from the B monomer of a new X-ray 
structure of PR in its agonistic conformation. The clarity of the electron density around 
the ligand allows us to conclude with a high degree of confidence that OrgA has been 
completely replaced by Asoprisnil during the soaking. The exchange is complete for 
both monomers with the ligand in an almost identical binding mode. To aid comparison 
with the previously published RU486 structure, in which the ligand soaks into only the 
B monomer, we will describe only the equivalent monomer from the new PR-Asoprisnil 
complex.
Helix-12 is well-ordered in its agonist conformation – This PR Asoprisnil complex is 
quite different from the public PR-Asoprisnil structures (PDB access codes: 2OVH and 
2OVM) and from the PR-RU486 structure (2W8Y). The difference between the previously 
published PR-Asoprisnil structures and this new structure are mainly located between 
residues 881 and 924, as the classic antagonistic displacement of helix-12 does not occur 
in this new structure (Figure 5.3). Excluding the c-terminal residues after helix-11, the 
PR-ago and PR-ant structures bound to Asoprisnil show a root mean square deviation 
(RMSD), calculated for their Cα atoms, of 0.65Å. Helix-12 is well ordered and in the 
agonist conformation compared to the poorly ordered helix-12 as observed when bound 
Figure 5.2: Figure 2 shows the 2Fo-DFc OMIT electron density maps around the ligand and 
Met909 for: A RU486, B Asoprisnil and C Org3H shown at 1.0 sigma. Electron densities suggest 
a more stable conformation of Met909 in the Asoprisnil and Org3H structures compared to the 
RU486 complex.
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to RU486. This is consistent with Asoprisnil’s reduced antagonistic activity and its ability 
to recruit co-activators. There is however disorder in region 895-905, the connecting 
loop between helix-11 and helix-12 of both monomers in the crystal. The loops of both 
monomers touch through a symmetry contact and are also disordered in both PR-ant 
structures bound to Asoprisnil.  
5.3.4 Soaking Asoprisnil into PR-Agonist crystals results in the same ligand-binding 
mode as co-expression  – Despite the new PR-Asoprisnil structure being in an agonistic 
conformation rather than the antagonistic conformation of the previously reported PR-
Asoprisnil structures [17] the binding mode of the ligand is comparable. Asoprisnil orients 
itself almost identically within the agonist and antagonist conformations of PR, making 
the same contacts with the receptor. The 3-keto group makes the classic interactions to 
Gln725 and Arg766 typical for oxosteroids, with the 17α attachment occupying a hydrophobic 
pocket consisting of Leu715, Leu718, Phe794, Leu797, Met801 and Tyr890 (Figure 5.4). This 
pocket, referred to as the 17α pocket, has previously been described for a structure of PR 
bound to Mometasone Furoate [21] and appears to provide additional room for ligand 
expansion irrespective of agonism or antagonism.
No direct or indirect polar interaction exists between the ligand and Asn719. The presence 
of a water-bridged interaction between steroidal ligands and Asn719 has been described 
in other PR-ligand complexes, including the binding of RU486 and Norethindrone [26], 
Figure 5.3: A shows the secondary structure of the PR-Asoprisnil complex generated by a soaking 
experiment described in this article. Helix-12 is colored red and is oriented in the classic agonist 
conformation. B shows the secondary structure of a previously described PR-Asoprisnil complex 
generated (2OVH) by co-expression with the ligand. Helix-12 is colored red and is shifted from 
the agonist position to allow the binding of a co-repressor peptide colored blue. Protein-ligand 
complexes were aligned using the Motif function in Yasara [31] and images generated using 
Pymol.
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but the 17β-methoxy group of Asoprisnil sterically precludes the presence of a water 
molecule at this position.
As can be seen in Figure 5.5, the steroid scaffolds of Asoprisnil from both the PRago 
and PRant complexes are relatively well overlaid with a small shift downward seen in 
Asoprisnil bound to the agonist conformation of PR. The 17α and 17β attachments 
of both compounds are also well overlaid. The most significant difference between 
Asoprisnil bound to the agonist conformation and the antagonist conformation of PR is a 
Figure 5.4: Binding mode of Asoprisnil with hydrogen bonding from Gln725 and Arg766 to the ligands 
3-keto group highlighted in magenta. Residues forming a hydrophobic pocket surrounding the 
17α group are also shown.
Figure 5.5: Asoprisnil from the PR-agonist conformation is shown (carbons colored green) and 
overlaid with Asoprisnil from the PR-antagonist conformation (carbons colored magenta). 
Asoprisnil from the PR-agonist conformation sits slightly lower in the pocket compared with 
Asoprisnil from the PR-antagonist conformation.
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0.9Å adjustment in the position of the oxime group. In the agonistic complex the oxime, 
and steroid core, appear to sit lower to reduce the clash with Met909 in helix-12. Due to 
the displacement of helix-12 in the antagonistic complex this clash is not possible
5.3.5 Met909 is better ordered in the Asoprisnil complex compared to equivalent 
RU486 structure  – In the past our group published an X-ray structure of RU486 bound 
to the agonist conformation of PR [16] which clearly demonstrated disorder of Met909 
in helix-12 due to a clash with the ligand (Figure 5.2A). This clash resulted in the 
destabilization of helix-12, measured by an increase in the b-factors of the helix compared 
to helix-12 bound to previously described full agonists. This provided a compelling model 
to explain the antagonistic activity of RU486.
Met909 in the PR-agonist complex bound to Asoprisnil does adopt a modified conformation 
compared to its position bound to other full agonists, but the new rotamer is well ordered 
as can be seen when comparing the electron density of each complex, shown in Figure 
5.2. The increased order of helix-12 and particularly Met909 in the Asoprisnil structure is 
consistent with the increased agonistic activity of the ligand compared to RU486.
As we investigated the molecular basis for this difference we considered the possibility 
that the reduced volume of Asoprisnil’s oxime, and its linear rather than branched nature, 
compared to the dimethylamine of RU486, may reduce its clash with Met909. However, 
Figure 5.6: Overlaid structures of PR-agonist structure bound to RU486 (carbons colored orange) 
compared to PR-agonist structure bound to Asoprisnil (carbons colored green). Hydrogen bonds 
between the ligand’s keto groups to Gln725 and Arg766 are shown in magenta. Helix-12 colored 
red with Met909 highlighted in both complexes (carbons colored red). The ligands overlay closely 
and appear to sterically impact on Met909 to a similar degree.
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comparison of the overlaid ligands does not suggest a significant difference in their spatial 
arrangements around the position of Met909 (Figure 5.6) and therefore other factors must 
be responsible which will be discussed in the following section.
5.3.6 Asoprisnil’s oxime group contributes to stabilization of Helix-12 in its agonistic 
conformation  –  As previously described [16,43] Glu723 in helix-3 plays an important role 
in stabilizing the agonist conformation of helix-12 by hydrogen-bonding to main chain 
amines in both Met908 and Met909 (Figure 5.7A). In addition, Glu723 is also able to make a 
hydrogen-bond to a water molecule in the bulk solvent. In the antagonistic conformation 
of PR bound to Asoprisnil, Glu723 points away from the ligand to make polar contacts 
with the solvent and, due to the displacement of helix-12, no longer makes stabilizing 
interactions to Met908 and Met909.
In the agonistic conformation of PR bound Asoprisnil, Glu723 is as expected stabilizing the 
agonist position of helix-12, but additionally, makes a hydrogen-bond to the ligand’s oxime 
group (Figure 5.7B). In this new state Glu723 strengthens the hydrogen-bond network that 
stabilizes helix-12 in its agonistic position. This interaction is not duplicated on binding of 
RU486 which suggests the agonist conformation of PR bound to Asoprisnil is more stable 
than the agonist conformation of PR bound to RU486. This relative increased stability of 
the agonist conformation when bound to Asoprisnil explains the ability of this complex to 
recruit co-activators and suggests the existence of the interaction with Glu723 pushes the 
receptor’s equilibrium toward agonism compared to RU486.
5.3.7 Glu723 is equivalent to Asp351, a residue crucial for the agonist/antagonist 
balance in ERα  –  Glu723 in PR is equivalent, based on sequence and structure alignments, 
to Asp351 in the estrogen receptor alpha (ERα) which plays a similar role in stabilizing the 
agonist conformation of helix-12. The importance of this residue has been demonstrated 
by studying the naturally occurring D351Y mutation and other synthetic mutations, which 
result in a loss of the receptors agonistic activity, consistent with the residues normal 
role in stabilizing the agonist conformation of the receptor. Selective modulators of 
ERα, referred to as SERMs and including Raloxifene and Tamoxifen contain an important 
basic amine function which is almost ubiquitous amongst this drug class. The role of 
this nitrogen is to form a salt-bridge to Asp351, requiring the amino-acid to adopt a 
new conformation and prevent it from undertaking its usual function of stabilizing the 
agonistic conformation of helix-12. [27, 44-53].
SERMs are therefore well characterized examples of ligands whose mixed profiles can partly 
be attributed to disrupting the stabilizing interaction of the conserved acidic residue at this 
position. We believe that Asoprisnil is the first characterized example of a ligand whose 
mixed profiles can be attributed to strengthening this same stabilizing interaction.
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5.3.8 Interaction with Glu723 is unlikely to explain partial agonism of Org3H   – 
The interaction between Asoprisnil and Glu723 is dependent on the presence of the 
11β-Benzaldooxime group and as such is unlikely to be a universal model for mixed 
profile compounds. For example, Org3H is a SPRM from a class of steroids incorporating 
11β-pyridinylphenyl groups, and therefore lacks the hydrogen-bond donating capacity 
of Asoprisnil’s oxime substituent. In an attempt to explain its partial agonism we 
selected Org3H as a candidate for characterization via X-ray crystallography following 
the same soaking procedure as we have described for Asoprisnil.
5.3.9 Org3H is bound to monomer B, but not to monomer A  – As is the case 
for our PR-Asoprisnil structure, the asymmetric unit contains two copies of the PR-
LBD. Visual inspection of the electron density within the ligand-binding pocket of 
the structure clearly shows that monomer B contains Org3H but OrgA is still present 
in monomer A and has not been replaced during the soaking. A similar observation 
was made when RU486 soaked into the B monomer of PR-Norethindrone crystals but 
failed to displace the original ligand from monomer A [16]. As Asoprisnil displaced 
OrgA in both monomers we can conclude that monomer A is accessible in the crystal, 
but must have lower affinity for Org3H or a slower rate of ligand entry compared 
to monomer B. As hypothesized in the RU486 study, this difference is likely to arise 
from conformational differences in the two crystallographically independent PR LBDs 
in the crystals. These differences are most prominent around the loop 785–808, a 
region previously hypothesized to be a route of entry for the ligand during the soaking 
experiments [16].
Figure 5.7: A illustrates the stabilizing interaction between Glu723 and helix-12 (colored red) 
by hydrogen-bonding to the backbone of Met908 and Met909. B shows the binding mode of 
Asoprisnil bound to the agonist conformation of PR with ligand to receptor hydrogen-bonds 
shown in magenta. Interactions between Glu723 and helix-12 (shown in red) are also shown. 
C shows a comparison between the effect of binding Asoprisnil (green) to PR and Raloxifene 
(blue) to ERα. Binding of Asoprisnil to PR contributes the stabilizing interactions between Glu723 
and the backbone of helix-12. On the other hand, the binding of Raloxifene to ERα results in 
Asp351 losing its interactions with the backbone of helix-12 as it now prefers to re-orientate and 
make a salt-bridge to the ligands basic amine.
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5.3.10 The steroidal core of Org3H binds differently than other steroids  –  The binding 
of OrgA in monomer A is practically identical to the previously described PR structures 
containing OrgA and requires no further description [26]. Org3H shares the classical 
interaction with Gln725 and Arg766 via its 3-keto group, with the A-ring in general binding 
in the conventional manner described for RU486 and Asoprisnil. In the second monomer 
Org3H shares the same scaffold as RU486 and Asoprisnil, but doesn’t overlay as closely 
as these two ligands after binding to the receptor (Figure 5.8). Whilst the conformation of 
the ligand is unchanged, the Org3H binding mode shows distinct unexpected differences, 
mostly around the D-ring, compared to the other steroids as it is shifted away from its 
typical position toward the 17α pocket. Org3H does not have a 17α attachment as seen 
for RU486 and Asoprisnil, but the repositioning of the D-ring is significant enough that 
the vinyl group on position 16α of Org3H is oriented in a similar position to the 17α 
groups of RU486 and Asoprisnil occupying a comparable space within the receptor as 
shown in Figure 5.8A and Figure 5.8B. This overlay would not be possible if the steroid 
scaffold was binding in the classic position.
5.3.11 Induced fit around Trp755 relieves clash with Met909  – The scaffold carbon atoms 
at C11 in RU486, Asoprisnil and Org3H are all located at approximately the same position 
in their various co-crystals. The pendant attachments of RU486 and Asoprisnil, attached 
Figure 5.8: A and B show the overlaid structures of Asoprisnil (carbons in green), RU486 (carbons 
in orange) and Org3H (carbons in cyan). The secondary structure of the PR-Asoprisnil structure 
is shown as a cartoon representation in green. The 17α side-chains of Asoprisnil and RU486 
overlay relatively closely with the 16α substituent of Org3H due to the displacement of this 
compounds D-ring. In A, positions 16 and 17 of Org3H and Asoprisnil are labeled. In B, position 
16 of Org3H and Asoprisnil are labeled.
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to C11, are also well overlaid and conserved. The phenyl group attached at C11 of Org3H 
is however significantly divergent from the other reference compounds (Figure 5.9). The 
pydridinylphenyl fills a pocket resulting from a rearrangement of Trp755. 
Figure 5.9: Overlaid structure of Asoprisnil (carbons in green), RU486 (carbons in orange) and 
Org3H (carbons in cyan). The secondary structure of the PR-Asoprisnil structure is shown as a 
cartoon representation in green. The 11β substituents of Asoprisnil and RU486 overlay closely 
but the 11β substituent of Org3H is clearly divergent.
Figure 5.10: A shows Trp755 from Asoprisnil bound complex (carbons in green) and from RU486 
bound complex (carbons in orange) showing the normally observed rotamer for this residue. In 
contrast, Trp755 from the Org3H bound complex is shown (carbons in cyan), demonstrating its 
ligand induced movement. B shows a similar scene to A, but with Org3H superimposed to show 
the clash it would make to Trp755 if the amino-acid was not shifted.
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Upon binding of Org3H, Trp755 rotates 120° around the bond between the residues Cα 
and Cβ bond and 100° around the bond between Cβ and Cγ (shown in Figure 5.10A 
and Figure  5.10B). The new orientation of Trp755 now packs against Leu726 in helix-3, 
providing space to accommodate the side-chain of Org3H (shown in Figure 5.11A and 
Figure 5.11B). The capacity for Trp755 to adopt novel positions has been described 
when the receptor binds to non-steroidal compounds [24-26]. In addition to these 
examples, the same plasticity has been noted for the equivalent residue, Trp741, in AR 
[34,54-59].
The pydridinylphenyl side-chain is able to occupy a channel pointing toward His888 to 
which it makes a water bridged H-bond from the ligands pyridine nitrogen shown in 
Figure 5.12. In addition to His888 and the ligand, the conserved water is also able to 
hydrogen-bond to the backbones of Tyr753 and Met756.
It has previously been observed that the Trp741 flip in AR (equivalent to Trp755 in PR) 
makes available a channel and potential interaction with His874 (equivalent to His888 
in PR), including the presence of the conserved water molecule. Comparison of all 
publicly available PR structures shows that this channel has not previously been 
described for this receptor (Figure 5.13). It appears that the unusual orientation of 
Org3H’s steroidal core is required to allow the 11β side-chain to adopt this position.
Figure 5.11: A shows a stick representation of Trp755 and a surface representation of the binding 
pocket of the PR-agonist structure bound to Asoprisnil (ligand hidden for clarity). B shows a stick 
representation of Trp755 and a surface representation of the binding pocket of the PR-agonist 
structure bound to Org3H (ligand hidden for clarity). The flipping of Trp755 in the Org3H bound 
complex expands the overall size of the pocket and provides the opportunity for novel structure-
based drug design.
88    Chapter 5
5.3.12 Effect of 16α attachment explains SAR suggesting that this substituent induces 
partial agonism  –  The group of McDonnell have previously reported the observation 
that 16α attachments on RU486 analogs result in partial agonist activity rather than the 
full antagonism that would otherwise be expected [38]. They also suggest that the basis 
for this effect is by altering the manner in which the crucial 11β group of RU486 and 
its analogs interact with the receptor, but that crystallographic data would be needed 
to confirm this. Our crystallography studies show that, due to the 16α attachment on 
Org3H, its steroidal scaffold binds in an atypical fashion which consequently leads to the 
ligands 11β having a reduced clash with Met909. Our PR-Org3H X-ray structure, the first 
of PR bound to a 16α substituted PR modulator, support McDonnell’s hypothesis and 
suggests that the changing interaction between the receptor and the 11β groups they 
observed is due to the utilization of the newly formed pocket behind Trp755.
Figure 5.12: Binding mode of Org3H with the water (oxygen shown as a red sphere) mediated 
hydrogen-bond to His888 highlighted. Additional interactions between the water molecule and 
Met756 are also shown.
Figure 5.13: The available PR LBD structures in the PDB were aligned using the MOTIF function 
in Yasara and the superimposed ligands extracted. A molecular surface encompassing the sum 
of the ligands was calculated by Pymol and shown colored cyan. Org3H was added to the ligand 
alignment and its molecular surface calculated and displayed as a red mesh. The portion of the 
red mesh visible represents the additional space required for the tolerance of this ligand that 
has not previously been described for this receptor.
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5.3.13 New position of Trp755 clashes with helix-12  – The divergent position of 
Org3H’s side-chain results in a reduced clash with Met909 compared to RU486 which is 
in agreement with the increased agonistic activity of Org3H compared to RU486. Met909 
adopts a different conformation compared to the rotamer reported when binding to the 
full agonist Norethindrone [16,21], but appears to be well tolerated (Figure 5.2), even 
making favorable hydrophobic contacts to the phenyl in the ligands 11β attachment. This 
prompted us to hypothesize that the remaining clash with Met909 may not be significant 
enough on its own to explain the reduced agonistic activity Org3H compared to full 
agonists. We therefore continued examining the structure to identify if any other factors 
were at play.
In its new position the Trp755 side-chain is directed toward Val912 in helix-12, and would 
clash with the position of this residue in either the RU486 or Asoprisnil (ago conformation) 
structures, as they would be within 2Å. To relieve this potential clash, Val912 is pushed 
away (~1.5Å average RMSD across all non-hydrogen atoms, but as much as ~2.5Å for 
some of the side-chain atoms) and we observe a shift of helix-12 not present in agonist 
structures or either the PRago-Asoprisnil or PRago-RU486 structures (Figure 5.14). 
We have previously described a PR structure bound to a full antagonist, OrgB, which 
also induces a flipping of Trp755 [26], but does not result in the clash with Val912 or the 
displacement of helix-12. So far, the indirect destabilization of helix-12, independent of 
Met909 appears to be unique to this series of compounds and may explain why these 
compounds are clearly mixed profile as measured in cell-based in vitro assays which 
typically characterize SPRMs as full antagonists
Figure 5.14: Trp755 and helix-12 from Asoprisnil bound complex (green) with Trp755 and helix-12 
from RU486 bound complex (orange) compared to Trp755 and helix-12 from the Org3H bound 
complex (cyan). Alternate position of Trp755 from the Org3H complex would clash with Val912 
from the Asoprisnil and RU486 complexes. This clash is relieved by a rotation of Val912 and a 
pushing away of the backbone of helix-12 in this region, suggesting a destabilization of the 
agonist position of helix-12.
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5.3.14 Stabilized receptor conformations provide a valuable approach for studying 
mixed profile modulators  – Understanding the molecular basis for mixed profile 
compounds is hampered by the difficulty in determining relevant co-crystal structures. Full 
agonists stabilize the receptor, and specifically helix-12, in a conformation suited to binding 
co-activating proteins and full antagonists stabilize the receptor in a conformation suited to 
binding co-repressing proteins. The apparent reason for the difficulty in co-crystallizing mixed 
profile compounds is that they do not fully stabilize the receptor in either conformation, 
adopting some degree of equilibrium between the two. This equilibrium allows mixed 
profile compounds to bind unique patterns of co-modulators compared to full agonists 
and antagonists, resulting in their potentially interesting biological effects. Unfortunately 
as a result it also renders them poorly suited to co-crystallization studies [60]. Recently we 
have seen the first publications describing methods to circumvent this problem, either by 
Structure PR-Asoprisnil PR-Org3H
Space group P2
1
P2
1
Unit cell (Å3) 58.61 64.70 69.99 57.66 64.37 70.47
β-Angle (°) 95.7 96.3
Resolution (Å) 43.3-2.08 (2.19-2.08) 47.4-1.90 (2.00-1.90)
Completeness (%) 99.8 (100) 100 (99.9)
Rmerge 0.103 (0.496) 0.082 (0.729)
Mn(I/σ) 6.3 (2.0) 8.7 (2.1)
Multiplicity 3.1 (3.0) 4.1 (4.0)
R factor/Rfreeb 20.4/25.1 20.8/24.5
Atoms 4217 4289
    Protein atoms 3967 4047
    Ligand atoms 66 64
    Water molecules 78 173
    Other molecules e.g. sulphate 5 5
r.m.s.d. bonds, Å 0.011 0.078
r.m.s.d. angles (°) 1.2 1.05
B-factors (average Å2 )
Main chain 36.0 40.5
Side chain 38.2 42.0
Water molecules 22.5 30.8
Ligand A-chain 30.9 50.1 (OrgA)
Ligand B-chain 29.3 37.5 (Org3H)
Wilson B-factor (Å2) 29.3 38.5
PDB identifier 4A2J 4APU
Table 5.1: Final crystallographic data and refinement statistics. (Data in parentheses indicate the 
last resolution shell. r.m.s.d., root mean square deviation.)
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introducing stabilizing mutations into the receptor [56,60,61] or by generating stable crystals 
of the receptor using a receptor stabilizing ligand and then exchanging this compound 
with other compounds of interest via soaking [16]. Both approaches have the potential to 
dramatically increase our understanding of the biological mechanisms underpinning partial 
agonism and provide novel insight for drug optimization.
5.3.15 Implications of new PR structures for drug-design  – All ligands elicit their 
behaviors by a combination of their steric and electrostatic character. The binding of PR 
agonists is the result of a well described combination of steric complementarity and specific 
electrostatic interactions, typically to Asn719, Gln725 and Arg766. Our understanding of the 
additional interactions that differentiate full antagonists and SPRMs from full agonists have 
until now been limited to the steric properties of bulky 11β substituents. The binding mode 
of Asoprisnil to the agonist state of PR is the first description of how additional electrostatic 
factors, specifically the interaction with Glu723 can alter biological properties of SPRMs. 
Altering the nature of that interaction by compound optimization has the potential to fine 
tune the characteristics of SPRMs with the aim to improve their therapeutic response.
In addition to this new insight into the potential value of modifying SPRMs via an electrostatic 
approach, the PR-Org3H co-crystal also provides valuable new information regarding 
the steric influences that will also benefit future drug design. In particular we show how 
modifications away from the 11β group, such as the presence of 16α groups, can influence 
the effect of the classic bulky substituent. This complex is also the first indication that SPRMs 
can illicit their responses without directly impeding helix-12 or clashing with Met909. A 
combination of the ligand-induced clash between Trp755 and Val912 in helix-12 and the limited 
clash with Met909 suggest a unique mechanism for Org3H’s mixed profile. 
Overall we suggest specific new directions for the design of SPRMs including the exploration 
of the pocket behind Trp755, modification of interactions with Glu723 and the generation of 
indirect clashes with helix-12.
5.4. Conclusions
We present here two new PR structures bound to partial agonists. The structures 
demonstrate that two distinct mechanisms explain the mixed profiles of the two ligands, 
indicating that both steric and electrostatic factors can contribute to this mixed PR activity. 
The additional information that has been learnt from the binding of Asoprisnil bound to 
the agonist conformation of PR illustrates the value of studying mixed profile compounds 
bound to both the agonist and antagonist conformations of their receptors as a useful tool 
for drug design. This also supports the growing use of stabilized receptor systems, either 
by mutation or following soaking strategies as shown here, to study otherwise inaccessible 
receptor-ligand complexes.
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Abstract
Selective progesterone receptor modulators (SPRMs), with mixed agonist-antagonist 
profiles, have the potential to improve the treatment and management of numerous 
women’s health conditions. Their identification is however hampered by difficulties 
in differentiating SPRMs from full antagonists in the classical cell-based transcription 
assays commonly employed in nuclear receptor drug-design. As a result, alternative 
technologies, such as gene expression profiling and peptide recruitment, are increasingly 
being applied with the aim to rapidly resolve ligand differences with greater resolution in 
early discovery. We present here the peptide-recruitment profiles for a representative set 
of progesterone receptor (PR) modulators which clearly discriminate full antagonists from 
the SPRMs and SPRMs from full agonists. Indeed, the resolution of the technique allows 
for the differentiation of compounds within these overall classifications. Furthermore, to 
be useful as tools in compound optimization all assays in early discovery must allow for the 
elucidation of structure-activity relationships (SAR) to guide further rounds of synthesis. 
With this in mind, we have solved the structures of the PR ligand-binding domain (LBD) 
in complex with Drospirenone, Lonaprisan, Org33628 and Onapristone, which together 
with our previously reported PR structures in complex with Mifepristone, Asoprisnil and 
an 11-pyridinylphenyl steroid, confirm that the degree of clash between the ligand and 
Met909 is the primary determinant of each compounds peptide-recruitment profile. Our 
data are consistent with a model of receptor activation where the receptor is in dynamic 
equilibrium between an active and inactive state. This has implications for SPRM design 
and potentially more branches of nuclear receptor drug discovery.
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6.1. Introduction
PR was one of the first characterized nuclear receptors and is a key regulator of normal 
female reproductive functions including ovulation, mammary gland and uterine 
development, implantation and pregnancy maintenance. PR is expressed as two proteins, 
PR-A and PR-B from a single gene [1], both sharing the typical domain structure of the 
steroid receptors incorporating a variable N-terminal domain, a highly conserved DNA-
binding domain and, most importantly for drug design, a moderately conserved ligand-
binding domain (LBD) [2]. The LBD combines a number of functions, including hormone-
binding, receptor dimerization and binding to other transcription co-modulating proteins. 
Both receptor isoforms are bound to heat shock proteins in their unliganded state which 
then dissociate on ligand-binding. Association with endogenous ligands also stimulates 
the formation of homodimers of the receptor and stabilizes the dynamic helix-12, at the 
C-terminal of the LBD, in the so-called agonist conformation. Helix-12 (also known as 
the AF-2 helix) sits at the c-terminal of the LBD covering the ligand-binding pocket and 
forming a lid. The correct positioning of helix-12, in addition to helix-3 and helix-4, forms 
a hydrophobic cleft on the surface of the domain which is a binding and recognition point 
for co-activating proteins which contain a LXXLL helical motif. This cleft also includes a 
negatively charged residue in helix-12 and a positively charged residue in helix-3 which 
form a charge clamp to cap the LXXLL containing helix of the co-activator. The receptor 
and co-activator complex recruits other transcriptional machinery and associates 
with specific regions of DNA referred to as response elements [3, 4]. This complex 
of transcriptional machinery is able to remodel chromatin in the response element 
containing genes, allowing RNA polymerase enzymes to transcribe them. In addition, co-
repressors also exist which associate with the receptor to remodel chromatin in such a 
way as to prevent the action of RNA polymerase. Co-repressors appear to require the 
same dissociation of heat shock proteins before they can bind to the nuclear receptors, 
but do not need helix-12 to be in its agonist position. Co-repressors are not dependent 
on the charge clamp for binding to the LBD and in fact are able to compete with binding 
of co-activators more easily when helix-12 is not in its agonist conformation due to their 
extended recognition motif LXX(I/H)IXXX(L/I) compared to LXXLL.
SPRMs are a new class of PR modulators characterized by mixed agonist/antagonist 
profiles resulting in differing effects on a variety of progesterone target tissues. There 
is currently significant interest in the use of SPRMs for conditions related to pregnancy, 
contraception, endometriosis and oncology [5–7]. The properties of SPRMs are often 
poorly reflected in classical in vitro models [8], with difficulties differentiating between 
antagonists such as Mifepristone [9, 10] and mixed-profile compounds retaining in vivo 
agonism in specific tissues such as Asoprisnil [11–17].
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Earlier X-ray crystallography studies of PR have improved our understanding of its 
interactions with ligands [18–23] and especially the molecular mechanisms that 
contribute to determining the agonistic/antagonistic characteristics of its modulators 
[24–28]. Amongst the most important observations have been the indications that the 
recruitment of co-modulators is driven by differences in ligand structure which determine 
the position of helix-12 and have the potential to be predictive for the pharmacological 
profile of new ligands. With this in mind, the use of peptide interactions (using whole or 
partial co-modulators or synthetic peptides) to cluster different classes of ligands and 
to identify novel nuclear receptor-modulating ligands has become an important drug-
design tool. Peptide interaction assays [29, 30] have most commonly been applied to the 
estrogen receptors [31–35] but also in small studies to the progesterone receptor where 
small numbers of ligands have been differentiated by differences in their interactions 
with a few peptides [8] or an array of peptides [36]. Recently, the first array experiment 
comparing multiple PR ligands to multiple co-modulators has been published (14). This 
study was able to differentiate SPRMs such as Asoprisnil from PR antagonists such as 
Mifepristone and Onapristone. However, the use of peptide recruitment methods for 
compound profiling and classification would have increased value if it were possible to 
differentiate compounds within the larger classical classes (full agonists, full antagonists 
and mixed profile compounds) and not just between them. For this to be possible a larger 
study would be required with a broader range of ligands and an increased number of 
peptides. We report here a significantly larger peptide-recruitment study for PR including 
19 ligands and 30 peptides in which we demonstrate the differentiation of compounds 
within and between the classical classifications. 
Furthermore, we are unaware of any peptide recruitment study which has been able to 
relate the differentiation of the ligands directly to the structural features which drive that 
differentiation. This step is required for peptide recruitment to guide new compound 
design and fulfill its potential as a drug discovery tool. Our group has previously published 
the X-ray structures of three of the compounds included in this peptide-recruitment study 
[24, 28] and include an additional four new structures here. The seven structures are 
representative of the different classes of PR modulator and include the full antagonists 
Onapristone, Mifepristone and Lonaprisan, the full agonist Drospirenone and the mixed-
profile compounds Asoprisnil, Org3H and Org33628 (see Table 1). We confirm that 
degree of clash (defined as an unacceptable van der Waals overlap) between ligand and 
Met909 is the primary driver for peptide recruitment differences between PR modulating 
compounds, but that additional stabilizing and destabilizing interactions fine tune ligand 
function.
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Table 6.1: Cell based agonism and antagonism, shown for Progesterone, Norethindrone, 
Drospirenone, Asoprisnil, Org3H, Lonaprisan, Org33628, Mifepristone and Onapristone. Agonism 
and antagonism shown as EC
50 
(nM) with percentage efficacies associated. Efficacy is measured 
by curve height at maximal effect and expressed as percentage of reference compound effect.
Compound Name PR-B Agonism 
EC
50
 (nM) & %Eff
PR-B Antagonism
EC
50
 (nM) & %Eff
Progesterone 0.7 & 93 >1000
Norethindrone 0.2 & 99 >1000
Drospirenone 2.5 & 76 1.2 & 19
Asoprisnil >1000 0.14 & 96
Org3H 0.7 & 47 0.5 & 33
Lonaprisan >1000 0.02 & 100
Org33628 >1000 0.2 & 100
Mifepristone >1000 0.1 & 96
Onapristone >1000 6.0 & 91
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6.2. Materials and Methods
6.2.1 Peptides - We searched the literature for proteins and peptides reported to bind 
through consensus co-activator or co-repressor motifs (LXXLL, LXXX(I/L)XXX(I/L), where 
L is leucine, I is isoleucine and X is any amino acid) to the ligand binding domain of a 
nuclear receptor. Emphasis was put on interacting proteins for which it has been shown 
that mutations in the interaction domain affect transcriptional activity of the cofactor-
receptor complex. In addition we included a number of sequences that were identified 
PEPTIDE SEQUENCE
ASC2_2 SPAMREAPTSLSQLLDNSGAPNVT
BN2 EYHEKRWLEGHIHHRIKSLLENS
BT1a ELFDAFQLRQLILRGLQDDIPYH
D22 LPYEGSLLLKLLRAPVEEV
DAX_3 GEDHPRQGSILYSLLTSSKQTHVA
DAX_3cys FCGEDHPRQGSILYSLLTSSKQTHVA
HRCoA_1 TGLAKHLLSGLGDRLCRLLRREREA
HRCoA_2 AEDRAGRGPLPCPSLCELLASTAVK
LXRaH12 ALRLQDKKLPPLLSEIWDVHE
PGC_1 DGTPPPQEAEEPSLLKKLLLAPANTQ
PRH12 EMSEVIAAQLPKILAGMVKPLLFHKK
RIP140_3 EKDLRCYGVASSHLKTLLKKSKVKD
RIP140_5 LERNNIKQAANNSLLLHLLKSQTIP
RIP140_6 SKNSKLNSHQKVTLLQLLLGHKNEE
RIP140_8 PVSPQDFSFSKNGLLSRLLRQNQDSYL
RIP140_9 EHRSWARESKSFNVLKQLLLSENCV
SHP_1 CPCQGAASRPAILYALLSSSLKAVP
SHP_2 TFEVAEAPVPSILKKILLEEPSSSG
SMRT_ID1 AVEHASTNMGLEAIIRKALMG
SMRT_ID2 GHQRVVTLAQHISEVITQDYTRHHP
SRC1_2 CPSSHSSLTERHKILHRLLQEGSPS
SRC1a_4 TSGPQTPQAQQKSLLQQLLTE
SRC2_1 DGQSRLHDSKGQTKLLQLLTTKSDQ
SRC2_3 QEPVSPKKKENALLRYLLDKDDTKD
SRC3_1 SNMHGSLLQEKHRILHKLLQNGNSP
SRC3_2 QEQLSPKKKENNALLRYLLDRDDPS
SRC3_3 NLEGQSDERALLDQLHTLLSNTDAT
TRAP220_1 GHGEDFSKVSQNPILTSLLQITGNG
TRAP220_2 PVSSMAGNTKNHPMLMNLLKDNPAQ
Table 6.2: Peptide sequences used within this study
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from phage display libraries [37]. The peptides are listed in table 2. Synthetic N-terminally 
biotinylated peptides representing the interaction motifs including flanking amino acids 
were obtained from NeoMPS (Strasbourg, France). 
6.2.2 Peptide Recruitment – Ligand dependent association between the PR-LBD 
and peptides was studied by TR-FRET. To this end, 10nM PR-LBD was incubated with 
0.1μM biotinylated peptide, 10μM ligand, 8nM allophycocyanin-labeled Streptavidin 
(PerkinElmer Life Sciences, Boston, MA), and 1.25nM LANCE Eu-W1024-labeled anti-GST 
antibody (PerkinElmer Life Sciences) in a buffer containing 50mM Tris.Cl (pH 7.2), 50mM 
KCl, 1mM EDTA, 1mM dithiothreitol and 0.1 mg/ml BSA. The reaction was performed in 
duplicate in 384-well plates in a total volume of 70 ul. Plates were centrifuged, sealed and 
incubated at room temperature for 4 hours. Subsequently, the FRET signal at 665 nm was 
read using an excitation wavelength of 320 nm in an Envision plate reader (Perkin Elmer).
6.2.3 Data Analysis and Clustering – Since each peptide shows a distinct ligand-
independent association with PR, data were normalized by calculating the 10log ratio of 
the ligand-induced signal and the vehicle (0.1% DMSO) control signal. Data were analyzed 
by hierarchical clustering using the Unweighted Pair Group Method with Arithmetic Mean 
linkage algorithm and a half square Euclidean distance metric using the Spotfire Decision 
Site package (Tibco).
6.2.4 Cell Based Activity Measurements  – PR agonist and antagonist data has been 
measured following procedures outlined in earlier publications [38–40]. Org2058, a PR 
agonist, [41] was used as a reference. Assays are run in a standardized fashion and results 
presented are the average of a duplicate test in two different experiments.
6.2.5 Expression and Purification of PR-LBD  – The PR LBD, comprising residues 
678–933, was cloned in pET15b (Novagen). Expression was performed in Escherichia 
coli BL21(DE3) star (Invitrogen) in 2xYT medium by overnight induction at 20°C in the 
presence of 10 µM OrgA (Figure 6.1). OrgA is a member of a compound class described 
as glucocorticoid receptor antagonists [42], but is a relatively potent PR partial agonist 
whose activity is described in a recent article [27]. Bacteria were lysed in buffer A (50 
mM Tris, pH 7.8, 250 mM NaCl, 10% glycerol, 10 mM b-mercaptoethanol) with 0.4 mM 
pefabloc (Roche Applied Science) and 50 µM OrgA and purified on nickel-nitrilotriacetic 
acid. Fractions were eluted with buffer A with 100 mM imidazole. Elution fractions were 
collected and treated with 2.5 wt/wt % thrombin (Kordia) overnight at 4°C to cleave 
the N-terminal His tag. Thrombin was removed by adding benzamidine-Sepharose (GE 
Healthcare), centrifuging for 10 min at 5000g, and harvesting the supernatant. To make 
the final crystallization sample, the protein was dialyzed to buffer A to which 1mM EDTA, 
1mM dithiothreitol, and 10 µM OrgA were added and subsequently concentrated in a 
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stirring cell to about 4 mg/ml as measured by its absorption at 280nm. The sample was 
stored at -70°C in aliquots of 50µl.
6.2.6 Crystallization  – Crystals of the PR LBD in complex with OrgA were grown at 
room temperature from 3.5µl drops hanging over a mother liquor of 20–30% polyethylene 
glycol 3350, 0.1M Hepes, pH6.5, 100mM Mg
2
SO
4
 and 10% (v/v) glycerol. Drops consisted 
of 2µl of protein sample and 1µl of mother liquor and 0.5µl 40% 1,3-propanediol. Kite-
shaped crystals usually appeared after about 3 days.
6.2.7 Ligand Replacement  – Crystals of the PR LBD in complex with OrgA were 
collected and transferred to mother liquor to which 0.25mM of either Drospirenone, 
Org33628, Lonaprisan or Onapristone were added. 0.25mM is a significant excess of each 
of these compounds. The crystals were stored in a sitting drop at room temperature. The 
solutions surrounding the crystals were replaced by fresh solution 10 times over a period 
of 2 weeks. After this period, the crystals were frozen and transferred for data collection.
6.2.8 Data Collection  – Diffraction data were collected using a Rigaku rotating-anode 
X-ray generator operating at 100mA and 50kV. The datasets for the PR-Drospirenone 
complex was collected to 2.1Å at 100K, the PR-Org33628 complex was collected to 2.0A, 
the PR-Lonaprisan complex was collected to 2.2Å and the data for the PR-Onapristone 
complex was collected to 2.5Å at 100K. All datasets were processed with d*TREK [43], 
and structures were solved and refined using the CCP4i interface of the CCP4 software 
suite [44]. Electron densities are shown in Figure 6.1.
Crystal structures of the PR-Mifepristone structure [24] and the PR-Asoprisnil and PR-
Org3H complexes [28], determined in the same manner, have previously been described 
and utilized for this further study.
6.2.9 Modelling and Visualisation   –  All distances have been measured and figures 
generated using PyMOL (The PyMOL molecular graphics system, Schrodinger, LLC).
6.3. Results and Discussions
6.3.1 Peptide recruitment has a better resolution than cell-based receptor activation 
assays - We analysed ligand-induced conformational changes of PR by performing peptide 
recruitment studies with 30 PR-interacting peptides and a diverse set of 19 ligands. Figure 
6.2 shows the results of unsupervised hierarchical clustering of the peptide recruitment 
data. For comparison, the activities of ligands in an agonistic and antagonistic MMTV-
luc reporter assay are depicted in the last two columns of the heat map. The clustering 
algorithm distinguishes 7 main clusters, where clusters 1-4 contain compounds like 
Onapristone, Mifepristone and Lonaprisan that are full antagonists in the reporter 
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Figure 6.1: The 2F
o
-DF
c 
OMIT electron density maps around the ligand and Gln725, Arg766 and 
Met909 for: A Onapristone, B Mifepristone, C Lonaprisan, D Org33628, E Asoprisnil, F Org3H and 
G Drospirenone are shown at 1.0 sigma.
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assays. Clusters 7 contain compounds that behave as full agonists in the cellular assay. 
Clusters 5 and 6 contain SPRMs with partial agonistic behavior. Interestingly, the peptide 
recruitment data show distinct profiles for compounds that cannot be distinguished in 
the reporter assay. For example, Onapristone (cluster 1) is a full antagonist in the reporter 
assay and shows a predominant negative effect on peptide recruitment. It displaces, 
for example, SRC1-derived peptides that bind to the receptor in its unliganded state. 
Mifepristone and Lonaprisan have a less pronounced effect on displacement of peptides 
and end up in a distinct subcluster. ORG 33628, which is a full antagonist in the reporter 
assay, shows a mixed profile and recruits some peptides whereas it displaces others. As 
a result, it resides in subcluster 3. Similar to what is seen for the antagonists, the peptide 
recruitment profiles separate partial compounds that have comparable efficacies in the 
reporter assay, as there is a clear difference between the peptide profiles in clusters 5 
and 6.  In summary, the peptide recruitment profiles clearly distinguish agonists, partial 
compounds and antagonists and have a higher resolution than the traditional reporter 
assay.
6.3.2 Both agonistic and antagonistic receptor conformations are biologically 
relevant for mixed profile compounds according to the equilibrium model for steroid-
receptor function – It is well understood that agonists and antagonists induce different 
conformational changes in PR [45, 46] with the demonstration that the C-terminus is able 
to adopt two different positions corresponding to the biological activity of the ligand [45, 
47] distinct from the conformation of the unliganded receptor. A third conformation was 
also identified in the presence of mixed-profile 16α-substituted analogs of Mifepristone 
[48]. It is now believed that full agonists promote interaction with co-activators and full 
antagonists change the conformation of the receptor to inhibit co-activator binding in favor 
of co-repressor binding [49], with mixed-profile compounds inducing an intermediate 
state of interaction between receptor and co-modulators [30, 50, 51]. According to the 
equilibrium model for nuclear receptor agonism/antagonism, mixed profile ligands partly 
stabilize the agonist conformation of their receptor [2, 24, 28, 30, 52, 53] and allow co-
activators to bind but with less efficacy than full agonists. It has also been shown for 
the steroid-receptors that the presence or absence of co-modulating proteins can alter 
the specific conformation of structures resulting from X-ray crystallography even after 
co-expression studies [54, 55]. Together these observations demonstrate that steroid-
receptor ligands alter a dynamic equilibrium of helix-12 rather than inducing a single 
fixed conformation [2] with the potential that differences in the equilibrium contribute 
to the function of the receptor [30].
6.3.3 Studying full antagonists in full agonist conformations of their receptors has 
value as a research tool – Our group has previously published X-ray structures of three 
full PR antagonists in complex with the agonist conformation of the receptor [24, 27]. 
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Figure 6.2: Peptide recruitment heat map with PR modulators on the Y axis and peptides on 
the X axis. Log values of peptide recruitment range from -0.4 (green) to 0.0 (black) to 0.8 (red). 
Data were analyzed by hierarchical clustering using the Unweighted Pair Group Method with 
Arithmetic Mean linkage algorithm and a half square Euclidean distance metric using the 
Spotfire Decision Site package (Tibco). The 2 furthest right columns represent the PRB agonistic 
and PRB antagonistic efficacies of each compound and are colored from 0 (black) to 100% (blue).
The agonistic conformation of the receptor when bound to these ligands was clearly 
not the lowest energy state. This was demonstrated by the presence of intermolecular 
clashes between the ligands and the receptor. However, both conformations are 
thermodynamically accessible, even if they exist only at very low concentrations in 
solution. The apparent low occurrence of complexes in these conformations makes 
attributing direct biological relevance unreliable, but they do provide a useful research 
tool by indicating the existence of clashes that are not present in the complexes of 
full agonists and their receptors. With this in mind, we have solved the structures of 
PR bound to the full antagonists Onapristone, Lonaprisan, the mixed-profile compound 
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Org33628 and the full agonist Drospirenone. These have been analysed together with 
the previously reported X-ray structures of the antagonist Mifepristone and mixed-profile 
compounds Org3H and Asoprisnil in an attempt to identify the key determinants for the 
described peptide recruitment profiles.
6.3.4 Met909 plays a crucial role in determining the potency, selectivity and function 
of PR modulators – The importance of Met909 for the function of PR has been well 
established. The residue forms part of the ligand-binding pocket of the receptor and 
contributes to van der Waals interactions with many potent ligands [23]. Met909 also 
plays a role in ligand selectivity as steroidal progestins can typically be differentiated from 
steroidal glucocorticoids and mineralocorticoids due to the presence of 11β-OH groups. 
This difference results from a potential clash between 11β-OH groups and Met909 in PR 
which is prevented by the smaller Leu753 in GR and Leu960 in MR. As the only AF-2 helix 
residue typically in contact with ligands, it is perhaps unsurprising that Met909 plays a 
crucial role in PR function. Even before the publication of the PR-Mifepristone complex 
[24), which demonstrated the destabilization of the agonist conformation of helix-12 by 
a clash between the ligand and Met909, mutation studies on the equivalent GR residue 
[Leu753) have indicated the crucial role played by residues at this position [56]. A number 
of reports describe ligands designed to induce clashes with Met909 which successfully 
reduced their agonistic activity [25, 26, 57, 58]. It has even been suggested that the 
degree of clash with Met909 might correspond directly to a reduction in agonism [59], a 
hypothesis we are now able to test for the first time.
6.3.5 Lonaprisan successfully replaces OrgA during soaking experiments from 
monomer B but not monomer A – The PR LBD forms homodimers endogenously and 
during crystallization. The non-steroidal partial agonist OrgA [27, 28] has a distinct 
structure compared to 11β-steroidals allowing us to clearly establish by visual inspection 
of the electron density within the binding pocket if it has been replaced during soaking 
experiments. In previous experiments [24, 27, 28] we have shown that exchange of ligand 
in monomer B occurs more readily than from monomer A and hypothesized this is a 
consequence of differences in the conformations altering either ligand affinity or rate 
of exchange. This trend continues with the successful exchange of OrgA by Lonaprisan 
in monomer B but not monomer A. The binding mode of OrgA, and its implications to 
the function of this ligand have previously been discussed [27] with no further insight 
resulting from this additional structure.
Lonaprisan adopts a conventional binding mode compared to other 11β-steroids with 
very close similarity to the binding mode of Mifepristone (Figure 6.3A). Both compounds 
make the typical hydrogen bonds to Gln725 and Arg766 via their 3-keto group which is 
ubiquitous for endogenous oxosteroid receptor ligands. Comparison of the steroidal 
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core of the ligands in the crystal complexes shows an extremely close alignment with 
the only significant difference being divergent puckering of the A-rings. The A-ring of the 
ligand in the PR-Lonaprisan complex adopts a low energy conformation as determined by 
ab initio calculations. As discussed earlier [24], the PR-Mifepristone complex contains a 
ligand whose A-ring is divergent from the calculated low energy conformation. This small 
difference may contribute to Lonaprisan’s increased potency compared to Mifepristone 
(Table 6.1).
6.3.6  Lonaprisan’s 17α-pentafluoroethyl may play a role in altering the agonist-
antagonist equilibrium in PR – It has also been suggested [60] that the 17α-pentafluoroethyl 
of Lonaprisan may contribute to the compounds higher PR antagonist potency and its 
pharmacological profile [8] compared to other 11β-steroids. As with the 17α-propynyl of 
Mifepristone, the 17α-pentafluoroethyl of Lonaprisan binds into a hydrophobic pocket 
that also accommodates the furoate group of Mometasone furoate [21]. This pocket 
is widely believed to provide additional space in which to extend ligands and increase 
their potency. Accomodation of the Lonaprisan’s 17α-pentafluoroethyl, compared to 
Mifepristone’s 17α-propynyl group requires a small displacement of Leu715 and Tyr890 
(Figure 6.4). In addition, the water molecule that forms bridging hydrogen-bonds 
between Mifepristone and Asn719 is absent in the PR-Lonaprisan complex. This absence 
results directly from the presence of the 17α-pentafluoroethyl which would otherwise 
include a fluorine atom within ~2Å of the water molecule (Figure 6.4).
In the Androgen receptor, a hydrogen bond network centered on Asn705, equivalent to 
Asn719 in PR, is crucial for agonistic activity. The network in AR stabilizes the agonistic 
conformation of the receptor and runs from Thr877 in helix-11 to the 17β-OH group in 
endogenous steroids to Asn705 in helix-3 and finally to the backbone of Asp890 in the 
loop preceding helix-12 [22]. The exclusion of the water molecule in the PR-Lonaprisan 
complex, resulting in the loss of the equivalent stabilizing interactions required for 
agonism in AR, might suggest an effect on pharmacology. However, there is evidence 
to suggest that this bridging function is less critical in PR. For example, the residue 
equivalent to AR residue Asn705 in MR is Asn770. Extensive X-ray, SAR and mutation studies 
have been conducted on Asn770 which demonstrate clearly the existence of a ligand-
mediated hydrogen bonding network which is critical for the activation of MR [61] in a 
similar fashion to the one described for AR [22, 62]. Agonistic steroidal ligands for GR and 
MR are typified by 11β-hydroxyl groups which hydrogen bond to Asn564 in GR and Asn770 in 
MR respectively. Despite the similarity between MR and PR, the endogenous PR agonist 
progesterone behaves as an antagonist of MR whilst 11β-hydroxyprogesterone is an MR 
agonist [63], indicating the importance of the hydroxyl group and interaction with Asn770 
in MR. As progesterone, lacking an 11β-hydroxyl is an agonist of PR we conclude that the 
interaction between ligand and Asn719 in PR is less critical than the equivalent interactions 
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Figure 6.3: In figures 3A-F the binding mode of Mifepristone in PR is shown with carbon atoms 
colored green. Hydrogen-bonding residues Gln725, Arg766 are also highlighted as is helix-12 
residue Met909. In each of the six blocks a second ligand-PR complex is overlaid for comparison. 
In 3A the Lonaprisan complex is overlaid onto the Mifepristone structure with carbons colored 
cyan. In 3B the Onapristone complex is overlaid onto the Mifepristone structure with carbons 
colored magenta. In 3C the Org33638 complex is overlaid onto the Mifepristone structure with 
carbons colored yellow. In 3D the Asoprisnil complex is overlaid onto the Mifepristone structure 
with carbons colored pink. In 3E the Org3H complex is overlaid onto the Mifepristone structure 
with carbons colored white. In 3F the Drospirenone complex is overlaid onto the Mifepristone 
structure with carbons colored blue.
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in MR and AR, suggesting the loss of the water molecule from the PR-Lonaprisan complex 
is unlikely to have major implications. Furthermore, these conclusions are in part 
supported by the presence of strong direct interactions between Asn719 in PR and some 
non-steroidal antagonists [27].
Whilst the apparent importance of Lonaprisan’s fluorines to the pharmacological profile 
of the compound [60] may result from rearrangements around the 17α pocket or the 
exclusion of a water molecule, it seems more likely that their presence is more important 
in altering the pharmacokinetics or pharmacodymanic profile of the compound.
6.3.7 Consideration of electron density, rather than final modeled position of 
Met909, required for the full understanding of ligand-effects – Lonaprisan includes a 
4-acetylphenyl group at its 11β position compared to the 4-dimethylalinine group of 
Mifepristone. Both groups overlay perfectly when the two PR structures are aligned, 
partly occupying the space taken by Met909 when bound to fully agonistic ligands. As 
a result, both structures show Met909 to be displaced toward Phe905. The final protein 
structures reported here and deposited at the PDB show a significant divergence 
between the conformation of Met909 when bound to either Mifepristone or Lonaprisan, 
Figure 6.4: Superimposed structures of the PR-Mifepristone complex (carbons green) and the 
PR-Lonaprisan complex (carbons cyan). The image focuses on the 17α substituent of each ligand 
and the water molecule hydrogen bonded to the 17β-OH of Mifepristone and Asn719 which is 
excluded from the PR-Lonaprisan complex by the ligands branched 17α group.
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but, this orientation is not reflected in a significant difference in the electron density at 
this position, with the partial electron densities around Met909, shown in Figure 6.1B for 
Mifepristone and Figure 6.1C for Lonaprisan being rather similar. However, due to the 
partial nature of the densities it is impossible to position the side-chain of Met909 with 
either accuracy or confidence in either structure. The slight improvement in the clarity of 
the density around Met909 for the Lonaprisan complex, suggests a different rotamer of the 
residue compared to the Mifepristone complex which was solved earlier. Both rotamers 
are within the likely positions of Met909 as determined by a rotamer library search (Figure 
6.5]. Therefore, despite a difference in the final coordinates of Met909 between these two 
reported structures, they should be considered identical.
6.3.8 Lonaprisan destabilizes the agonist conformation of PR in a similar manner 
to Mifepristone – The publication of Mifepristone bound to the agonist conformation 
demonstrated the direct clash between the ligands 11β side-chain and Met909 in helix-12 
[24]. The result of this was to increase the flexibility of helix-12 compared to the binding 
of the full agonist Norethindrone as determined by an analysis of the receptors B-factors. 
This indicated a ligand-mediated shift in the receptors agonist-antagonist equilibrium 
towards antagonism.
Figure 6.5: Rotamers of Met909 extracted from a backbone dependent rotamer library based on 
the specific Phi&Psi dihedral angles of this region of the PR-Drospirenone.
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As shown earlier, Lonaprisan adopts a highly similar binding mode compared to 
Mifepristone and makes an almost identical clash with Met909. The result of this clash is 
the same destabilization of helix-12 and increase in its flexibility. 
6.3.9 Similarity of binding modes and interaction with Met909 between Lonaprisan 
and Mifepristone is reflected in similar peptide recruitment profiles – Overall, the 
binding modes of Lonaprisan and Mifepristone are very similar with some small changes 
between their respective 17α groups. This similarity in binding, particularly around their 
11β attachments and their interaction with Met909, is reflected in their near identical 
peptide recruitment profiles with both compounds clustering together and demonstrating 
antagonistic profiles.
In order to determine the validity of these observations we decided to compare the 
interaction with Met909 for representatives of the various peptide recruitment clusters 
to determine if there was a strong relationship between the two approaches. Not all 
compounds readily exchanged during the soaking experiment, but, in addition to the 
previously published structures of PR bound to Mifepristone, Asoprisnil and Org3H, as well 
as the Lonaprisan structure just discussed, we have been able to generate Drospirenone, 
Org33628 and Onapristone structures which represent each of the main clusters.
6.3.10 The cis fusion between Onapristone’s rings C and D results in an increased 
clash with Met909 compared to Mifepristone – Onapristone is characterized by a cis 
fusion between rings C and D as shown in Table 1, and is the best known example of 
the 13α class of steroidal anti-progestins. Like Mifepristone and Lonaprisan it shows 
full antagonistic efficacy in our cell-based reporter assay, but it demonstrates an even 
more antagonistic peptide recruitment profile than either Mifepristone or Lonaprisan. In 
order to determine the molecular basis for this antagonistic peptide recruitment profile 
we followed the previously described soaking procedure to generate a PR-Onapristone 
complex in its agonist state.
As for both the Mifepristone and Lonaprisan structures, Onapristone has exchanged 
with OrgA during soaking in monomer B, but not in monomer A. Compared to the other 
ligands in this study, the electron density around the steroidal core of Onapristone is the 
least well defined (Figure 6.1), which is already an indication that this compound is less 
well tolerated in the agonistic binding pocket of PR. There is however sufficient density to 
suggest that the steroidal core of Onapristone grossly aligns with those of Mifepristone 
and Lonaprisan. Onapristone’s 3-keto group is oriented a little higher in the pocket, but 
is still able to hydrogen-bond to Gln725 and Arg766 (Figure 6.3B). As we might expect, 
the cis fusion of rings C and D, rather than the more typical trans fusions of the other 
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steroids in this study, has a dramatic effect on this end of the molecule. The 13α-methyl 
of Onapristone, rather than the more common 13β-methyl requires a small movement 
of Leu718 to be tolerated (Figure 6.6A), but the most significant change appears to be a 
shortening of the overall length of the steroid and alterations to the exit vector of the 
4-dimethylalinine group on position 11β which is now further pointed in the direction of 
Phe905 (Figure 6.6B). 
In the previously discussed PR-Mifepristone and PR-Lonaprisan complexes the presence 
of bulky 11β attachments clashes with Met909 which then has to adopt a new position. 
Even with this reorganistion, the clash is not fully resolved, resulting in the destabilization 
of helix-12. In the case of the PR-Onapristone complex, the position of its 11β attachment, 
due to the change in stereochemistry at position 13, will induce a clash with both Met909 
in both its typical agonistic position, but also in the position induced by Mifepristone 
and Lonaprisan. As can be seen clearly in the electron density of the PR-Onapristone 
complex, the presence of both this ligand and Met909 is incompatible. We suggest that 
this increased clash with Met909, compared to all other ligands in this study, will shift the 
equilibrium further toward antagonism which is then reflected in the compounds peptide 
recruitment profile.
6.3.11 Increased agonistic profile of Org33628 compared to Mifepristone, Lonaprisan 
and Onapristone results from reduced clash with Met909 – Org33628 is highlighted as an 
interesting compound in the peptide recruitment profiling as it appears to be the most 
antagonistic compound (decreasing binding of co-activator peptides) that also increases 
the binding of other co-activators. By comparison, neither Onapristone nor Mifepristone 
nor Lonaprisan increase the binding of any co-activators. Based on our previous 
Figure 6.6: Superimposed binding modes of Mifepristone in complex with PR (carbons in green) 
and Onapristone in complex with PR (carbons in magenta). 
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observations we would therefore expect Org33628 to make a decreased clash with Met909 
and therefore allow the equilibrium to shift in the direction of agonism compared to the 
previous antagoniststs. To confirm this we once again generated a complex of PR-Org33628 
following the same soaking procedure as before. Interestingly, Org33628 is able to soak 
into both monomers with sufficient efficacy to fully displace OrgA. Overlaying monomer 
A with monomer B of the PR-Org33628 complex demonstrates identical binding modes 
for the compound without suggesting why Org33628, but not the previous antagonists, 
is able to exchange in both monomers. For the sake of comparison we continued analysis 
only on monomer B which showed very clear electron density with the binding pocket 
allowing us to model the position of the ligand with a high degree of certainty. Org33628 
shares the same steroidal core as Mifepristone which align perfectly when the two 
complexes are overlaid (Figure 6.7). Org33628’s tetrahydrofuran group (position 17) is 
accommodated within the binding pocket without any additional reorganization of the 
protein required.
The most striking difference between the PR-Org33628 complex and the previously 
discussed PR-Mifepristone and PR-Lonaprisan structures is the position of Org33628’s 
11β side-chain (Figure 6.8A). Despite having the same steroidal core as Mifepristone 
and Lonaprisan, the side chain of Org33628 sits lower in the binding pocket compared 
to the other two ligands towards Met759, which adopts a new conformation to relieve 
Figure 6.7: Superimposed binding modes of Mifepristone in complex with PR (carbons in green), 
Lonaprisan in complex with PR (carbons in cyan) and Org33628 in complex with PR (carbons in 
yellow).  
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the potential clash. This requires Gln725 to also move slightly, but does not prevent it 
hydrogen-bonding to the ligands 3-keto group (Figure 6.8B). 
The most interesting outcome of this lower position of Org33628’s acetylphenyl is a 
reduced clash with Met909 which can best be seen in the electron densities in Figure 6.1. 
Unlike the previously described structures, the electron density around Met909 in the PR-
Org33628 complex is complete, indicating a better tolerance for this ligand and explaining 
how Org33628 shifts the equilibrium further towards agonism compared to the previous 
antagonists as illustrated in peptide recruitment. 
The structural basis for the difference in positioning of Org33628’s 11β attachement 
is however difficult to explain. The electron densities are of sufficient resolution and 
completeness to be confident of this observation. However, further studies are needed 
to explain why these compounds bind in different fashions. Interestingly, the 11β side-
chain of Asoprisnil, which also has the same steroidal core as the other compounds, binds 
in a similar fashion to Org33628.
6.3.12 Asoprisnil and Org33628 make similar interactions with Met909, with the 
increased agonistic activity of Asoprisnil resulting from compensating stabilizing 
interactions – We have recently published a PR-Asoprisnil complex in the agonist 
conformation following the same soaking approach used here [28). Comparison of the 
electron density of Met909 in the PR-Asoprisnil complex shows that it closely resembles the 
electron density of Met909 in the PR-Org33628 complex, which should indicate a similar 
peptide recruitment profile. However, the peptide recruitment profile of Org33628 is 
clearly more antagonistic than the profile of Asoprisnil. This is however not surprising 
as the previous study on the PR-Asoprisnil complex revealed a previously unknown 
stabilizing interaction between the oxime group in the 11β side-chain of Asoprisnil and 
Glu723 in helix-3. This interaction enhanced the natural function of Glu723 in stabilizing the 
agonist conformation of helix-12 (Figure 6.8). It therefore appears to be the case that 
interaction with Met909 is the key determinant of ligand function, but that other factors 
can also influence the final agonist-antagonist equilibrium.
6.3.13 The mixed-profile compound Org3H makes a minimal clash with Met909, 
comparable to full agonists such as Drospirenone, and appears to induce its mixed-
profile in a novel manner – The presence of a large 11β-pyridinylphenyl attachment 
on Org3H should, on the face of it, be an excellent candidate for making a large clash 
with Met909 and inducing full antagonism. Despite this, Org3H is only moderately more 
antagonistic in peptide recruitment than a full agonist such as Drospirenone. We have 
previously published a PR-Org3H complex which we can compare to the PR-Drospirenone 
complex reported here.
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Figure 6.8 Shows the binding mode of Asoprisnil bound to the agonist conformation of PR with 
ligand to Glu723 hydrogen-bonds shown in magenta. Interactions between Glu723 and helix-12 
are also shown.
Perhaps surprisingly, the pyridinylphenyl group of Org3H has only a small influence on 
the electron density around Met909 compared to the electron density around Met909 in the 
PR-Drospirenone complex (Figure 6.1). This is because the pyridinylphenyl group is able 
to avoid clashing with Met909 by occupying a novel pocket resulting from the “flipping” 
of Trp755 [28). In fact, there appears to be a good chance that the increased antagonism 
(measured in either cell reporter assay or peptide recruitment) of Org3H compared to the 
full agonist results from a clash independent of Met909, with the rearrangement of Trp755 
causing a clash with Val912 in helix-12 [28]. This further suggests that whilst clashes with 
Met909 are the typical structural basis for influencing PR function, other factors remain.
6.3.14 The degree of clash between ligand and Met909 is the primary determinant of 
peptide recruitment profile – The ligands from the seven PR X-ray structures discussed in 
this paper, including the four structures reported here for the first time, were included in 
peptide recruitment matrix, allowing us to compare specific recruitment profiles against 
degree of clash with Met909. The peptide recruitment profiles indicate the following 
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order of the ligands, ranked from most antagonistic to most agonistic: Onapristone 
> Mifepristone > Lonaprisan > Org33628 > Asoprisnil > Org3H > Drospirenone. Visual 
inspection of the electron density around Met909 in each complex (Figure 6.1) shows 
disruption by Onapristone to indeed be the most extensive, followed by Mifepristone and 
Lonaprisan.  This corresponds with the observed differences in their peptide recruitment 
profiles with Onapristone displaying a more antagonistic profile than Mifepristone, which 
itself has a marginally more antagonistic profile than Lonaprisan. 
Compared to the three most antagonistic compounds which show only partial electron 
density around Met909, both the Org33628 and Asoprisnil complexes are well ordered 
around this residue in agreement with their reduced antagonistic peptide recruitment 
profiles. They do however demonstrate a different rotamer compared to the full agonist 
Drospirenone which might explain their reduced agonistic character. Asoprisnil displays 
a significantly more agonistic peptide recruitment profile compared to Org33628, 
reducing the binding of less peptides and increasing the binding of more. This difference 
is not reflected in the electron density around Met909 which are very similar in the two 
complexes. However, as discussed earlier, Asoprisnil makes additional helix-12 stabilizing 
interactions via Glu723 which are not present in the Org33628 complex and are the likely 
basis for Asoprisnil’s increased agonistic profile. Interestingly, this indicates that whilst 
degree of clash to Met909 is the primary determinant of the peptide recruitment profile, 
other factors can mitigate this effect.
Unlike the five other 11β-substituted steroids in this study, Org3H does not clash with 
Met909 and in fact makes favourable van der Waals contacts with the residue which why it 
presents the most agonistic peptide recruitment profile of the 11β-substituted steroids. 
In fact, in complex with Org3H, the electron density around Met909 is very similar to the 
full agonist Drospirenone in this study and the full agonist Norethindrone presented in an 
earlier study [24] and suggests that Org3H should induce a similar peptide recruitment 
profile to the full agonists which it largely does. However, there are differences in the 
peptide recruitment profiles between Org3H and Drospirenone which are likely to result 
from the Org3H induced displacement of Trp755 which results in the residue clashing 
with Val912 and partly displacing helix-12. Again, this leads us to draw the conclusion that 
degree of clash with Met909 is the primary determinant of specific peptide recruitment 
profile, but that other interactions exist which have the potential to fine tune the activity 
of new ligands.
It is also interesting to note just how divergent the positioning of 11β side-chains can be, 
and how much this can be influenced by minor modifications to the ligand (Figure 6.9). 
This demonstrates the challenge for drug-designers working on a series and presuming 
each compound is binding in a similar manner.
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Figure 6.9: Overlay, taken from superposition of protein complexes, of Asoprisnil, Org3H, 
Lonaprisan, Org33628, Mifepristone and Onapristone with emphasis on their 11β substituents.
6.3.15 Peptide recruitment profiling is a useful tool for differentiating between 
ligands, but is unlikely to be predictive of clinical activity – We have shown that peptide 
recruitment methods are able to differentiate between the major classes of PR modulators 
(agonists, antagonists and mixed profile compounds) as well as between compounds 
within these classes. This underscores that medicinal chemistry should not presume that 
each individual compound within a single class is binding to its target in a similar manner. 
As such, the method has value in drug discovery for profiling new chemical entities and 
selecting candidates for further classification, particularly by identifying compounds 
with unique profiles or those sharing similar profiles to known actives. However, specific 
biological outcomes result from a sum of direct interaction with PR, as well as the ligands 
pharmacodynamic and pharmacokinetic characters, non-genomic progestogenic effects 
and cross-activity on other steroid receptors [64–66]. These activities are not captured in 
this assay. Furthermore, whilst the method employed here utilizes a number of peptide 
fragments derived from endogenous co-modulating proteins, it is dangerous to draw 
biological conclusions from any specific association outside the context of the cellular 
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or tissue environment. This is especially true as this assay utilizes only partial fragments 
of the co-modulators and the ligand-binding domain of the receptor independent of the 
remainder of the protein and therefore excludes inter-domain cross-talk influences.
6.3.16 Stabilized receptor conformations provide a valuable approach for studying 
mixed profile modulators – Understanding the molecular basis for mixed profile 
compounds has in the past been hampered by the difficulty in determining relevant co-
crystal structures [67]. The apparent reason for the difficulty in co-crystallizing mixed 
profile compounds is that they do not fully stabilize the receptor in either agonist or 
antagonist conformation, adopting some degree of equilibrium between the two. This 
equilibrium allows mixed profile compounds to bind unique patterns of co-modulators 
compared to full agonists and antagonists, resulting in their potentially interesting 
biological effects, but renders them poorly suited to co-crystallization studies [67]. 
Recently we have seen the first publications describing methods to circumvent this 
problem, either by introducing stabilizing mutations into the receptor [67–69] or by 
generating stable crystals of the receptor using a receptor stabilizing ligand and then 
exchanging this compound with other compounds of interest via soaking [24, 27, 28].
6.4. Conclusions
We present here the peptide recruitment profiles for a selection of PR modulators 
spanning the range of full agonists, full antagonists and mixed profile SPRMs. The various 
compounds demonstrate different affinities for the array of included peptides that 
correlate to the most common classifications of PR modulators. For example, Asoprisnil, 
generally considered as a SPRM based on its in vivo pharmacology, but which behaves as 
a full antagonist in our cell-based transactivation assays, is classified as a mixed-profile 
modulator by peptide recruitment. The resolution of this model is also sensitive enough 
to differentiate compounds within the classic groupings with Onapristone appearing to 
be more antagonistic than Mifepristone. 
Additionally we report the structures of the PR LBD in its agonist conformation bound 
to Onapristone, Lonaprisan, Org33628 and Drospirenone which suggest that the most 
important driver for differing peptide recruitment profiles is the ligands interaction with 
Met909. However, our earlier work with Asoprisnil and Org3H also suggest that additional 
stabilizing and destabilizing interactions also play a role in fine tuning the activity of 
compounds within the same gross chemical classes.
Furthermore, whilst the attachment at the 11β position of each steroid is providing the 
clash with helix-12, the structure of the steroidal core itself is just as important as the 
structure of the side-chain in determining the antagonistic function of the ligand. This has 
obvious implications for future drug-design.
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Abstract
The difference between biologically active molecules and drugs is that the latter balance 
an array of related and unrelated properties required for administration to patients. 
Inevitability, during optimization, some of these multiple factors will conflict. Although 
informatics has a crucial role in addressing the challenges of modern compound 
optimization, it is arguably still undervalued and underutilized. We present here some 
of the basic requirements of multi-parameter drug design, the crucial role of informatics 
and examples of favorable practice. The most crucial of these best practices are the need 
for informaticians to align their technologies and insights directly to discovery projects 
and for all scientists in drug discovery to become more proficient in the use of in silico 
methods.
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7.1. Introduction
In all industries with a high technical component, from architecture to car design, the 
utilization of computers to improve quality of work and increase efficiency has been 
embraced. Computers are now crucial tools in all stages and aspects of drug design 
and development, from the identification of disease related genes to the interpretation 
of clinical trial data, illustrated by the growing number of marketed drugs for which 
computational methods have played a significant contributing factor in their design. These 
include Norfloxacin, Losartan, Zolmitriptan, Dorzolamide, Zanamivir and Amprenavir [1]. 
Despite this, the pharmaceutical industry, with science and innovation at its core, has 
been slow to fully utilize information technology within many areas of the traditional 
drug design sciences. More specifically, we have to challenge the preconception that the 
role of informatics is merely to support existing practices and in future, identify new ways 
of addressing problems that can only be undertaken computationally. 
As the drug discovery industry looks to decrease attrition rates in discovery, there is the 
recognition that a recurring historical failure of compound optimization has been the 
emphasis on individual properties [2, 3] with potency the most likely to be chased early 
[4, 5]. The life of a compound optimization project often begins with a rush to improve 
potency, with limited regard for the critically important drug-like properties that separate 
biologically active compounds from commercial drugs. Only after sufficient potency is 
achieved, will attention switch to optimizing the numerous other criteria required 
[6]. If the discovery team is fortunate, this might require a limited amount of further 
modification, but frequently the project will have painted themselves into an area of 
undesirable chemical space, requiring dramatic and time consuming new modifications 
or the acceptance of an ultimately unsatisfactory compromise. The evidence is that 
drug-designers appreciate these issues, but have been either unable, or at least slow, to 
heed these lessons and change the way in which they approach compound optimization, 
with the physical properties of compounds currently being synthesized in projects still 
differing significantly from current oral drugs [4].Increasing access to drug-likeness assays 
earlier in the discovery process during the 1990’s has been shown to reduce attrition 
rates for pharmacokinetics (PK) in recent years [7]. Whilst this suggests a move in the 
right direction, it may just be the same compounds are being excluded earlier in the 
pipeline, which, whilst clearly desirable, is not as valuable as systematically focusing 
design on more drug-like compounds to begin with. It should also be recognized that 
generating terabytes of data alone is not sufficient to ensure projects move away from 
chasing potency and other restricting single parameter approaches. In fact, generating 
ever larger datasets without strategies, processes and tools for their analysis can so 
overwhelm teams that they actually decrease the number of data-driven decisions made 
[8]. We begin by introducing some of the key issues in multi-parameter drug design before 
presenting some of the molecular informatics practices required to achieve these goals.
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7.2. Solving the Rubik’s Cube
The process of multi-parameter optimization is comparable to solving a Rubik’s cube [9]. 
Each face represents a required character i.e. potency, stability or selectivity, and chang-
ing one face will affect another face, perhaps detrimentally. As with a Rubik’s cube, ad-
dressing one parameter (solving one face of the cube) is relatively straightforward if you 
ignore each of the other parameters, but will not result in a completed puzzle. Some-
times solving the puzzle will require you to sacrifice a completed face, taking a local step 
back, in order to make a global step forward. 
For the Rubik’s cube, all faces are of equal value and weight, but is this the case for 
drug-design parameters? It can be argued that, for a specific compound, stability is less 
important than potency, but how do you separate parameters for which their total sum 
equals biological activity? Why decide at the beginning of a project to improve target 
engagement by increasing potency when it might be possible to improve PK and gain the 
same biological outcome?
All drugs are a result of compromise, but a more balanced approach to compound opti-
mization would give all drug activity and property parameters equal weight and search 
for satisfactory compromise amongst them from the beginning rather than desperate 
late stage concession. This approach also has the potential to deliver a number of com-
pounds, with differing, but equivalent compromises of the relevant properties rather 
than a set of compounds dominated by one property. Delivering a set of non-dominated 
solutions with varying properties is also more attractive to project pipelines compared to 
a stream of me-too compounds.
7.3. Discovery Informatics Providing a Foundation
The ability to generate meaningful activity and property data in a timely fashion, rapid 
enough to keep pace with design cycles, is the foundation required to support all multi-
parameter drug design. Project teams need access to accurate and precise heterogeneous 
data, generated by multiple and potentially geographically dispersed disciplines. This 
requires strictly adhered to protocols and authorization steps [10], and the need to 
disseminate data by the minimum number of user interfaces using globally consistent 
analysis processes.
Historically, teams would be responsible for gathering project relevant data and storing it 
in whatever generic application was available to them, most often Excel, which would be 
shared amongst the team on an irregular basis. Mistakes in these composites accumulate 
over time, with every manual data intervention a potential source of introducing error. 
Collecting these datasets was dependent on the team being able to navigate a network 
of data sources, identifying all relevant information and ensuring that it was collected in a 
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timely fashion. Analysis depended on whichever statistical method a particular researcher 
favored (which may be different from other people in the same team).
As a basis for multi-parameter drug discovery this situation is totally unsatisfactory, and 
remains the status in many organizations [11]. It can however be addressed by the design 
of tailored information management systems [12], the first descriptions of which include, 
‘ArQiologist’ from ArQule [13], ‘ADAAPT’ from Amgen [14], ‘OSIRIS’ from Actelion [15] 
and Johnson & Johnson´s ‘ABCD’ system [11].
Organon Biosciences (now part of Merck & Co) developed its own “Integrated Project 
View” (IPV) providing drug designers with access to all pharmacological activity data 
generated for each project alongside data generated by its DMPK groups, analytical 
chemistry data and calculated data generated in silico. The IPV system is available at each 
team member’s desktop and also in team meeting rooms, allowing data to be discussed 
and challenged by individual researchers or by teams. 
Analysis of raw data, without proper consideration of how it was generated is dangerous, 
and drug-designers should be aware of general factors underlying data generation and 
able to discuss issues underpinning interesting compounds and outliers. It is therefore 
crucial that those who generate data are in regular discussion with those who use 
the data to design new compounds. The use of IPVs at Organon ‘ended’ the sharing 
of data via Excel spreadsheets, as well as the previous hazard of data being generated 
and stored in hard copies in researchers’ desk drawers. Information management tools 
enable scientists to browse recent results or specifically query the activity of thousands 
of compounds against multiple assays simultaneously. The IPV system links directly to 
industry standard data-mining tools, further facilitating multi-dimensional data analysis 
for even the novice.
There is evidence to suggest that the most productive source of lead compounds is from 
previous optimization projects [16]. Compound optimization is so challenging that if a 
series progresses along the pipeline, and is shown to be drug like and safe, we should 
be obliged to identify every other application for which that series may be used. This 
can include follow-up compounds for the same target [17] or transfer to related targets. 
Systems to record all previously generated data, and tools to mine these resources, 
will facilitate this form of lead identification. The most important contributing factor to 
the success of these information systems are bench scientists who see their value and 
actively generate and deposit data in routine fashion following agreed protocols. This 
can be an issue, especially as the bench scientists are often not the end user of the data 
they generate and therefore do not always benefit directly from access to these systems.
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7.4. Dealing with Unexpected Results & Outliers in Data
Data should drive drug discovery, even if those data are at odds with conventional 
wisdom, with teams allowing data to shape ideas rather than searching for data that 
supports predefined hypotheses. 
One hindrance to multi-parameter drug design has been our focus on outliers during the 
design process. After making 100 non-selective compounds it is very tempting to promote 
the first selective compound to the top of the interest list and redesign all chemical plans 
around it. This strategy can work, but when the resulting compounds lack selectivity we 
blame the multiple conflicting parameters challenge, rather than consider that the base 
compound was simply an outlier or one-off (a unique set of properties combining to 
produce a unique outcome). Uniquely active substitutions restrict flexibility the team 
may need later and risk stranding projects when the substituent does not survive the 
increasingly complex and diverse assays later in lead optimization.
Despite this, outliers in data are often the most interesting results as they potentially 
indicate novel biological activity. Caution should be exercised though, as they may just 
as easily indicate issues with the generation or management of the experimental data. 
Retesting and reanalysis of chemical composition might be time consuming, but is more 
efficient in the long term than basing design decisions on erroneous data. Teams should 
routinely evaluate their series on all relevant properties (not just potency) to identify 
outliers, as well as identifying compounds that have unusual property combinations 
including NCEs that behave inconsistently across assays or for which the combination of 
two properties in one compound is unique.
It may not always be obvious which compounds are outliers, especially early in projects 
when data for comparison is limited, so project teams should be performing periodical 
reevaluation of their total data pool looking for compounds that buck trends or show 
unusual combinations of behaviors. These ‘interesting’ compounds are potentially hugely 
valuable to projects and can be identified with very limited resources provided adequate 
data management systems are in place.
Provided the activity of the outlier can be confirmed with some confidence, resources 
should be allocated to understanding its molecular basis. As with all aspects of chemical 
design, the deeper our understanding the easier an outcome is to replicate or improve. 
Determining the molecular basis for activity can be investigated in parallel to rapid 
exploration of the chemical space around outliers, but not replaced by it.
Unexplained activity is often a result of our lack of knowledge or understanding, 
demonstrating a need to improve the appreciation design chemists have of protein-
ligand interactions. This includes the balance between enthalpy and entropy and 
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the contribution of weak interactions such as halogen bonds, including distances and 
geometries [18, 19]. Due to their marginal net value, weak interactions are very difficult 
to rationally design into complexes, but may help to explain nuances in structure-activity 
relationship (SAR) data which can then direct new synthesis, without forgetting that they 
can also provide justification for over-analysis [19].
Related to this issue is the question of how many compounds must we generate to 
be confident we have fully explored a specific area? The less we understand about 
the factors contributing to the activity of a compound the more NCEs we will need to 
synthesize in order to feel confident we have been comprehensive. In the reality of time 
and resource restricted projects there is the frequent danger of cutting corners here and 
basing decisions on insufficient examples of compounds and data.
7.5. Is there a “God’s Number” for Compound Optimization
To return to the Rubik’s cube analogy, a standard cube consists of 54 outer squares in 
6 different colors, allowing for 43,252,003,274,489,856,000 different configurations [9]. 
Even this number is small compared to the estimated 1060 drug-like molecules it may 
be possible to synthesize [20]. Estimating one second per turn, sampling all possible 
configurations of the Rubik’s cube would require 1400 trillion years, but despite this, no 
possible configuration of the cube is ever more than 20 moves from being solved (the 
so called God’s number) [21]. Whilst it may always be theoretically possible to solve any 
Rubik’s cube formation in so few moves, in practice, it usually takes more.
For most drug-design projects, hundreds or even thousands of compounds must be 
generated to progress from initial hit to development candidate, but in retrospect, how 
many individual chemical steps are the initial hits away from the final development 
candidate or drug? Anecdotally, we have seen that for internal projects to progress 
from screening hit to development candidate requires hundreds of compounds to be 
synthesized, but less than 20 retrospective steps and typically less than 10 steps are 
required to actually achieve the goal. Earlier studies have identified how remarkably 
similar launched drugs are to their leads, [16] which are themselves most often derived 
from earlier optimization efforts or from endogenous ligands.
Others have investigated the ideal path to generate optimized drug leads, specifically 
investigating how ligand-efficiency changes can help determine if projects should 
continue exploration at one position or whether to abandon the approach in favor of other 
directions [29]. In terms of guiding project teams through the challenges of drug-design, 
a better understanding of successful and unsuccessful decision making in compound 
optimization might provide some guidance on how long to pursue one chemical sub-
series. Additionally, research to further quantify the collective actions of medicinal 
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Determining a specific ‘God’s number’ for compound optimization would require a list of 
marketed drugs and the initial lead from which they are derived as well as defined rules on 
what constitutes a ‘step’. There is no comprehensive resource of drugs and their leads, and a 
reported attempt to generate such a list describes the numerous hurdles involved including 
lack of reporting and multiple leads contributing to individual drugs [22], but does include a 
useful partial list. Walter Sneader has authored a book containing ‘drug prototypes’ of drugs 
[23] which has already been used to compare the physical and chemical differences between 
leads and drugs [24] and more recently a collection of 60 lead-drug pairs, including binding data 
to their target of interest, has been published [3] what is striking when browsing these 60 pairs 
is how similar many of the final drugs are to their lead, as shown in Table 1A with examples of 
more significant modifications from lead to drug shown in Table 1B for comparison. 
The limited number of steps between the leads and final drugs in so many cases illustrates 
the requirement to initiate compound optimization from the best possible starting points, 
and perhaps also the need to fully explore the chemistry around your lead before making 
larger synthetic steps. This also raises the concern that the limited steps we see for these 
successful pairs may demonstrate our inability to optimize compound series when bigger and 
more involved design intervention is required. If this is the case, it further reflects a failure in 
our ability to routinely optimize ‘difficult’ compounds and indicates a need to improve our 
approach. 
Examination of the change in simple physicochemical properties on going from lead to drug 
reveals that the separation between lead-like and drug-like physiochemical space is relatively 
small in most cases. Figure 1 shows a principal component plot, where PC1 and PC2 represent 
80% of the variance in a range of calculated descriptors (clogP [3], Molecular Weight, H-bond 
acceptors, H-bond donors, calculated logS, number of rings and number of rotatable bonds, 
data generated using MOE [25] descriptors and procedures) for the 60 lead-drug pairs. Ellipses 
are drawn each covering 90% of leads (blue) and 90% of drugs (red).
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chemists, and specifically, preferred directions for compound optimization, will help 
improve de novo design tools and other  in silico methods. For example, a recent paper 
demonstrates that the 3745 licensed single-entity drugs in the KEGG DRUG database are 
all based on just 236 conserved core structures and 506 peripheral fragments whose 125 
chemical attachment patterns depended on the core [30].
Whilst there remains a great deal more knowledge to extract from these analysis of 
earlier projects, amongst the most important lessons seems to be to ensure teams don’t 
focus excessive resources exploring one area of chemical space around their leads at 
the expense of other potentially valuable directions. Project teams should not treat 
drug-design as a journey along a straight path, with each new compound following the 
last, but rather imagine the process to be like navigating a maze where barriers will be 
encountered requiring teams to retrace their steps and follow alternative directions.
7.6. Navigating the Maze of Compound Optimization
The key to drug design and discovery is being able to judge when to stick by a choice 
you have previously made and fully explore its opportunities and when to step back and 
follow a different direction. A key requirement of achieving this is for drug designers to 
resist the natural tendency to hope that “…the next compound I make might be the final 
compound”, toward a mind-set that says “…the next compound I make should be the next 
step toward my final goal”. Every compound, active or inactive is a step on a journey; with 
both helping to build the understanding necessary to eventually make the compound 
that will become the drug. This requires projects to begin with a mindset of exploration 
and to retain it until strong evidence indicates focus on a specific area is required.
The progression of a discovery project should be typified by a growing knowledge and 
understanding of the problems at hand and the potential to address them, with the latter 
stages characterized by bringing together previously successful approaches (molecular 
groups) to deliver interesting candidates. This can only be possible if the team has 
determined a sufficiently diverse SAR by adequately exploring the total chemical space 
around their series. It should then be possible to look back to earlier work to identify 
Of course a drug may end up having similar physicochemical properties to its lead despite 
having undergone radical structural rearrangements; Figure 1 nonetheless shows that the 
lead and drug PC areas overlap to a remarkable degree and in many cases drugs will not differ 
dramatically from their leads. Overall, six drugs lie outside the red “drug-like” oval of PC space. 
Interestingly, three of these drugs are not delivered orally and need not be bound by the same 
physicochemical limits as oral drugs. The remaining four are Aliskiren, a renin inhibitor and three 
HIV-1 protease inhibitors, Saquinivir, Atazanavir and Ritonavir. These compounds show that it 
remains possible to deliver drugs with properties failing to satisfy the Lipinski rule of 5 provided 
strong design rationale is in place especially if supported by SBDD and intelligent bioisosteric 
substitutions (26–28), leading to clinically important drug molecules despite violating Lipinksi 
guidelines.
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an R-group providing selectivity when the current selectivity inducing R-group has to be 
sacrificed in search of improved stability.
Like trying to escape a maze, at a certain point, progression will be hindered leaving 
you literally or figuratively lost. When crossing the maze the natural action when this 
state is reached is to track back to a previous crossing, the point at which a decision 
was made, and to choose a different path. Nothing is gained from repeatedly covering 
the same ground. Whilst it sounds trivial, the courage required to step back from a very 
potent sub-series toward a less potent more drug-like series is often the most important 
differentiator of success. Rewarding chemists based on the numbers of compounds they 
produce, or numbers of compounds above a certain activity threshold, has in the past 
been a common practice within the industry, with the danger of reducing the openness 
of chemists to step back from compound sub-series that are delivering bonuses even if 
they are unlikely to deliver drugs.
7.7. Building on the Strongest Possible Foundation
It has been suggested that the presence of compounds with poor drug-like properties 
within our pipelines can be traced back to the nature of HTS hits and the associated hit-
to lead practices [31]. Improving the overall quality of corporate screening collections 
has been an industry wide goal for a number of years, with better collections generating 
higher quality and more progressable hits. It is amongst the most important of all 
cheminformatics tasks to identify weaknesses in screening collections, such as poor 
physical properties or lack of diversity, and then facilitate the selection of compounds to 
purchase or synthesize to address these limitations [32]. 
If the quality of leads is the key determinant for success in lead optimization, and ADME-
Tox issues are more difficult to optimize than potency [33], then prioritization during 
high-throughput screening (HTS) triage must be directed to selecting more progressable 
compounds even at the expense of potency. Despite it being generally recognized that 
hit prioritization is the most important medicinal chemistry decision to be taken during a 
project [33], too often this evaluation will be based on limited biological data, unreliable 
‘chemical-eye’ [34] and ‘gut-feeling’. Given this limited information, it is not surprising 
that potency and ease of chemical synthesis tend to dominate selection rationale [35]. 
To be successful, a validated hit should have a surmountable number of liabilities and a 
maximum potential for progression, including a balanced profile of potency, efficiency, 
drug-likeness and selectivity, and medicinal chemists must consider each of these issues 
to improve the selections they make [36]. 
The use of ligand-efficiency measures [37] can be a useful aid, provided sufficient reliable 
data is available, but must be accompanied by other knowledge approaches to HTS 
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triage. This will include approaches to manage systematic errors in screening such as 
plate effects, cell toxicity or enzyme degradation, as well as knowledge-based removal 
of known toxicophores and frequent hitters. In silico models to predict other undesirable 
activities such as hERG liabilities and gene toxicity have value for prioritization of hits 
even if a safety alert this early is no guarantee that the liability will still be present at the 
end of compound optimization. Cheminformatics methods are also important for the 
clustering of hits, analog identification and the rapid design of libraries around hits.
Whilst not a long term strategy for success in drug-design, there are cases, especially for 
new targets where rapid increase in potency might be required to allow validation of the 
biological hypothesis under-pinning the project [35]. However, even in these situations, 
desirable drug-likeness will facilitate comparison of in vitro and early in vivo results [5]. 
This will help avoid the common stumbling block of potent compounds in vitro showing 
no in vivo activity without teams being able to conclude if the biological rationale is 
wrong, if the compound is still not sufficiently potent, or if PK is the critical limiting issue.
7.8. In Silico Methods for Lead Finding
The use of in silico methods for the identification of drug leads from databases of small 
molecules, commonly referred to as virtual screening (VS), has been extensively reviewed 
and critically evaluated in recent years, including the following 3 articles [38–40]. The first 
examples of compounds derived from VS approaches appear to be entering the clinic and 
even the market [39], but the overall impact of the approach remains open for discussion. 
The efficacy of VS in ‘positive design’, for the selection of biologically active compounds 
directed to a specific target [40], like all aspects of CADD, can be improved by increasing 
the molecular understanding of the target structures or SAR that VS queries are built 
upon, and by ensuring the chemical integrity (stereo-isomers, tautomeric states etc) of the 
library compounds being searched [41]. There remain deficiencies in the methodologies 
used, although this is less evident in ligand-based VS compared to structure-based VS, 
where scoring, protein flexibility and the inclusion of water remain ‘holy grails’ [39].
‘Negative design’, for the elimination of the majority of inactive or inappropriate 
compounds [40], to remove reactive, toxic or non drug-like compounds, was originally a 
popular VS approach to pre-filter databases, but have since found a role in improving the 
quality of corporate screening collections [42]. 
The crossover between VS methods and HTS work flows is not a new concept [42, 43], and 
is not limited only to ‘negative design’, with informatics methods also having an important 
role in selecting subsets of compounds to test (focused screening). Focused screening is 
a standard practice when dealing with some target classes such as protein kinases [44] 
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demonstrating huge enrichment improvements compared to full HTS [45]. They allow 
teams to focus on higher quality chemical space and use lower throughput assays with 
higher precision not compromised by the requirements of speed and capacity [46]. Again, 
the kinase family provides a clear demonstration, with the now common application of 
cross-screening (kinase-profiling or selectivity-screening) strategies where a small subset 
of kinase inhibitor like compounds is tested against a panel of kinase targets rather than 
the single target more common in HTS [47]. The value of this chemogenomic approach 
is that compound potency as well as selectivity can be evaluated simultaneously which 
facilitates a more compound centric approach to early discovery with the quality of lead 
compounds contributing to the prioritization of targets and not pharmacology alone [47]. 
As ADME-Tox assays become increasingly high-throughput, including them in these types 
of strategies will further improve our ability to identify progressable leads from primary 
screening [5], facilitating multi-parameter optimization in the future.
7.9. Chemogenomics: Informatics Bridging Chemistry & Biology
The broadest definition of Chemogenomics is the understanding of the interaction between 
all possible ligands with all possible targets, but at a more practical level is characterized 
by the focused screening of libraries or compounds against multiple targets [48, 49], 
and the related informatics methods for ligand and target classification and selection. 
Knowledge management is so fundamental to these activities that chemogenomics is 
often considered to be an informatics discipline [50], where targets are classified and 
studied as protein families, to facilitate the transfer of insight from one member of a 
family to another [51]. The first systematic application of such methods is often credited 
to the SARAH (structure-activity relationship homology) project at GSK relating protein 
sequence to small molecule SAR [52]. Additionally, less formal approaches allowing 
multidisciplinary researchers opportunity to leverage technology and knowledge gained 
from work on one target to other related targets have been common for a longer time.
Molecular informatics resources for chemogenomics or family-based research in general, 
are growing in breadth and depth from both a target and ligand perspective. As an 
example, nuclear receptor target information is gathered by both the NUREBASE project 
[53] and the NucleaRDB project [54]. The NucleaRDB is accompanied by the Nuclear 
Receptor Structure Analysis Server (NRSAS) for structure prediction and related services 
[55], and the Nuclear Receptor Mutation Database [56] as well as further domain specific 
analysis [57]. These tools allow for informed selection of selectivity panels and homology 
modeling amongst other protein bioinformatics activities.
Chemogenomics tools from the ligand perspective center around databases of molecules 
linked to bioactivity data (quantitative and qualitative), including raw screening data in 
PubChem [58] and Chembank [59] and commercial SAR databases such as WOMBAT [60], 
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amongst others [61–63]. These tools facilitate the determination of specific properties 
differentiating between activity on specific target families, the elucidation of privileged 
scaffolds or the identification of interesting new bioisosteres. As with VS, chemogenomics 
therefore has the potential to provide better start points and directions for compound 
optimization.
The value of these ligand and target based chemogenomics resources are without question, 
but can be improved by their direct integration with in house data resources. Big-pharma 
especially have decades of screening and related data that may lack the chemical diversity 
of the publicly available data, but is likely to be of higher quality and more importantly, 
multi-parameter in nature. Integrating this legacy data into chemogenomics projects is 
a way to leverage that historical knowledge and provide competitive advantage [63]. 
Examples of this include Novartis linking 2.5 million in house compounds to a number of 
public databases [64] and Pfizer who built a data warehouse containing nearly 5 million 
chemical structures from their own internal repositories combined with data from public 
sources [65].
7.10. Information-Rich Compounds
Each step on the journey toward the delivery of a compound into development should 
increase knowledge and molecular understanding in the form of improved SAR, which, 
despite difficulties in extrapolation to the design and evaluation of new compounds, 
is the central pillar of all medicinal chemistry projects [66]. SAR has traditionally been 
elucidated on paper and in the heads of medicinal chemists. This suffers from subjective 
analysis, becomes increasingly more difficult as the number of compounds and properties 
increase, and is not suitable for considering multiple parameters simultaneously. SAR 
elucidation is therefore increasingly a ‘data-mining’ task with both bench chemists and 
computational chemists making use of tools to visualize and interpret multivariate data 
for their compound series [67, 68]. 
All SAR and quantitative SAR (QSAR) are dependent on the data from which they are 
derived, relying on the presence of informative compounds with a broad range of 
distinguishable physical-chemical properties. In the past, Craig plots and Topliss schemes 
have been used to help select synthetic modifications that will ensure either systematic 
chemical exploration or the generation of a property rich dataset for QSAR studies. As we 
wrestle with the complexities of multi-parameter drug design, these types of information 
generating methods may sound attractive, but have passed out of fashion since the 
implementation of parallel synthesis. It is now easier to make all available substituents 
[69] rather than carefully selecting an information rich subset. This is not necessarily a 
disadvantage and should still allow the drawing of the same conclusions as from the 
consecutive application of either Topliss or Craig approaches, but in practice, energy is 
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focused on generating analogs of the most active compounds without investing time in 
understanding the patterns and trends generated. Convincing project teams to commit 
resources to generate information rich compounds, that we suspect are unlikely to be 
active, but will be useful in improving understanding, is required if the project is to have 
access to good models early in the process.
7.11. Defining Constraints for Predictive Models
A key responsibility of any computational drug discovery group is the design of general 
and bespoke predictive models. Provided data is available, models can be generated to 
address any issue in which activity or property is related to compound structure. The 
quality of any model will be determined by the method used, the ability to select the 
most appropriate molecular descriptors, its applicability to the compounds it will be 
applied to, and the validity of the data the model is based on [10]. Regardless of which 
models are used, teams must ensure they re-evaluate their applicability routinely, and in 
the case of project specific models, regularly update them. Last year’s design insight can 
quickly become this year’s misleading dogma.
The quality of models alone does not determine their value within projects, with technical 
[70] and psychological factors [71] playing roles. Informatics often relies on complex 
methods that may seem inaccessible to the non-expert and therefore practitioners must 
make the effort to find ways to explain concepts if they want colleagues to fully support 
them and ensure project teams recognize and appreciate the relative accuracy of any 
theoretical prediction of a compound’s activity.
Crucially, practitioners must be able to determine when the application of a model is 
useful, i.e. optimally retaining or excluding the relevant set of desirable or undesirable 
compounds. This will depend on the predictive power of the model and likelihood that 
the properties it selects on will be present in the application set (low presence requires 
more accurate models to impact decision making) [70].
Drug-designers should also appreciate that predicted tolerance across a range of a 
property (i.e. cLogP between 2 and 5) is likely to have a bell shaped curve distribution, 
with either extremity being less desirable chemical space than the mode (peak of curve 
value). This is particularly pertinent when dealing with multiple properties and criteria. 
A compound may satisfy every defined constraint in lead optimization, but if all these 
criteria are only just met, what is the likelihood the compound will survive to the market? 
A compound achieving only minimum levels of solubility, potency and stability will 
probably require higher dosing, putting more pressure on the compound’s selectivity 
and toxicity profile. It is therefore important to avoid the ‘tick-box’ approach to multi-
parameter design, checking off each parameter in isolation of others, and to holistically 
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evaluate the value of the most progressed compounds.
Applying parallel models, predicting multiple end points (solubility, stability, potency), 
and excluding those that do not satisfy specific constraints, can be a very powerful way 
to address some of the challenges of multi-parameter optimization [72]. Tools such as 
Pipeline Pilot, KNIME and InforSense provide infrastructure, via single workflow systems 
[73]. These can apply consecutive models excluding failing compounds at each step [2], or 
be used to calculate all values for all compounds allowing us to identify balanced profiles.
7.12. Computational Methods for Multi-Objective Optimization
Recently, the first examples of techniques for objectively defining compromise between 
multi-parameters, referred to as multi-objective optimization (MOOP), have been 
described [74–77].
MOOP techniques try to simultaneously optimize numerous dependent properties 
to deliver a series of satisfactory compromises, and avoid single objective dominant 
solutions. The two approaches currently described to achieve this are weighted scoring 
functions and Pareto-based methods [78]. Weighted scoring functions sum each 
individual design parameter (novelty, solubility, potency etc) with a weighting function 
associated with each parameter. Pareto-based methods are used to identify multiple 
solutions representing various compromises between the drug design parameters by 
selecting solutions that make at least one individual parameter better off without making 
any other parameter worse [79].
Examples of MOOP methods in cheminformatics can be found in the following excellent 
recent reviews on the topic [78, 80], and include its use in combinatorial library design 
[74] and De Novo ligand design [81].
7.13. The Medicinal Chemistry Knowledge Worker
Without a doubt, the ability of pharmaceutical companies to manage and exploit their 
corporate knowledge is a crucial differentiator for success [82]. In the same way that the 
-omics technologies, dealing with their own “data-explosion”, are now inseparable from 
bioinformatics, medicinal chemistry must become inseparable from cheminformatics 
[83]. Molecular biology has rapidly increased its ratio of in silico scientists compared to 
bench scientists and improved overall knowledge of informatics methods across its entire 
community. Medicinal chemistry has in part resisted this necessary change, but will have 
to address this deficiency in the short term, learning to treat computer literacy as a 
core skill of the bench chemist [84]. As projects increase the percentage of work being 
outsourced and the volume of the data to analyse, medicinal chemists must increasingly 
become knowledge workers, able to use informatics methods to manage their projects, 
track literature and competitor intelligence resources as well as extract the most detail 
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from their own SAR. Increasingly this is becoming the norm, with medicinal chemists 
utilizing various knowledge-based tools to achieve this. 
Less common is for bench chemists to utilize more complex informatics tools which is 
unfortunate as experienced design chemists with additional understanding and insight 
of their SAR derived from the use of informatics tools will inevitably design better 
compounds. Achieving this requires the provision of training, time to apply these 
approaches and intuitive user interfaces, with most organizations utilizing web enabled 
systems to deliver these services [85]. Engaging bench chemists to undertake their own 
in silico experiments, supported by informatics experts, who are themselves freed to 
focus on more complex and difficult computational challenges, should be a crucial goal 
for modern drug discovery. 
A commonly cited argument for encouraging chemists to undertake their own modeling 
is to increase their feeling of ownership, as they are more likely to consider a model they 
have developed themselves and then devote time to synthesizing molecules based on it 
[86]. Such anti-collaborative attitudes, if they do really exist, should not be tolerated, but 
it is undeniable that a feeling of shared ownership does encourage the use of models.
In addition to model building, the modern chemist must embrace a move from 2D to 3D 
drug design. Determining how differences between compounds, including conformation 
and electrostatics, alter their activity requires tools to compare them in 3D, and a 
feeling for how different groups influence shape and conformation. Scaffold hopping, 
consideration of pharmacophores, compound overlaying as well as any side-group 
modification, without sufficient 3D consideration, runs the risk of false comparison. 
Bench chemists must be able to consider the 3D implications of the design decisions 
they make daily, requiring access to software, an understanding of the basic principles of 
force fields and the differences between local and global minima. These considerations 
are also important when studying ligand-receptor complexes, as are the skills to map 
different properties onto binding pockets, overlay multiple complexes, compare pockets, 
visualize non-bonded interactions for common fragments and the use of probe tools 
to identify regions of the binding pocket that are favorable for the addition of specific 
groups. Numerous tools exist to facilitate these activities [87], but perhaps the sheer 
volume and diversity available is a hindrance to their broader use.
7.14. Modelers as Core Discovery Team Members
Most drug discovery organizations will already have teams of scientists within their 
molecular modeling/cheminformatics/CADD groups adept at handling and utilizing 
multiple datasets [88], but too often these skills and methods sit at the periphery of the 
project teams [46]. Any successful informatics strategy must be focused on meeting the 
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requirements of the modern drug-design, which is only possible when fully integrated 
within the discovery process [46]. Most pharmaceutical companies utilize a project 
team structure with a small team of pharmacologists, molecular biologists and chemists 
leading the drug discovery project. The inclusion of computational chemists as core 
decision makers within these teams is extremely important, as this is the only way to 
ensure that the modelers are fully informed about the problems at hand, able to define 
the questions they will tackle, and have influence to ensure their methods are taken 
up. CADD must be considered a core technology within discovery projects rather than 
a service, with modelers sharing equal ownership and responsibility for projects. This 
challenges modelers to become broader and more knowledgeable of all aspects of the 
drug discovery process and behave as drug hunters and not just informatics or IT support 
for projects. It is also an absolute requirement that the molecular modeling experts 
within an organization are also in close contact with their bench colleagues. Cross-
fertilization and stimulation of ideas between the two disciplines will increase the quality 
and efficiency of both groups. 
A recurring hindrance to the timely application of molecular informatics has been the 
availability of resources. Too often modelers are assigned to multiple projects, dividing 
their time over numerous diverse problems. This situation prevents the computational 
chemist from focusing sufficiently on each problem, resulting in the use of sub-optimal 
approaches and delaying the delivery of bespoke models and insight. Modelers should be 
equally engaged as lead chemists, who are rarely asked to work on multiple projects in 
lead optimization, and share with them an equal appreciation of SAR, planned synthesis 
and other project issues. 
Modeling groups also tend to be composed largely if not exclusively of PhD level scientists 
without access to technicians, whose presence would allow research scientists to focus 
more time on the interpretation and exploitation of data and less time on its generation 
and management.
Another hurdle to the timely application of CADD can be the desire of computational 
chemists to improve their models before applying them in the hope that its next iteration 
will be an improvement on the previous version. As scientists we are naturally eager to 
produce the most accurate and relevant output, always striving to improve the quality 
of our work, but this can result in repeated delays. We have to become better at saying, 
‘good is good enough’ and to accept that the search for perfection will actually diminish 
positive impact on drug design. This requires modelers to accept the risk of being wrong, 
itself requiring management to foster an environment where presenting a challenging, 
but potentially valuable new idea is encouraged.
145Multi-Parameter Compound Optimization
 
Ch
ap
te
r 
7
It is important for the success of CADD groups that they have an expert in each of the most 
important fields (methods or target families) who can define best practice and monitor 
and critically evaluate developments in their area. However, it is at least as important that 
all CADD scientists, representing this skill base within projects, have a broad knowledge 
of the field and are able to apply a diverse range of computational medicinal chemistry 
approaches. A failing of molecular modelers in the past has been a reluctance to apply 
a more appropriate in silico technique outside the realm of their particular expertise. 
Productive computational medicinal chemists will identify the question most important 
to the team and then identify which of a broad array of tools can be used to devise 
strategies to formulate answers. 
Experimental design, without consideration for data analysis is flawed, and the generation 
of increasingly large data resources within projects, without provision of the resources 
required for its analysis and exploitation ensures that research fails to benefit fully from 
the investments it makes at the bench or within its automated laboratories.
7.15. Integrating Computational and Synthetic Chemistry
Bench-based medicinal chemists and their computational medicinal chemistry colleagues 
share the same primary goal, which is the design of new and commercially relevant 
chemical entities. This shared objective can create tension between these two overlapping 
disciplines with a series of often repeated criticisms directed in both directions.
The most common objection from computational chemists toward their bench colleagues 
is a lack of willingness to synthesize the compounds they suggest. From the opposite 
direction we often hear the comment, “Your idea for a new NCE looks great on the 
computer screen, but how will I be able to synthesize it?” 
Experienced and knowledgeable modelers are able to ensure compounds suggested by 
CADD can actually be synthesized within the constraints of a normal design strategy. 
Designing compounds utilizing available building blocks, intermediates and the reactions 
already being used within a project may also help encourage the synthesis of NCEs based 
on modeling and informatics, with the drawback that this narrow approach doesn’t allow 
CADD methods to challenge the existing presumptions and dogmas of the project and 
may result in simply pre-empting choices the bench chemist would have made anyway.
Modelers should not hesitate to challenge the synthetic chemist to make difficult 
compounds if supported by reliable models or insight. A compound being more difficult 
to make is insufficient argument not to make it, but it is the responsibility of the modeler 
to demonstrate why they strongly believe it should be considered to the synthetic 
chemist. The synthetic chemist in turn has the responsibility to make the compound if 
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the rationale is strong enough, even if this means not making compounds of their own 
design. There is always a reason not to make a compound, as no compound, even those 
on the market, is ever perfect. It is therefore possible to place unrealistic and artificial 
barriers in front of any challenging idea, inevitably at the cost of the project.
There also remains a common misconception that the promise of computational 
approaches in rational drug-design is to allow the reduction of bench chemists employed 
by pharma. There is in fact a growing argument that for CADD to have impact, more 
chemists are required, not fewer. CADD will suggest new directions and new chemical 
space to explore, and will require chemists to undertake newer and more difficult synthesis 
than they might choose otherwise. All of this will be in addition to the chemistry that the 
bench chemists want to investigate themselves, and only partially compensated by the 
ability to identify and discontinue unproductive chemical space. Therefore projects with 
a high CADD component are likely to require more and not less chemists. The benefit to 
the drug-discovery company will be more diverse compounds coming from projects with 
a wider range of properties and characteristics eventually resulting in more and better 
drugs in the pipeline, where efficiency and value is really generated. Given an estimate of 
95% attrition in clinical development [7], just a 5% reduction in this failure would achieve 
a doubling of the number of compounds reaching the market [4], which should be more 
efficient and better value than the alternative of doubling the number of compounds 
going into development.
In today’s climate of pharma mergers, consolidation and streamlining, arguments for 
greater manpower may fall on deaf ears, but with the increasing availability of outsourced 
chemistry [89], it should still be possible to sufficiently support more information-driven 
drug design.
7.16. Getting more from Structure-Based Drug Design
Protein-ligand co-crystals are one of the most valuable resources for molecular design, 
providing an excellent opportunity to optimize compounds rationally. It can however 
be argued that their application within multi-parameter design projects is not yet being 
fulfilled. The first barrier has been the mindset that SBDD is only a tool for improving 
potency or selectivity by altering the number and strength of intermolecular interactions. 
SBDD can be just as useful in identifying regions that will tolerate the addition of 
solubilizing groups or selecting which functions can be safely removed or protected 
without losing activity on the target.
Historically there has been a separation between the structural biologists generating new 
protein-ligand complexes and the modelers and medicinal chemists responsible for new 
compound design, but that gap can be bridged. Modelers should become more structural 
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biology aware, making use of electron density and R-factors as measures of flexibility and 
not just final coordinates [46, 90]. We have found that giving modelers the training to be 
able to independently calculate density and models from X-Ray diffraction data, along 
with direct support from structural biology experts, ensures a fuller appreciation of the 
subtleties and nuances in the structures they are basing decisions upon, resulting in more 
informed and reliable compound design.
X-Ray structures, as with all forms of data, are dependent on timely availability to ensure 
their true value. Historically, SBDD was undertaken later in projects and used to improve 
already well optimized compound series, but there is growing acceptance that access to 
co-crystals will have greater impact the earlier in the process they can be obtained. The 
later projects have access to this resource, the more entrenched the poor characteristics 
of compound series are likely to be. Instead of hoping SBDD can help dig you out of a 
hole, projects will be better served using it to avoid traps in the first place. The growing 
influence of Fragment-based drug design (FBDD) contributes to this view.
7.17. FBDD and Related Informatics
FBDD hits, due to their reduced size and complexity, tend to have lower potency than HTS 
hits, but higher or at least comparable ligand-efficiencies and are more progressable. Due 
to the complexity of most compounds in corporate screening collections there is a good 
possibility that HTS hits will include both good and bad interactions with the target. FBDD 
hits, by contrast are feature poor, reducing the potential to include bad interactions. 
FBDD is also able to sample chemical space more efficiently than HTS due to the lower 
number of potential fragments compared to drug-like molecules [91]. Since Abbott’s first 
description of the practice [92] its adoption industry wide has been rapid with 17 clinical 
candidates derived from FBDD already reported in a 2009 review [93]. This success is 
despite the fact FBDD is often applied only after the failure of traditional screening.
As with all screening campaigns, the quality of the fragment library will determine the 
eventual outcome, and therefore, building fragment libraries is the first crucial step in 
FBDD. The most frequently applied design rules for fragment libraries are based on Astex’s 
‘rule of three’ [94] (MW ≤300 Da, ClogP ≤3, H-bond donors ≤3 and rotatable bonds ≤3) 
as well as additional measures such as polar surface area ≤60 Å2 [93] and consideration 
of synthetic tractability [95]. Additional target specific restrictions can be included based 
on available knowledge, for example, our own fragment library includes kinase hinge-
binding fragments created from an analysis of the kinase crystal structure entries of the 
Protein Data Bank.
After the design of fragment libraries, either generic or target focused, and the triage of 
potential hits, the next informatics goals revolve around the expansion of fragments to 
148    Chapter 7
better occupy the binding pocket or the linking together of multiple fragments in one 
pocket. As such, fragment hits typically require access to experimentally determined 
structural data describing binding to targets for direct optimization [96], which 
is especially the case due to the lack of in vitro measured data for SAR analysis [95]. 
Methods to theoretically predict binding modes are hampered by the difficulty of using 
docking methods to predict binding orientations of small molecules, and the ubiquitous 
SBDD issues addressed earlier. 
Informaticians are used to approaching drug design from a fragment perspective as we 
often reduce complex molecules to smaller substructures for the calculation of various 
properties including logP and potential toxicology [97]. It is therefore not a surprise that 
De Novo design methods already provide an array of methods for the optimization and 
joining of fragments in the context of their targets [98, 99]. 
De Novo design is also the subject of recent publications related to its application in 
MOOP studies [81, 100, 101] as its role in FBDD makes it essential to ensure optimization, 
even from these attractive start-points, follows tractable paths. De Novo design methods 
also pose the challenge of translating in silico ideas into synthetically amenable plans, 
which continues to be difficult, not least because synthetic feasibility is a subjective 
measure dependent on a chemists experience and knowledge [102].
The requirement for access to X-ray co-crystals and availability of protein in suitable form 
for screening, limits the number of amenable targets to which FBDD can be applied. 
Abbott, a founder and current leader in FBDD, estimate that it is a method applicable to 
just 30% of their targets [96]. Medicinal chemist’s, reluctant to work on low potency hits, 
are a further hindrance to the application of FBDD [91].
7.18. Technology Development
Molecular informatics remains subject to rapid new technology development within 
academia, commercial research organizations (CROs) and directly within industry. 
Ensuring this effort is directed to solving the actual problems drug-designers face within 
their discovery projects is important to maximize this effort and avoid the generation 
of ‘white elephant’ applications. Strong partnerships between industry and academia 
are crucial here, and should involve broad collaboration, long term commitment and 
bidirectional sharing of knowledge.
There is an argument that real scientific breakthroughs in computational drug design 
methodologies have been scarce in recent years [46], but there is scope to ensure the 
most value can be extracted from existing methods. This means optimizing how we embed 
them in the drug discovery process and tailor current applications to our needs. Examples 
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within Merck include expert user tools such Fleksy [103], a flexible protein docking 
method developed in collaboration with the Computational Drug Discovery group at the 
Radboud University in Nijmegen and based on the existing FlexX [104] and FlexE [105] 
docking methods. Non-expert tools include SyGMA [106], a method for the prediction of 
metabolic transformations based on rules derived from the MDL Metabolite Database 
[107] and IBIS [108], a bioisoster generator relying on a combination of theoretically 
proposed and experimentally derived bioisosters from the BIOSTER database [109] and 
the mining of our in house corporate databases. Both SyGMA and IBIS are web tools 
available to, and heavily used by, bench scientists via a common web interface.
IBIS is a result of mining 188 assays covering 61 targets from 6 target families, from 
Organon and Schering-Plough projects, to identify and record every tolerated chemical 
change made during compound optimization. This allows anybody from to query which 
groups have in the past shown similar or better activity compared to their query, and 
as such is an important tool for retaining corporate knowledge. This will return the 
bioisosters all experienced medicinal chemists will name, but also many less well known 
examples, putting the knowledge of generations of drug-designers at everybody’s 
fingertips. Queries against this database can be more specific, for example, it can be 
used to suggest only bioisosters that are more polar than the input and already appear 
regularly in drug databases, and, as an additional chemogenomics consideration, all 
bioisosters are additionally classified by target-family allowing for more specific decision 
making. If knowledge is the most important resource in the pharmaceutical and biotech 
industries [69], then these methods are crucial to ensure it is retained and exploited.
7.19. Concluding Remarks
We often compare drug discovery to finding a needle in a haystack. If this was the case, 
then we might presume that the increasing scale and industrialization of drug discovery 
should be bearing fruit as we have spent the last decades developing tools to more rapidly 
discard hay. Unfortunately this does not appear the case. The haystack analogy also fails 
to consider that each piece of hay can easily be discarded as it is clearly not a needle, 
and that when you eventually find the needle you can be sure that your task is complete. 
Drug discovery can therefore better be compared to searching for a very specific needle in 
a very large stack of other needles. Like molecules in chemical space, many of the needles 
will appear to be virtually identical or at least very similar. Finding the small differences 
that separate the majority of needles from the small group of desired needles is a 
significant problem, but cannot be solved by focusing on just one or two characteristics. 
Informatics will provide the most important tools within the medicinal chemist’s arsenal 
for the exploration and comprehension of these issues. 
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Summary
Dr. Smith was an extremely talented and successful drug designer applying his considerable 
chemistry knowledge to a variety of projects. He had been working for a large multi-
national pharmaceutical company for many years, and was involved in the development 
of several blockbuster drugs. Dr. Smith took a traditional approach to drug design, initially 
making a wide variety of compounds for each target, and then successively focusing 
synthesis within the most active chemical space until the "ideal" compound was attained. 
Dr. Smith had very little interest in why the compound elicited its response, but had a good 
track record in delivering active molecules. One day, during his regular morning walk to 
work past a local lake, he saw a man in the water drowning. Bravely, he dived into the 
lake and rescued the unknown man from the cold water, stayed with him on the bank until 
he was sure the man had recovered, and then continued his walk. A few hundred metres 
further along he saw a second person also struggling in the icy water, and once again he 
dived in to save him. Already astonished at the events of the morning, he was astounded 
when a few hundred metres further along he saw a third person drowning. As he prepared 
to jump in once again he saw his colleague, Dr. Jones, and called for him to also jump in 
to help. Dr. Jones stayed on the bank, looking around and paying little attention to the 
activity in the lake. Dr. Jones was also a drug designer, but considered his methods to be 
a more modern "rational" approach. He sought to understand the molecular basis for the 
activity of compounds, and then use this information to design newer and better drugs. 
He had not worked as long for the company, but after a difficult start he was beginning 
to demonstrate his own ability to deliver excellent compounds for his projects. Dr. Smith 
saved the drowning man alone before returning to the bank and furiously addressing his 
colleague; “Why didn’t you help me?” he exclaimed.  Dr. Jones turned to his colleague and 
answered: “You can keep jumping into the icy water if you want, but I am going to stay 
here and try to figure out who keeps pushing these people into the lake!”
This adaptation of an old proverb is not supposed to suggest that Dr. Jones is smarter 
than Dr. Smith because he chooses to get to the heart of the problem, or that Dr. Smith’s 
approach is more effective because he saved the third person (the pragmatic solution) 
whilst Dr. Jones was thinking about a problem for which he may never find a solution. 
The purpose of the story is to demonstrate that there is a difference in mind-set which is 
reflected in modern drug design.
Over the last twenty years the science of drug discovery has become target rather than 
indication driven, with research directed at specific proteins known to mediate disease. The 
success of this approach is dependent on a deep understanding of those molecular targets 
and the biological processes to which they contribute. The role of the computational drug 
designer is to provide, following multi-parameter optimization strategies, the molecular 
basis and rationale for the selection and design of new compounds. Insight into the target 
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protein, knowledge of existing chemical space directed to that target, proficiency with a 
broad toolkit of scientific software and familiarity with the universal rules of medicinal 
chemistry are all required to be successful. 
The progesterone receptor (PR) is a member of the nuclear receptor super-family and 
specifically the steroid receptor sub-family. It plays a crucial role in the initiation and 
maintenance of pregnancy as well as many other women’s health conditions related 
to menstruation and the endometrium. Drug interventions for PR are important in a 
number of areas in reproductive medicine with further applications in oncology. The 
most important endogenous ligand of PR is progesterone, but other natural progestins 
also exist with weaker activities. 
The progesterone receptor is modulated by several classes of compounds, each of which 
illicit different responses with the potential to treat different indications. Progestins 
are used as oral contraceptives both as a constituent of a combination approach, in 
conjunction with an estrogen, or alone as a progestin-only intervention. The use of 
progestins in contraceptives decreases the production of gonadotropins such as follicle-
stimulating hormone and luteinizing hormone via the pituitary-hypothalamic axis which 
in turn prevents ovulation. Ingested progesterone is almost completely inactivated in 
the liver, and so synthetic analogs are required to make orally active progestin drugs. 
The progestins used in combination oral contraceptives include one of; norethindrone, 
norethindrone acetate, ethynodiol diacetate, levonorgestrel (active isomer of norgestrel), 
desogestrel or norgestimate. 
In addition, Mifepristone (RU486) is a potent anti-progestin used as an abortive agent 
within 50 days of the last menses. Mifepristone binds to PR, preventing the binding 
of endogenous progestins and therefore blocking the normal hormone response. This 
results in progesterone withdrawal bleeding and the detachment of the conceptus from 
the uterine wall.
Drug discovery directed toward this target remains a fertile area with significant 
potential to improve patient treatment and create commercial benefit. In particular, the 
development of mixed profile progesterone receptor modulators, often referred to as 
Selective Progesterone Receptor Modulators (SPRMs) whose activity falls between full 
agonist and full antagonist, is the focus of both drug discovery and this thesis. SPRMs 
have mixed agonist-antagonist properties and occupy an intermediate position in the 
spectrum between full agonists such as Progesterone and full antagonists such as 
Mifepristone. Whilst none have yet made it to the market, it is believed that SPRMs have 
the potential to treat many women’s health conditions with improved efficacy and safety 
profiles. 
159Summary
 
Su
m
m
ar
y
Enabling the "rational" design of improved SPRMs requires an improved understanding 
of the subtle structure-activity relationships that result in different ligand induced 
receptor responses. This text includes several studies that share the goal of extending 
our understanding of the molecular basis for ligand-induced mixed profile activities.
The thesis begins with two chapters introducing the reader to basic aspects of the 
research that underpins the later chapters. Chapter 1 provides a general summary of 
computational drug discovery whilst Chapter 2 introduces the steroid receptors and 
several key aspects of drug design toward them. This includes issues related to affinity, 
selectivity and function and is based on a review article to which I contributed. Chapter 
3 is an invited review article published recently in a steroid hormones textbook which 
discusses the available drug design approaches that can be utilised when developing 
mixed-profile modulators. Chapter 4 is the first of the research articles, originally published 
in The Journal of Biological Chemistry, in which we describe three new X-ray structures of 
progesterone receptor ligand-binding domains bound to compounds from a structurally 
related but functionally divergent series. The compounds exhibit different binding modes 
corresponding to their agonistic or antagonistic nature with fine differences in interaction 
with the receptor explaining the previously incomprehensible ligand-mediated 
differences. The ligands were themselves developed in a drug design project to which I 
contributed. Chapter 5 is a second research article, also published originally in The Journal 
of Biological Chemistry, in which two further new progesterone receptor X-ray structures 
are described in complex with mixed profile ligands. The structures demonstrate that two 
distinct mechanisms explain the mixed profiles of the two ligands, indicating that both 
steric, and described for the first time, electrostatic factors, can contribute to mixed PR 
activity. The structures suggest specific directions for drug design including interactions 
with the receptor and the existence of a previously undescribed pocket. Chapter 6 is 
the third and final research article, prepared for submission to The Journal of Biological 
Chemistry, including the peptide-recruitment profiles for a representative set of PR 
modulators which clearly discriminate full antagonists from the SPRMs and SPRMs from 
full agonists. Indeed, the resolution of the technique, for which this article is the largest 
and most thorough report, allows for the differentiation between compounds within 
these overall classifications. In conjunction with the peptide recruitment work we also 
publish a further four new progesterone receptor X-ray structures which suggest that the 
degree of clash between the ligand and the residue Met909 is the key determinant of each 
compounds peptide-recruitment profile. 
In total we report nine new progesterone receptor structures which significantly enrich 
our knowledge of this drug target and provide further insight into the mechanisms of 
mixed profile compounds of the steroid hormone receptors in general. 
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Chapter 7 is a keynote review article, published after invitation, in Drug Discovery Today 
in 2011 discussing the challenges of multi-parameter drug design.
The thesis concludes with a brief CV and a complete personal bibliography as well as a 
summary of the other steroid receptor articles I have contributed to but which are not 
included in this thesis. The last chapter is my opportunity to thank those people that have 
supported my work over the years.
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Overzicht en opzet van de dissertatie
Dr. Smith is een buitengewoon getalenteerde en succesvolle ontwikkelaar van 
geneesmiddelen die zijn grote scheikundige kennis inzet voor uiteenlopende projecten. 
Hij werkt al jarenlang bij een grote farmaceutische multinational waar hij betrokken is 
geweest bij de ontwikkeling van diverse blockbuster geneesmiddelen. Dr. Smith gaat 
bij de ontwikkeling van geneesmiddelen traditioneel te werk. Eerst maakt hij per target 
een groot aantal verschillende verbindingen, om vervolgens middels synthese binnen 
de meest werkzame chemische ruimte de "ideale" verbinding te bepalen. Waarom een 
verbinding zorgt voor de bewuste reactie interesseert hem nauwelijks maar hij kan bogen 
op een goede staat van dienst als het gaat om het vinden van werkzame moleculen. Op 
een dag ziet hij tijdens zijn gebruikelijke wandeling naar het werk langs de oever van een 
meer dat er iemand dreigt te verdrinken. Zonder zich te bedenken duikt hij het meer in 
en redt de onbekende man uit het koude water. Hij vervolgt zijn wandeling pas wanneer 
hij er zeker van is dat de man is hersteld. Na een paar honderd meter ziet hij nog iemand 
die voor zijn leven vecht in het ijskoude water, en ook nu springt hij het meer in om hem 
te redden. Alsof dat niet genoeg is, ziet hij tot zijn grote verbazing een paar honderd 
meter verderop weer een drenkeling. Terwijl hij zich opmaakt om opnieuw het water in 
te springen, ziet hij een collega, dr. Jones, en vraagt hem hetzelfde te doen. Dr. Jones 
blijft echter aan de kant staan, kijkt wat rond en toont weinig belangstelling voor wat er 
zich afspeelt in het meer. Dr. Jones ontwikkelt ook nieuwe geneesmiddelen maar vindt 
zijn eigen aanpak moderner en "rationeler". Hij probeert eerst inzicht te krijgen in de 
moleculaire basis voor de werkzaamheid van de verbindingen om aan de hand van die 
informatie nieuwe en betere geneesmiddelen te maken. Hij is nog niet zo lang in dienst 
bij de onderneming, maar na een moeizaam begin wordt duidelijk dat hij op zijn eigen 
manier uitstekende stoffen creëert voor zijn projecten. Dr. Smith redt de drenkeling op 
eigen kracht en terug aan land haalt hij woedend uit naar zijn collega: "Waarom heb je 
me niet geholpen?" Daarop keert dr. Jones zich tot zijn collega met het antwoord: "Van 
mij mag je elke keer weer in het ijskoude water springen, maar ik blijf liever aan de kant 
om uit te vinden wie die mensen alsmaar het meer in duwt!"
Met deze variant op een oude wijsheid willen we niet beweren dat dr. Jones slimmer is 
dan dr. Smith omdat hij de kern van de zaak wil onderzoeken, of dat de aanpak van dr. 
Smith effectiever is omdat hij de drenkelingen redt (de pragmatische oplossing) terwijl 
dr. Jones nadenkt over een probleem waarvoor hij misschien nooit een oplossing vindt. 
Wat we willen duidelijk maken is dat er verschillende manieren van denken zijn die terug 
te vinden zijn in de hedendaagse ontwikkeling van geneesmiddelen.
In de afgelopen twintig jaar heeft de wetenschap zich op dit gebied meer laten leiden 
door de target dan door de indicatie en is het onderzoek gericht geweest op bepaalde 
eiwitten waarvan bekend is dat zij een rol spelen bij ziekten. Het welslagen van deze 
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benadering is afhankelijk van een grondig inzicht in die moleculaire targets en de 
biologische processen waartoe zij bijdragen. De taak van de computerondersteunde 
ontwikkeling van geneesmiddelen is om aan de hand van optimaliseringsstrategieën 
met meerdere parameters te voorzien in de moleculaire basis en rationale voor de keuze 
en totstandbrenging van nieuwe verbindingen. Inzicht in het target-eiwit, kennis van 
bestaande chemische ruimte die is gericht op die target, vaardigheid in een breed pakket 
van ondersteunende wetenschappelijke software en bekendheid met de algemene regels 
van medicinale scheikunde zijn stuk voor stuk nodig om te kunnen slagen. 
The progesteronreceptor (PR) maakt deel uit van de superfamilie van kernreceptoren en 
specifiek van de subfamilie steroïde receptoren. Hij speelt een cruciale rol bij het tot stand 
brengen en in stand houden van zwangerschap en in talrijke andere gezondheidskwesties 
in verband met menstruatie en het endometrium. Geneesmiddelen voor PR zijn van groot 
belang op een aantal gebieden van de reproductieve geneeskunde en vinden tevens 
toepassing in de oncologie. Het belangrijkste endogene ligand van PR is progesteron, 
maar er zijn ook andere natuurlijke progestagenen met een zwakkere werkzaamheid. 
De progesteronreceptor wordt gemoduleerd door diverse soorten verbindingen, die elk 
een andere reactie opwekken en derhalve in beginsel geschikt zijn voor uiteenlopende 
indicaties.  
Progestagenen worden gebruikt als oraal contraceptivum, zowel in combinatie met een 
estrogeen als zelfstandig, als behandeling met uitsluitend progestageen. Bij toepassing 
als contraceptivum zorgen progestagenen voor een verminderde productie van 
gonadotrofinen zoals het follikel-stimulerend hormoon en het luteïniserend hormoon 
via de as hypofyse-hypothalamus, wat op zijn beurt ovulatie voorkomt. De werking 
van toegediend progesteron wordt vrijwel volledig teniet gedaan in de lever, zodat 
synthetische analoge hormonen nodig zijn om oraal werkzame geneesmiddelen met 
progestagenen te maken. De progestagenen die in combinatie met orale contraceptiva 
worden gebruikt zijn norethindrone, norethindrone-acetaat, ethynodiol-diacetaat, 
levonorgestrel (actieve isomeer van norgestrel), desogestrel of norgestimaat. 
Daarnaast is Mifepristone (RU486) een krachtig anti-progestageen dat binnen vijftig 
dagen na de laatste menstruatie wordt toegepast als abortivum. Mifepristone bindt 
zich aan PR en voorkomt zo het aanhechten van endogene progestagenen, waarmee 
de normale hormonale reactie wordt geblokkeerd. Door de anti-progestagene werking 
ontstaan bloedingen en laat het vruchtzakje los van de baarmoederwand.
Onderzoek naar nieuwe geneesmiddelen voor deze target blijft een vruchtbaar werkterrein 
met duidelijke kansen op een betere behandeling en commercieel voordeel. In het 
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onderzoek naar nieuwe geneesmiddelen – en in deze dissertatie – ligt de nadruk in het 
bijzonder op de totstandbrenging van PR-modulatoren van een gemengd profiel, veelal 
selectieve PR-modulatoren (SPRMs) genoemd, waarvan de werkzaamheid ligt tussen 
volledig agonistisch en volledig antagonistisch. SPRMs hebben gemengde agonistische en 
antagonische eigenschappen en bevinden zich halverwege het spectrum tussen volledige 
agonisten zoals progesteron en volledige antagonisten zoals Mifepristone. Hoewel ze nog 
niet op de markt zijn gebracht, wordt aangenomen dat SPRMs in beginsel geschikt zijn 
voor de behandeling van een groot aantal aandoeningen bij vrouwelijke patiënten, en dat 
zij zorgen voor meer doeltreffendheid en veiligheid. 
Voor een "rationele" totstandbrenging van verbeterde SPRMs is meer inzicht nodig in 
de subtiele relaties tussen structuur en werkzaamheid die leiden tot de verschillen in de 
door het ligand opgewekte receptorreacties. In dit document zijn diverse onderzoeken 
opgenomen die alle als doel hebben meer inzicht te verkrijgen in de moleculaire basis 
voor door een ligand opgewekte vormen van werkzaamheid met een gemengd profiel.
De dissertatie begint met twee hoofdstukken ter inleiding van de basisaspecten van het 
onderzoek dat ten grondslag ligt aan de latere hoofdstukken. Hoofdstuk 1 biedt een 
algemeen overzicht van computerondersteund geneesmiddelenonderzoek en hoofdstuk 2 
introduceert de steroïde receptoren en diverse daarmee samenhangende kernbegrippen 
binnen het geneesmiddelenonderzoek, bv. in verband met affiniteit, selectiviteit en 
functie. Hoofdstuk 2 is gebaseerd op een overzichtsartikel waaraan ik heb bijgedragen. 
Hoofdstuk 3 is een op uitnodiging geschreven overzichtsartikel dat onlangs is verschenen 
in een leerboek over steroïde hormonen, en gaat in op de beschikbare methoden voor de 
ontwikkeling van modulatoren met een gemengd profiel. Hoofdstuk 4 is het eerste van de 
onderzoeksartikelen – oorspronkelijk gepubliceerd in The Journal of Biological Chemistry 
– waarin we een beschrijving geven van drie nieuwe röntgenstructuren van domeinen 
van PR-ligandbinding die hechten aan verbindingen van een structureel gerelateerde 
maar functioneel divergente reeks. De verbindingen vertonen diverse bindwijzen 
naargelang hun agonistische of antagonistische aard. Nuanceverschillen in de interactie 
met de receptor verklaren de voorheen onbegrijpelijke verschillen die ontstonden 
onder invloed van het ligand. De liganden zelf zijn voortgekomen uit een project voor de 
ontwikkeling van nieuwe geneesmiddelen waaraan ik heb bijgedragen. Hoofdstuk 5 is 
een tweede onderzoeksartikel, eveneens in eerste instantie gepubliceerd in The Journal 
of Biological Chemistry, waarin nog twee nieuwe röntgenstructuren van PR's worden 
beschreven in samenhang met liganden met een gemengd profiel. Uit de structuren blijkt 
dat het gemengde profiel van beide liganden wordt verklaard uit twee onderscheiden 
mechanismen, hetgeen erop wijst dat zowel sterische als – voor het eerst beschreven 
– elektrostatische factoren kunnen bijdragen tot gemengde PR-werkzaamheid. De 
structuren suggereren specifieke richtingen voor de geneesmiddelenontwikkeling, zoals 
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interacties met de receptor en het bestaan van een tot nu toe onbeschreven pocket. 
Hoofdstuk 6 is het derde en laatste onderzoeksartikel, geschreven voor indiening bij The 
Journal of Biological Chemistry. Hierin wordt ingegaan op de peptidebindingsprofielen 
voor een representatieve set PR-modulatoren die duidelijk onderscheid maken tussen 
volledige antagonisten en SPRM's en tussen SPRM's en volledige agonisten. Het is 
dankzij de resolutie van deze techniek, waarvan dit artikel het langste en grondigste 
verslag is, zelfs mogelijk binnen deze algemene classificaties onderscheid te maken 
tussen verbindingen. In samenhang met het werk over peptidebinding publiceren we 
nog vier nieuwe röntgenstructuren van PR's die erop wijzen dat de mate waarin het 
ligand en het residu Met909 conflicteren de belangrijkste bepalende factor is voor het 
peptidebindingsprofiel van elke verbinding. 
In totaal maken we melding van negen nieuwe PR-structuren die een aanmerkelijke 
verrijking van onze kennis over deze target betekenen en nader inzicht bieden 
in de mechanismen van verbindingen met een gemengd profiel van de steroïde 
hormoonreceptoren in het algemeen. 
Hoofdstuk 7 is een keynote overzichtsartikel dat – na uitnodiging – in 2011 in Drug 
Discovery Today is gepubliceerd en ingaat op de uitdagingen van de ontwikkeling van 
geneesmiddelen aan de hand van meerdere parameters.
Het proefschrift sluit af met een kort CV en een volledige persoonlijke bibliograpie als ook 
een overzicht van de andrere steroïd recceptoren artikelen aan die ik heb bijgedragen in 
dit proefschrift. In laatste hoofdstuk maak ik van de gelegenheid gebruik om iedereen te 
bedanken die mij in de loop der jaren in mijn werk heeft ondersteund.
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direction.
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opportunities to grow, initially by representing informatics aspects of Schering-Plough’s 
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identify synergies and potential quick wins immediately after the merger.
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1. Additional Publications Not Included in Thesis
In addition to the publications included within this thesis, I have also contributed to a 
number of other peer reviewed articles and patents related to steroid receptor biology. 
These publications are summarised below.
1.1 Computational Design, Synthesis, and Evaluation of Miniproteins as Androgen 
Receptor CoActivator Mimics. 
(2009) Chemical Communications.
Insertion of 3 to 4 mutations, based on in silico modelling, in a diverse set of 
natural miniproteins generates potent androgen receptor (AR) binders and a 
clear insight into the structure–activity relationship of such coactivator mimics 
concerning helix length.
1.2 Systematic Structure-Function Analysis of Androgen Receptor L701 Mutants 
Explains the Properties of the Prostate Cancer Mutant L701H. 
(2009) Journal of Biological Chemistry.
One mechanism of prostate tumors for escape from androgen ablation therapies 
is mutation of the androgen receptor (AR). We investigated the unique properties 
of the ARL701H mutant, which is strongly stimulated by cortisol, by a systematic 
structure-function analysis. Most amino acid substitutions at position 701 did not 
affect AR activation by 5-dihydrotestosterone. Further analysis of the AR Leu701 
variants showed that AR L701M and AR L701Q, like AR L701H, had changed 
ligand responsiveness. AR L701M was strongly activated by progesterone but 
not by cortisol, whereas the opposite was observed for AR L701Q and AR 
L701H. Next, we analyzed a panel of structurally related steroids to study which 
of the OH groups at positions 11, 17 and 21, which discriminate cortisol from 
progesterone, underlie the differential responses to both hormones. The results 
showed that the 17-OH group was essential for activation of AR L701H and AR 
L701Q, whereas its absence was important for activation of AR L701M. Modeling 
indicated a conserved H-bonding network involving the steroidal 17-OH group, 
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His701 or Gln701, and the backbone of Ser778. This network is absent in Leu701 
and in other mutants. A hydrophobic leucine or methionine at position 701 is 
unfavorable for the 17-OH group. Our results indicate that the specific amino 
acid residue at position 701, its interaction with the backbone of Ser778, and 
the steroidal 17-hydroxyl group of the ligand are all important for the distinct 
transcriptional responses to progesterone and cortisol of ARmutants, including 
the prostate cancer mutant L701H.
1.3 Discovery and Optimization of a Selective Non-Steroidal Glucocorticoid 
Receptor Antagonist. 
(2011) Bioorganic & Medicinal Chemistry Letters.
High-throughput screening of 3.87 million compounds delivered a novel series 
of non-steroidal GR antagonists. Subsequent rounds of optimisation allowed 
progression from a non-selective ligand with a poor ADMET profile to an orally 
bioavailable, selective, stable, glucocorticoid receptor antagonist.
1.4 Org 214007-0 is A Selective Glucocorticoid Receptor Modulator with Full Anti-
Inflammatory Properties and Improved Therapeutic Index.
(2012) PLOS ONE 
Glucocorticoids (GCs) such as prednisolone are potent immunosuppressive 
drugs but suffer from severe adverse effects, including the induction of insulin 
resistance. Therefore, development of so-called Selective Glucocorticoid 
Receptor Modulators (SGRM) is highly desirable. Here we describe a non-
steroidal Glucocorticoid Receptor (GR)-selective compound (Org 214007-0) with 
a binding affinity to GR similar to that of prednisolone. Structural modelling of 
the GR-Org 214007-0 binding site shows disturbance of the loop between helix 
11 and helix 12 of GR, confirmed by partial recruitment of the TIF2-3 peptide. 
Using various cell lines and primary human cells, we show here that Org 214007-
0 acts as a partial GC agonist, since it repressed inflammatory genes and was 
less effective in induction of metabolic genes. More importantly, in vivo studies 
in mice indicated that Org 214007-0 retained full efficacy in acute inflammation 
models as well as in a chronic collagen-induced arthritis (CIA) model. Gene 
expression profiling of muscle tissue derived from arthritic mice showed a 
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partial activity of Org 214007-0 at an equi-efficacious dosage of prednisolone, 
with an increased ratio in repression versus induction of genes. Finally, in mice 
Org 214007-0 did not induce elevated fasting glucose nor the shift in glucose / 
glycogen balance in the liver seen with an equi-efficacious dose of prednisolone. 
All together, our data demonstrate that Org 214007-0 is a novel SGRMs with an 
improved therapeutic index compared to prednisolone. This class of SGRMs can 
contribute to effective anti-inflammatory therapy with a lower risk for metabolic 
side effects.
1.5 Variable loss of functional activities of androgen receptor mutants in patients 
with androgen insensitivity syndrome.
(2012) Journal of Clinical Endocrinology. Submitted
Androgen Receptor (AR) gene mutations in androgen insensitivity syndrome 
(AIS) are associated with a variety of clinical phenotypes. The aim of the present 
study was to compare the molecular properties and potential pathogenic nature 
of 11 AR variants with a broad variety of functional assays. Eight variants were 
unknown, while three variants were sofar partially described. p.Arg609Met, 
p.Leu701Phe, p.Ser741Tyr, p.Arg775Leu and p.Ile915Thr were identified in 
complete AIS (CAIS) patients, p.Cys177Gly and p.Phe814Cys were found in 
partial AIS (PAIS) patients and p.Lys913X was found in a patient with a female 
gender identity of which the exact phenotype description was not available. 
Three AR variants in the patient cohort: p.Asp691del (CAIS), p.Leu723Phe 
(severe AIS) and p.Ala766Ser (PAIS), were only partially described by others. 
Variant receptors were functionally analysed in vitro for different steps in AR 
functioning. These tests included transcriptional activation, interactions with 
coactivator motif (FxxLF-like) peptides, nuclear dynamics with Fluorescence 
Recovery After Photobleaching (FRAP), intracellular distribution using green 
fluorescent protein (GFP) tagged proteins and ligand binding characteristics 
by measuring the equilibrium dissociation constant (Kd). In addition structural 
consequences of the variants were investigated by molecular modelling. 
Loss of transcriptional activity of the AR variants could well be explained by 
loss of one or more steps in AR functioning. Transcriptional activation data 
and the FxxLF-like peptide binding assays correlated well for all variants, with 
exception of p.Arg609Met, p.Leu723Phe and p.Arg775Leu, which displayed a 
relatively higher peptide binding activity compared to measured transcriptional 
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activity. Some variants (p.Cys177Gly, p.Asp691del, p.Leu723Phe, p.Ala766Ser, 
p.Phe814Cys and p.Ile915Thr) had intermediate or wild–type values in both the 
transcription activation and peptide binding assays. All transcriptionally inactive 
variants (p.Lys913X, p.Ser741Tyr, p.Leu701Phe, p.Arg609Met, p.Arg775Leu) 
had a reduced or absent DNA binding. All investigated ligand binding domain 
(LBD) variants with a low to intermediate transcriptional activity displayed 
aberrant Kd values as was also reflected in the decreased nuclear translocation 
of GFP-tagged mutants at low hormone concentrations and indirectly resulted 
in loss of activity in subsequent steps in the cascade of AR function. Molecular 
modelling approaches have been used to suggest the structural consequences 
of p.Asp691del, p.Leu701Phe, p.Leu723Phe, p.Ser741Tyr, p.Arg775Leu, 
p.Phe814Cys and p.Ile915Thr mutations. Remarkably two variants, pAsp691del 
and p.Ile915Thr, displayed significant functional activities under different 
conditions in different assays, although the clinical phenotype was CAIS. The 
molecular phenotypes based on five different functional assays and molecular 
modelling, predicted possible activities of the variant receptors in vivo and 
match in most cases (80%) the clinical phenotypes.
1.6 Non-Steroidal Glucocorticoid Receptor Modulators. 
(2006) WO2006084917. Patent
The present invention provides non-steroidal compounds that modulate 
glucocorticoid receptor activity. More particularly, the present invention 
provides high affinity nonsteroidal compounds which are agonists, partial 
agonists or antagonists of the glucocorticoid receptor.
1.7 N-substituted Azetidine Derivatives. 
(2012) WO2012084711. Patent
The present invention relates to a new series of N-substituted azetidine 
derivatives, i.e. a series of Selective Estrogen Receptor Modulator (SERM) 
fragments derivatized with an N-substituted azetidine group, to pharmaceutical 
compositions comprising these compounds, and to their use in therapy, in 
particular to their use for the prevention or treatment of ovulatory dysfunction, 
uterine cancer, endometrium cancer, ovarian cancer, endometriosis, 
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osteoporosis, prostate cancer, benign prostatic hypertrophy, and breast cancer, 
in particular estrogen receptor (ER)-positive breast cancer, more in particular 
ER-positive hormone treatment-resistant breast cancer.
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Colleagues and collaborators…
Serendipity is a word often associated with scientific discovery and particularly medical 
breakthroughs. It can be differentiated from simple luck by the requirement for the 
recipient of serendipity to show the mental discernment and keen practical sense to 
benefit from their good fortune. The danger is that we give ourselves too much credit 
and do not recognise that sometimes we are just plain lucky. In this respect I am grateful 
for countless examples of good luck that I have blindly benefitted from and for which I 
deserve no credit.
Without exaggeration, meeting Jacob de Vlieg was a life changing moment of good 
fortune that has defined my career. All PhD candidates express their gratitude toward 
their promoting professor, but in my case, these thanks are especially heartfelt. Jacob 
has consistently shown faith in my abilities and provided me opportunity to grow and 
develop. My entire professional life has been conducted with Jacob as my boss, at 
Unilever, Organon and most recently at the Netherlands eScience Center. Many people 
are amused by the fact that Jacob is the only person who has ever given me a job, but I 
prefer to think of him as the only person I would choose to have as a boss. It has been a 
pleasure and an honour to work for a person of whom I have the utmost respect. After 
fifteen years I am still in awe of his boundless energy and determination.
I am also grateful to Ross McGuire who was my direct supervisor for the majority of the 
time at Organon and who has encouraged me to complete this thesis. My understanding 
of medicinal chemistry and the role of informatics has developed during endless 
conversations with Ross and I am indebted to him for all those hours of discussions and 
advice. I am also thankful for having somebody to share the mantle of being “Young, 
Gifted and Black”, even if it meant I spent ten years being called Ross and vice versa.
I met René van Schaik before beginning my Unilever placement, and became colleagues 
on joining Organon together. Along with Jacob and Ross, René was instrumental in 
defining and delivering the new model for molecular informatics in basic pharmaceutical 
research that is discussed in Chapter 7. His wide scientific and technical knowledge, 
coupled with his drive and enthusiasm, makes him a fantastic colleague at the eScience 
center, and I would be lost without his input.
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Rolien Bosch is a valued collaborator, who contributed directly to this project as well 
as another initiative with the Erasmus Medical School, and was always an enthusiastic 
partner in whatever work we undertook together. I would also like to thank her for more 
cups of coffee, pieces of candy and inappropriate conversations than I care to remember. 
I am also in debt to her for the numerous times she kept me awake during long lectures 
and meetings. I owe a special thanks to Rolien and her beautiful family for opening their 
hearts and lives to my own family. I feel extremely fortunate that we have been able to 
share the adventure of raising our families so closely. One of life’s great pleasures for Rita 
and I is sitting with Roy and Rolien and watching our children grow up together as we 
finish off another bottle of Sangiovese or Vernaccia di San Gimignano.
Another instance of my great fortune was to find myself working within the department 
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